<!DOCTYPE html> <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus - Hemmingsen, B - 2017 | Cochrane Library</title> <meta property="og:title" content="Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus - Hemmingsen, B - 2017 | Cochrane Library" /> <meta property="og:url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012204.pub2/references" /> <meta property="og:type" content="article" /> <meta property=”og:image” content=”https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png” /> <meta content="initial-scale=1.0, width=device-width" name="viewport" /> <meta name="dc.identifier" scheme="DOI" content="10.1002/14651858.CD012204.pub2" /> <meta name="citation_title" content="Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus" /> <meta name="citation_author" content="Bianca Hemmingsen" /> <meta name="citation_author_institution" content="Herlev University Hospital" /> <meta name="citation_author_email" content="biancahemmingsen@hotmail.com" /> <meta name="citation_author" content="David P Sonne" /> <meta name="citation_author_institution" content="Gentofte Hospital, University of Copenhagen" /> <meta name="citation_author" content="Maria‐Inti Metzendorf" /> <meta name="citation_author_institution" content="Institute of General Practice, Medical Faculty of the Heinrich‐Heine‐University D&uuml;sseldorf" /> <meta name="citation_author" content="Bernd Richter" /> <meta name="citation_author_institution" content="Institute of General Practice, Medical Faculty of the Heinrich‐Heine‐University D&uuml;sseldorf" /> <meta name="citation_journal_title" content="Cochrane Database of Systematic Reviews" /> <meta name="citation_publisher" content="John Wiley &amp; Sons, Ltd" /> <meta name="citation_issue" content="5" /> <meta name="citation_doi" content="10.1002/14651858.CD012204.pub2" /> <meta name="citation_date" content="2017" /> <meta name="citation_online_date" content="2017/05/10" /> <meta name="citation_abstract_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012204.pub2/abstract" /> <meta name="citation_fulltext_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012204.pub2/full" /> <meta name="citation_pdf_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012204.pub2/pdf/CDSR/CD012204/CD012204.pdf" /> <meta name="citation_issn" content="1465-1858" /> <meta name="citation_language" content="en" /> <meta name="citation_keywords" content="Adamantane [analogs &amp; derivatives, therapeutic use]; Blood Glucose [metabolism]; Diabetes Mellitus, Type 2 [complications, *prevention &amp; control]; Dipeptidyl‐Peptidase IV Inhibitors [*therapeutic use]; Exenatide; Fasting; Glucagon‐Like Peptide 1 [*analogs &amp; derivatives]; Glucose Intolerance; Glycated Hemoglobin A [metabolism]; Hypoglycemic Agents [therapeutic use]; Incretins [*therapeutic use]; Liraglutide [therapeutic use]; Metformin [therapeutic use]; Nitriles [therapeutic use]; Peptides [therapeutic use]; Pyrrolidines [therapeutic use]; Randomized Controlled Trials as Topic; Risk Factors; Venoms [therapeutic use]; Vildagliptin" /> <script type="text/javascript" src="//script.crazyegg.com/pages/scripts/0056/6375.js" async="async"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <script type="text/javascript">var o={auth:{customerIds:["P#DRAAEAC","EAL00000056729","DRAA3TITLES","TSINGH009S","EAL0001468","EAL00000045347"],individualId:null,brandedCustomer:"EAL0001468",roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=UTF-8" http-equiv="content-type" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/favicon.ico" rel="Shortcut Icon" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" rel="canonical" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="zh-CN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh_TW&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="zh-TW" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;hr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="hr-HR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="x-default" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="en-US" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="fr-FR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;de&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="de-DE" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ja&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ja-JP" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ko&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ko-KR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ms&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ms-MY" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fa&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="fa-IR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pl&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="pl-PL" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pt&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="pt-PT" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ru&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ru-RU" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;es&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="es-ES" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ta&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ta-IN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;th&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="th-TH" rel="alternate" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;aui&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <link href="&#x2f;html&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1513680834000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718256000" rel="stylesheet" type="text/css" /> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 13},getRevision:function(){return"605.1"},getVersion:function(){return"13.0"},isAir:function(){return false},isChrome:function(){return false},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return false},isMac:function(){return true},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="EfT7x5RD";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dreferences\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012204\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012204\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article References"},article:{availableLanguage:["en","es","ms","za"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012204.pub2",title:"Dipeptidyl\\u2010peptidase (DPP)\\u20104 inhibitors and glucagon\\u2010like peptide (GLP)\\u20101 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus",firstPublishedDate:"May 10, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Metabolic and Endocrine Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;custom&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <style type="text/css"></style> <script src="//assets.adobedtm.com/6e626c9ec247e474f6b98eb15a79a185cf7e26a5/satelliteLib-b0f13d7a13ebe8b0b1b00a9f0730a084926e292f.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1581422282000" type="text/javascript"></script> <![endif]--> </head> <body class=" yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div id="js-cookie-message" class="cookie-message cookie-message--hidden system-message-container"> <div class="container"> <a href="#" class="fa fa-times js-cookie-close pull-right" aria-label="Close cookies message"></a> <div class="system-message-wrapper container"> <i class="fa fa-exclamation-triangle" aria-hidden="true"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/N7XGCZUQPW4C675JNSTYTLUDN7XB/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a href="#" class="btn secondary js-cookie-close js-cookie-accept">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/"> <span class="brand-name">The Cochrane Library</span> <img class="brand-logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_logo.png" alt="Cochrane Library logo" title="Cochrane Library" /> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="owel__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=EfT7x5RD&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012204.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012204.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a href="/en/browse-by-topic" class="btn secondary">Browse</a>
<a href="/en/advanced-search" class="btn primary advanced-search-button">Advanced search</a>
</div>
</div>
<a href="#" class="toggle-menu-switch"><i class="fa fa-bars" aria-hidden="true"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<p class="auxiliary-menu-item access">Access provided by: <strong>Tsinghua University</strong></p>
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="bvrs__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="language-selector-modal-content" style="display: none;" data-modal-title="Language selection" data-size="large"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div> <a href="/en/cdsr/doi/10.1002/14651858.CD012204.pub2/references/en" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD012204.pub2/references/es" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <button class="btn primary btn-cancel" type="button">Cancel</button> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012204.pub2%2Freferences" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
</a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
<div class="access-provider-mobile">
<p class="access">Access provided by: <strong>Tsinghua University</strong></p>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class=" nav-root-item parent">
<a href="#">Cochrane Reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_14" role="presentation">
<a aria-labelledby="layout_14" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews" role="menuitem">
Search Reviews (CDSR)
</a>
</li>
<li class=" child-nav-item" id="layout_15" role="presentation">
<a aria-labelledby="layout_15" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews&#x2f;topics" role="menuitem">
Browse Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_18" role="presentation">
<a aria-labelledby="layout_18" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;table-of-contents" role="menuitem">
Issues
</a>
</li>
<li class=" child-nav-item" id="layout_17" role="presentation">
<a aria-labelledby="layout_17" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;editorials" role="menuitem">
Editorials
</a>
</li>
<li class=" child-nav-item" id="layout_19" role="presentation">
<a aria-labelledby="layout_19" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;special-collections" role="menuitem">
Special Collections
</a>
</li>
<li class=" child-nav-item" id="layout_20" role="presentation">
<a aria-labelledby="layout_20" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;supplements" role="menuitem">
Supplements
</a>
</li>
<li class=" child-nav-item" id="layout_13" role="presentation">
<a aria-labelledby="layout_13" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;about-cdsr" role="menuitem">
About the CDSR
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_22" role="presentation">
<a aria-labelledby="layout_22" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central" role="menuitem">
Search Trials (CENTRAL)
</a>
</li>
<li class=" child-nav-item" id="layout_114" role="presentation">
<a aria-labelledby="layout_114" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central&#x2f;about-central" role="menuitem">
About CENTRAL
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_29" role="presentation">
<a aria-labelledby="layout_29" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca" role="menuitem">
Browse Clinical Answers
</a>
</li>
 <li class=" child-nav-item" id="layout_91" role="presentation">
<a aria-labelledby="layout_91" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca&#x2f;about" role="menuitem">
About Clinical Answers
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_116" role="presentation">
<a aria-labelledby="layout_116" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-library" role="menuitem">
About the Cochrane Library
</a>
</li>
<li class=" child-nav-item" id="layout_34" role="presentation">
<a aria-labelledby="layout_34" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochrane&#x2e;org&#x2f;about-us" role="menuitem">
About Cochrane
</a>
</li>
<li class=" child-nav-item" id="layout_121" role="presentation">
<a aria-labelledby="layout_121" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-reviews" role="menuitem">
About Cochrane Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_92" role="presentation">
<a aria-labelledby="layout_92" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;author-information" role="menuitem">
Information for authors
</a>
</li>
<li class=" child-nav-item" id="layout_188" role="presentation">
<a aria-labelledby="layout_188" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;releases" role="menuitem">
What&#039;s new
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_177" role="presentation">
<a aria-labelledby="layout_177" href="https&#x3a;&#x2f;&#x2f;www&#x2e;wiley&#x2e;com&#x2f;network&#x2f;cochranelibrarytraining" role="menuitem">
Cochrane Library Training
</a>
</li>
<li class=" child-nav-item" id="layout_44" role="presentation">
<a aria-labelledby="layout_44" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;access" role="menuitem">
Access options
</a>
</li>
<li class=" child-nav-item" id="layout_150" role="presentation">
<a aria-labelledby="layout_150" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;permissions" role="menuitem">
Permissions and reprints
</a>
</li>
<li class=" child-nav-item" id="layout_93" role="presentation">
<a aria-labelledby="layout_93" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;media" role="menuitem">
Media information
</a>
</li>
<li class=" child-nav-item" id="layout_97" role="presentation">
<a aria-labelledby="layout_97" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;contact-us" role="menuitem">
Contact us
</a>
</li>
<li class=" child-nav-item" id="layout_125" role="presentation">
<a aria-labelledby="layout_125" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;terms-and-conditions" role="menuitem">
Terms and conditions
</a>
</li>
<li class=" child-nav-item" id="layout_176" role="presentation">
<a aria-labelledby="layout_176" href="https&#x3a;&#x2f;&#x2f;hub&#x2e;wiley&#x2e;com&#x2f;docs&#x2f;cochrane-library&#x2f;cochrane-library-known-issues-DOC-16221&#x3f;referrer&#x3d;cochrane" role="menuitem">
Known issues
</a>
</li>
</ul>
</li>
<li class="about-link"><a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img id="etlj__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <section class="content-language-banner system-message-container" data-content-language="en" data-portal-language="en" style="display: none"> <div class="container"> <a href="#0" class="fa fa-times content-language-banner-close pull-right" aria-label="Close"></a> <i class="fa fa-globe" aria-hidden="true"></i> <div class="system-message-title">Content Language Selection</div> <div class="system-message-description">Your language preference is set to <strong class="language">English</strong>. Where translations are available, article sections will display in this language. Return to <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=reset-content-language&p_p_cacheability=cacheLevelPage" class="language secondary">English</a>.</div> </div> </section> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div id="content" class="">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="rjus__column1__0" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools"> <li class="cdsr-nav-link pulldown-menu readcube-menu closed"> <a href="#0" class="pulldown-menu-trigger"> <i class="icon fa fa-file-pdf-o"></i>View PDF <i aria-hidden="true" class="fa fa-caret-up"></i> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/pdf/full/en" class="download media pdf-link-full pdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/epdf/full/en" class="download media pdf-link-full readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/pdf/standard/en" class="download media pdf-link-standard pdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/epdf/standard/en" class="download media pdf-link-standard readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/pdf/abstract/en" class="download media pdf-link-abstract pdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/epdf/abstract/en" class="download media pdf-link-abstract readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="cdsr-nav-link cite-article-link" data-article-id="CD012204.PUB2" data-modal-title="Cite this Review"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/#"> <i class="icon fa fa-share"></i>Cite this Review </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-english-only-message="Please note, that requesting permissions is available in English only. Apologies for any inconvenience." href="/cdsr/doi/10.1002/14651858.CD012204.pub2/#" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false"> <span class="request-permissions-icon"></span> Request Permissions </a> </li> <li class="cdsr-nav-link comment-on-review"> <a id="comment-on-review" class="js-old-version-modal-trigger" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/comment" data-new-version="" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience."> <i class="icon fa fa-comment"></i>Comment on Review </a> </li> <li class="cdsr-nav-link comment-on"> <span>Read comments on this Review(0)</span> </li> </ul> <ul class="share clearfix"> <li class="cdsr-nav-link print-cdsr-link" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012204.pub2/print" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;zh&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh&quot;,&quot;title&quot;:&quot;概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Data and analysis&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;}]}]"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/#"> <i class="icon fa fa-print"></i>Print </a> </li> <li class="cdsr-nav-link share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012204.pub2/full"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/#"> <i class="icon fa fa-share-alt"></i>Share </a> </li> <li class="cdsr-nav-link"> <a href="/c/portal/login" class="article-not-followed cochrane-link signin"> <span class="article-follow-display"><i class="icon fa fa-plus"></i>Follow</span> </a> </li> </ul> <ul id="linked-articles" data-type="cdsr" class="linked-content tools clearfix linked-content-trigger"> <li> <a href="#0"> <span class="linked-to-this"> Linked to this Review <span class="linked-content-count"></span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> </li> </ul> <ul class="linked-content-dropdown"> <li data-type="cca" class="linked-cca"> <p>Cochrane Clinical Answers</p> </li> <li data-type="editorial" class="linked-editorials"> <p>Editorials</p> </li> <li data-type="podcast" class="linked-podcasts"> <p>Podcasts</p> </li> <li data-type="sc" class="linked-sc"> <p>Special Collections</p> </li> </ul> <ul class="nav-long-form"> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-sec1-0007"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-sec1-0001"> Summary of findings </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-sec1-0002"> Background </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-sec1-0003"> Objectives </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-sec1-0004"> Methods </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-sec1-0005"> Results </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-sec1-0006"> Discussion </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/appendices#CD012204-sec1-0012"> Appendices </a> </li> </ul> <ul> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/information"> Information </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/information#authors"> Authors </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/information#history"> History </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/information#keywords"> Keywords </a> </li> </ul> <ul> <li class="cdsr-nav-link bold-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/#"> <i class="icon fa fa-globe"></i>Translation notes </a> </li> </ul> <ul> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references"> References </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#dataAndAnalyses"> Data and analyses </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/#"> <i class="icon fa fa-line-chart"></i>Figures and tables </a> </li> <li class="cdsr-nav-link download-stats-data-link " data-download-href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/table_n/CD012204StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/table_n/CD012204StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <i class="icon fa fa-download"></i>Download statistical data </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i>Related content <span class="note podcast-indicator">Podcast available</span> </a> </li> </ul> </nav> </div> <article class="information" data-article-id="CD012204.PUB2"> <header> <h1 class="publication-title"><h1 lang="en" class="publication-title">Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus </h1></h1> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div><h2 class="title section-collapse-title"> References <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <section class="references bibliographies" id="references"> <section> <div class="section-header" id="CD012204-bbs1-0001"> <h3 class="title">References to studies included in this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD012204-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD012204-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD012204-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD012204-bbs1-0005">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_includedStudies" id="CD012204-bbs2-0001"> <div class="reference-title-banner"> <h4 class="title">Ariel 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0001"> <div class="citation-journal">Ariel D, Kim SH, Abbasi F, Lamendola CA, Liu A, Reaven GM. <span class="citation-title">Effect of liraglutide administration and a calorie‐restricted diet on lipoprotein profile in overweight/obese persons with prediabetes</span>. <span class="citation"> Nutrition, Metabolism, and Cardiovascular diseases </span><span class="pubYear">2014</span>;<span class="volume">24</span>(12):1317‐22. [PUBMED: 25280957]<a class="crsref citation-link central-link" data-crsref="5606841" href="" ref="info:x-wiley/crsRef/5606841" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+liraglutide+administration+and+a+calorie%E2%80%90restricted+diet+on+lipoprotein+profile+in+overweight/obese+persons+with+prediabetes+&author=D+Ariel&author=SH+Kim&author=F+Abbasi&author=CA+Lamendola&author=A+Liu&author=GM+Reaven&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0002"> <div class="citation-journal">Kim S, Abbasi F, Lamendola C, Liu A, Ariel D, Schaaf P, et al. <span class="citation-title">Liraglutide for overweight, older individuals with prediabetes</span>. <span class="citation"> Diabetes </span><span class="pubYear">2013</span>;<span class="volume">62</span>(0):A260. <a class="crsref citation-link central-link" data-crsref="5606842" href="" ref="info:x-wiley/crsRef/5606842" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+for+overweight,+older+individuals+with+prediabetes&author=S+Kim&author=F+Abbasi&author=C+Lamendola&author=A+Liu&author=D+Ariel&author=P+Schaaf&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0003"> <div class="citation-journal">Kim SH, Abbasi F, Lamendola C, Liu A, Ariel D, Schaaf P, et al. <span class="citation-title">Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2013</span>;<span class="volume">36</span>(10):3276‐82. [PUBMED: 23835684]<a class="crsref citation-link central-link" data-crsref="5606843" href="" ref="info:x-wiley/crsRef/5606843" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23835684" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Benefits+of+liraglutide+treatment+in+overweight+and+obese+older+individuals+with+prediabetes&author=SH+Kim&author=F+Abbasi&author=C+Lamendola&author=A+Liu&author=D+Ariel&author=P+Schaaf&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0004"> <div class="citation-journal">Kim SH, Liu A, Ariel D, Abbasi F, Lamendola C, Grove K, et al. <span class="citation-title">Pancreatic beta cell function following liraglutide‐augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo‐controlled study</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2014</span>;<span class="volume">57</span>(3):455‐62. [PUBMED: 24326527]<a class="crsref citation-link central-link" data-crsref="5606844" href="" ref="info:x-wiley/crsRef/5606844" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24326527" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pancreatic+beta+cell+function+following+liraglutide%E2%80%90augmented+weight+loss+in+individuals+with+prediabetes:+analysis+of+a+randomised,+placebo%E2%80%90controlled+study+&author=SH+Kim&author=A+Liu&author=D+Ariel&author=F+Abbasi&author=C+Lamendola&author=K+Grove&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0005"> <div class="citation-other">NCT01784965. <span class="citation-title">Liraglutide and a calorie restricted diet augments weight loss and decreases risk of type 2 diabetes and CVD</span>. clinicaltrials.gov/ct2/show/NCT01784965 Date first received: 4 February 2013. <a class="crsref citation-link central-link" data-crsref="5606845" href="" ref="info:x-wiley/crsRef/5606845" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD012204-bbs2-0002"> <div class="reference-title-banner"> <h4 class="title">Kelly 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0006"> <div class="citation-journal">Kelly AS, Bergenstal RM, Gonzalez‐Campoy JM, Katz H, Bank AJ. <span class="citation-title">Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes</span>. <span class="citation"> Diabetes </span><span class="pubYear">2012</span>;<span class="volume">61</span>(0):A112. <a class="crsref citation-link central-link" data-crsref="5606847" href="" ref="info:x-wiley/crsRef/5606847" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+exenatide+vs.+metformin+on+endothelial+function+in+obese+patients+with+pre%E2%80%90diabetes+&author=AS+Kelly&author=RM+Bergenstal&author=JM+Gonzalez%E2%80%90Campoy&author=H+Katz&author=AJ+Bank&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0007"> <div class="citation-journal">Kelly AS, Bergenstal RM, Gonzalez‐Campoy JM, Katz H, Bank AJ. <span class="citation-title">Effects of exenatide vs. metformin on endothelial function in obese patients with pre‐diabetes: a randomized trial</span>. <span class="citation"> Cardiovascular Diabetology </span><span class="pubYear">2012</span>;<span class="volume">11</span>:64. [PUBMED: 22681705]<a class="crsref citation-link central-link" data-crsref="5606848" href="" ref="info:x-wiley/crsRef/5606848" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22681705" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+exenatide+vs.+metformin+on+endothelial+function+in+obese+patients+with+pre%E2%80%90diabetes:+a+randomized+trial+&author=AS+Kelly&author=RM+Bergenstal&author=JM+Gonzalez%E2%80%90Campoy&author=H+Katz&author=AJ+Bank&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0008"> <div class="citation-other">NCT00546728. <span class="citation-title">The vascular effects of exenatide versus metformin in patients with pre‐diabetes</span>. clinicaltrials.gov/ct2/show/NCT00546728 Date first received: 17 October 2007. <a class="crsref citation-link central-link" data-crsref="5606849" href="" ref="info:x-wiley/crsRef/5606849" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD012204-bbs2-0003"> <div class="reference-title-banner"> <h4 class="title">Martinez‐Abundis 2015 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0009"> <div class="citation-other">Martinez‐Abundis E, Gonzalez‐Heredia T, Hernandez‐Corona DM, Gonzalez‐Ortiz M. <span class="citation-title">Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance</span>. Diabetes<span class="pubYear">2015</span>; Vol. 64, issue 0:A635‐6. <a class="crsref citation-link central-link" data-crsref="5606851" href="" ref="info:x-wiley/crsRef/5606851" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+linagliptin+on+glycemic+control+and+variability+in+patients+with+impaired+glucose+tolerance+&author=E+Martinez%E2%80%90Abundis&author=T+Gonzalez%E2%80%90Heredia&author=DM+Hernandez%E2%80%90Corona&author=M+Gonzalez%E2%80%90Ortiz&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD012204-bbs2-0004"> <div class="reference-title-banner"> <h4 class="title">McLaughlin 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0010"> <div class="citation-journal">McLaughlin T. <span class="citation-title">Exenatide/diet vs diet alone for treatment of prediabetes</span>. <span class="citation"> Diabetes </span><span class="pubYear">2011</span>;<span class="volume">60</span>(Suppl 1):34‐LB. <a class="crsref citation-link central-link" data-crsref="5606853" href="" ref="info:x-wiley/crsRef/5606853" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Exenatide/diet+vs+diet+alone+for+treatment+of+prediabetes&author=T+McLaughlin&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0011"> <div class="citation-other">NCT02084654. <span class="citation-title">Exenatide and weight loss for diabetes prevention</span>. clinicaltrials.gov/ct2/show/NCT02084654 Date first received: 2 December 2013. <a class="crsref citation-link central-link" data-crsref="5606854" href="" ref="info:x-wiley/crsRef/5606854" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0012"> <div class="citation-journal">Tam JK, McLaughlin TL, Lamendola CA, Lerner KD, Peck M, Liu LF. <span class="citation-title">Effect of exenatide on weight and metabolic profile in obese insulin‐resistant individuals and results after drug discontinuation</span>. <span class="citation"> Endocrine Reviews </span><span class="pubYear">2013</span>;<span class="volume">34</span>(3):SUN‐854. <a class="crsref citation-link central-link" data-crsref="5606855" href="" ref="info:x-wiley/crsRef/5606855" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+exenatide+on+weight+and+metabolic+profile+in+obese+insulin%E2%80%90resistant+individuals+and+results+after+drug+discontinuation+&author=JK+Tam&author=TL+McLaughlin&author=CA+Lamendola&author=KD+Lerner&author=M+Peck&author=LF+Liu&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD012204-bbs2-0005"> <div class="reference-title-banner"> <h4 class="title">Rosenstock 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0013"> <div class="citation-other"><span class="citation-title">CLAF237A2357</span>. www.clinicaltrialsregister.eu/ctr‐search/rest/download/result/attachment/2005‐002778‐30/1/17121 (accessed 9 May 2017). <a class="crsref citation-link central-link" data-crsref="5606857" href="" ref="info:x-wiley/crsRef/5606857" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0014"> <div class="citation-other">EudraCT 2005‐002778‐30. <span class="citation-title">A multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LAF237) 50 mg QD in subjects with impaired glucose tolerance (IGT)</span>. www.clinicaltrialsregister.eu/ctr‐search/trial/2005‐002778‐30/DE Date first registered: 11 August 2005. <a class="crsref citation-link central-link" data-crsref="5606858" href="" ref="info:x-wiley/crsRef/5606858" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0015"> <div class="citation-other">NCT00237250. <span class="citation-title">Efficacy and safety of vildagliptin in subjects with impaired glucose tolerance</span>. www.clinicaltrials.gov/ct2/show/NCT00237250 Date first received: 9 October 2005. <a class="crsref citation-link central-link" data-crsref="5606859" href="" ref="info:x-wiley/crsRef/5606859" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0016"> <div class="citation-journal">Rosenstock J, Foley JE, Rendell M, Landin‐Olsson M, Holst JJ, Deacon CF, et al. <span class="citation-title">Effects of the dipeptidyl peptidase‐IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2008</span>;<span class="volume">31</span>(1):30‐5. [PUBMED: 17947341]<a class="crsref citation-link central-link" data-crsref="5606860" href="" ref="info:x-wiley/crsRef/5606860" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17947341" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+the+dipeptidyl+peptidase%E2%80%90IV+inhibitor+vildagliptin+on+incretin+hormones,+islet+function,+and+postprandial+glycemia+in+subjects+with+impaired+glucose+tolerance+&author=J+Rosenstock&author=JE+Foley&author=M+Rendell&author=M+Landin%E2%80%90Olsson&author=JJ+Holst&author=CF+Deacon&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD012204-bbs2-0006"> <div class="reference-title-banner"> <h4 class="title">Rosenstock 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0017"> <div class="citation-other">NCT00500370A. <span class="citation-title">Pilot study of effects of exenatide on body weight in non‐diabetic, obese patients</span>. clinicaltrials.gov/ct2/show/NCT00500370 Date first received: 10 July 2007. <a class="crsref citation-link central-link" data-crsref="5606862" href="" ref="info:x-wiley/crsRef/5606862" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0018"> <div class="citation-journal">Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, et al. <span class="citation-title">Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre‐diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2010</span>;<span class="volume">33</span>(6):1173‐5. [PUBMED: 20332357]<a class="crsref citation-link central-link" data-crsref="5606863" href="" ref="info:x-wiley/crsRef/5606863" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20332357" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+exenatide+and+lifestyle+modification+on+body+weight+and+glucose+tolerance+in+obese+subjects+with+and+without+pre%E2%80%90diabetes+&author=J+Rosenstock&author=LJ+Klaff&author=S+Schwartz&author=J+Northrup&author=JH+Holcombe&author=K+Wilhelm&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0019"> <div class="citation-journal">Trautmann M, Northrup J, Cao D, Glass L, Holcombe J. <span class="citation-title">Exenatide was associated with body weight reduction and normalisation of impaired glucose tolerance in non‐diabetic, obese patients</span>. <span class="citation"> Journal of Diabetes </span><span class="pubYear">2009</span>;<span class="volume">1</span>(0):A196‐7. <a class="crsref citation-link central-link" data-crsref="5606864" href="" ref="info:x-wiley/crsRef/5606864" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Exenatide+was+associated+with+body+weight+reduction+and+normalisation+of+impaired+glucose+tolerance+in+non%E2%80%90diabetic,+obese+patients+&author=M+Trautmann&author=J+Northrup&author=D+Cao&author=L+Glass&author=J+Holcombe&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD012204-bbs2-0007"> <div class="reference-title-banner"> <h4 class="title">SCALE {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0020"> <div class="citation-journal">Astrup A, Fujioka K, Violante Ortiz R, Jensen CB, Lillerre SK, O'Neil P. <span class="citation-title">Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56‐week randomised, controlled, scale obesity and prediabetes trial</span>. <span class="citation"> Obesity Facts </span><span class="pubYear">2015</span>;<span class="volume">8</span>(0):42. <a class="crsref citation-link central-link" data-crsref="5606866" href="" ref="info:x-wiley/crsRef/5606866" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+liraglutide+3.0+Mg+in+adult+overweight+and+obese+weight+loss+responders+without+diabetes:+results+of+the+56%E2%80%90week+randomised,+controlled,+scale+obesity+and+prediabetes+trial+&author=A+Astrup&author=K+Fujioka&author=R+ViolanteOrtiz&author=CB+Jensen&author=SK+Lillerre&author=P+O'Neil&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0021"> <div class="citation-other">Bjorner JB, Brett JH, Meincke HH, Kolotkin RL. <span class="citation-title">The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF‐36: 3‐year data</span>. Diabetologia<span class="pubYear">2016</span>; Vol. 59:S330. <a class="crsref citation-link central-link" data-crsref="5606867" href="" ref="info:x-wiley/crsRef/5606867" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effect+of+liraglutide+3.0+mg+for+weight+management+on+HRQoL,+as+measured+by+SF%E2%80%9036:+3%E2%80%90year+data+&author=JB+Bjorner&author=JH+Brett&author=HH+Meincke&author=RL+Kolotkin&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0022"> <div class="citation-journal">Bjorner JB, Fujioka K, Lay A, Brett J, Kolotkin R. <span class="citation-title">Liraglutide 3.0 mg improves health utilities in weight management compared with placebo</span>. <span class="citation"> Diabetes </span><span class="pubYear">2015</span>;<span class="volume">64</span>(0):A565‐6. <a class="crsref citation-link central-link" data-crsref="5606868" href="" ref="info:x-wiley/crsRef/5606868" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+3.0+mg+improves+health+utilities+in+weight+management+compared+with+placebo&author=JB+Bjorner&author=K+Fujioka&author=A+Lay&author=J+Brett&author=R+Kolotkin&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0023"> <div class="citation-journal">Bluher M, Hermansen K, Greenway F, Fujioka K, Donsmark M, Jensen CB, et al. <span class="citation-title">Early weight loss with liraglutide 3.0 mg is good predictor of clinically meaningful weight loss after 56 weeks</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2015</span>;<span class="volume">58</span>(1):S310. <a class="crsref citation-link central-link" data-crsref="5606869" href="" ref="info:x-wiley/crsRef/5606869" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Early+weight+loss+with+liraglutide+3.0+mg+is+good+predictor+of+clinically+meaningful+weight+loss+after+56+weeks+&author=M+Bluher&author=K+Hermansen&author=F+Greenway&author=K+Fujioka&author=M+Donsmark&author=CB+Jensen&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0024"> <div class="citation-other">EudraCT 2008‐001049‐24. <span class="citation-title">Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with comorbidities</span>. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐001049‐24/IE Date first registered: 15 September 2008. <a class="crsref citation-link central-link" data-crsref="5606870" href="" ref="info:x-wiley/crsRef/5606870" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0025"> <div class="citation-journal">Fujioka K, Wilding JPH, Astrup A, Greenway F, Halpern A, Krempf M, et al. <span class="citation-title">Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: the SCALE obesity and prediabetes trial</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2014</span>;<span class="volume">57</span>(1):S368‐9. <a class="crsref citation-link central-link" data-crsref="5606871" href="" ref="info:x-wiley/crsRef/5606871" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+liraglutide+3.0+mg+for+weight+management+in+overweight/obese+adults:+the+SCALE+obesity+and+prediabetes+trial+&author=K+Fujioka&author=JPH+Wilding&author=A+Astrup&author=F+Greenway&author=A+Halpern&author=M+Krempf&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0026"> <div class="citation-journal">Gaal LV, Pi‐Sunyer X, Hemmingsson JU, Claudius B, Svendsen CB, Bays H. <span class="citation-title">Liraglutide 3.0 mg: weight‐loss dependent and independent effects</span>. <span class="citation"> Obesity Facts </span><span class="pubYear">2015</span>;<span class="volume">8</span>(0):41‐2. <a class="crsref citation-link central-link" data-crsref="5606872" href="" ref="info:x-wiley/crsRef/5606872" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+3.0+mg:+weight%E2%80%90loss+dependent+and+independent+effects&author=LV+Gaal&author=X+Pi%E2%80%90Sunyer&author=JU+Hemmingsson&author=B+Claudius&author=CB+Svendsen&author=H+Bays&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0027"> <div class="citation-journal">Kolotkin RL, Fujioka K, Wolden ML, Brett JH, Bjorner JB. <span class="citation-title">Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management</span>. <span class="citation"> Clinical Obesity </span><span class="pubYear">2016</span>;<span class="volume">6</span>(4):233‐42. [PUBMED: 27198973]<a class="crsref citation-link central-link" data-crsref="5606873" href="" ref="info:x-wiley/crsRef/5606873" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27198973" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Improvements+in+health%E2%80%90related+quality+of+life+with+liraglutide+3.0+mg+compared+with+placebo+in+weight+management+&author=RL+Kolotkin&author=K+Fujioka&author=ML+Wolden&author=JH+Brett&author=JB+Bjorner&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0028"> <div class="citation-journal">Kolotkin RL, Meincke HJ, Manning LS, Bjorner JB. <span class="citation-title">Impact of weight loss on patient‐reported outcomes in the SCALE obesity and prediabetes trial of liraglutide 3.0 mg as adjunct to a diet and exercise (D&amp;E) programme</span>. <span class="citation"> Value in Health </span><span class="pubYear">2015</span>;<span class="volume">18</span>(7):A674‐5. [PUBMED: 26533777]<a class="crsref citation-link central-link" data-crsref="5606874" href="" ref="info:x-wiley/crsRef/5606874" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Impact+of+weight+loss+on+patient%E2%80%90reported+outcomes+in+the+SCALE+obesity+and+prediabetes+trial+of+liraglutide+3.0+mg+as+adjunct+to+a+diet+and+exercise+(D&E)+programme+&author=RL+Kolotkin&author=HJ+Meincke&author=LS+Manning&author=JB+Bjorner&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0029"> <div class="citation-journal">Krempf M, Astrup A, Fujioka K, Greenway F, Halpern A, Lau DC, et al. <span class="citation-title">Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 Mg in overweight and obese adults: the scale obesity and prediabetes randomised trial</span>. <span class="citation"> Obesity Facts </span><span class="pubYear">2015</span>;<span class="volume">8</span>(0):210. <a class="crsref citation-link central-link" data-crsref="5606875" href="" ref="info:x-wiley/crsRef/5606875" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26087902" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Additional+analyses+of+the+weight%E2%80%90lowering+efficacy+of+liraglutide+3.0+Mg+in+overweight+and+obese+adults:+the+scale+obesity+and+prediabetes+randomised+trial+&author=M+Krempf&author=A+Astrup&author=K+Fujioka&author=F+Greenway&author=A+Halpern&author=DC+Lau&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0030"> <div class="citation-journal">Krempf M, Astrup A, Roux C, Fujioka K, Greenway F, Halpern A, et al. <span class="citation-title">Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: the SCALE obesity and prediabetes randomised trial</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2014</span>;<span class="volume">57</span>(1):S368. <a class="crsref citation-link central-link" data-crsref="5606876" href="" ref="info:x-wiley/crsRef/5606876" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+3.0+mg+reduces+body+weight+and+improves+cardiometabolic+risk+factors+in+overweight/obese+adults:+the+SCALE+obesity+and+prediabetes+randomised+trial+&author=M+Krempf&author=A+Astrup&author=C+Roux&author=K+Fujioka&author=F+Greenway&author=A+Halpern&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0031"> <div class="citation-journal">Lau DC, Davies M, Pi‐Sunyer FX, Wilding J, Manning LS, Jensen CB, et al. <span class="citation-title">Hypoglycemia reported with liraglutide 3.0 mg in overweight and obese adults with and without prediabetes: results of the randomized, double‐blind, placebo‐controlled 56‐week scale obesity and prediabetes trial</span>. <span class="citation"> Endocrine Society's 97th Annual Meeting and Expo; 2015 Mar 5‐8; San Diego (CA) </span><span class="pubYear">2015</span>:OR07‐2. <a class="crsref citation-link central-link" data-crsref="5606877" href="" ref="info:x-wiley/crsRef/5606877" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Hypoglycemia+reported+with+liraglutide+3.0+mg+in+overweight+and+obese+adults+with+and+without+prediabetes:+results+of+the+randomized,+double%E2%80%90blind,+placebo%E2%80%90controlled+56%E2%80%90week+scale+obesity+and+prediabetes+trial+&author=DC+Lau&author=M+Davies&author=FX+Pi%E2%80%90Sunyer&author=J+Wilding&author=LS+Manning&author=CB+Jensen&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0032"> <div class="citation-journal">Lau DC, Fujioka K, Astrup A, Greenway F, Halpern A, Krempf M, et al. <span class="citation-title">Liraglutide 3.0 Mg reduces body weight and improves HRQoL in overweight or obese adults without diabetes: SCALE obesity and prediabetes randomized, double‐blind, placebo controlled, 56‐week trial</span>. <span class="citation"> Obesity Facts </span><span class="pubYear">2015</span>;<span class="volume">8</span>(0):185. <a class="crsref citation-link central-link" data-crsref="5606878" href="" ref="info:x-wiley/crsRef/5606878" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+3.0+Mg+reduces+body+weight+and+improves+HRQoL+in+overweight+or+obese+adults+without+diabetes:+SCALE+obesity+and+prediabetes+randomized,+double%E2%80%90blind,+placebo+controlled,+56%E2%80%90week+trial+&author=DC+Lau&author=K+Fujioka&author=A+Astrup&author=F+Greenway&author=A+Halpern&author=M+Krempf&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0033"> <div class="citation-journal">Lau DC, Greenway F, Fujioka K, Astrup A, Halpern A, Krempf M, et al. <span class="citation-title">Additional analyses of the weight‐lowering efficacy of liraglutide 3.0 mg in adults with overweight and obesity: the SCALE obesity and prediabetes randomized trial</span>. <span class="citation"> Canadian Journal of Diabetes </span><span class="pubYear">2015</span>;<span class="volume">39</span>(0):S48. <a class="crsref citation-link central-link" data-crsref="5606879" href="" ref="info:x-wiley/crsRef/5606879" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Additional+analyses+of+the+weight%E2%80%90lowering+efficacy+of+liraglutide+3.0+mg+in+adults+with+overweight+and+obesity:+the+SCALE+obesity+and+prediabetes+randomized+trial+&author=DC+Lau&author=F+Greenway&author=K+Fujioka&author=A+Astrup&author=A+Halpern&author=M+Krempf&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0034"> <div class="citation-journal">Lau DC, Krempf M, Astrup A, Roux CW, Fujioka K, Greenway F, et al. <span class="citation-title">Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with overweight/obesity: the SCALE obesity and prediabetes randomised trial</span>. <span class="citation"> Canadian Journal of Diabetes </span><span class="pubYear">2015</span>;<span class="volume">39</span>(0):S48‐9. <a class="crsref citation-link central-link" data-crsref="5606880" href="" ref="info:x-wiley/crsRef/5606880" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+3.0+mg+reduces+body+weight+and+improves+cardiometabolic+risk+factors+in+adults+with+overweight/obesity:+the+SCALE+obesity+and+prediabetes+randomised+trial+&author=DC+Lau&author=M+Krempf&author=A+Astrup&author=CW+Roux&author=K+Fujioka&author=F+Greenway&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0035"> <div class="citation-journal">Lau DCW, Wilding JPH, Astrup A, Fujioka K, Greenway F, Halpern A, et al. <span class="citation-title">Liraglutide 3.0 mg improves insulin secretion and action in overweight/ obese adults without type 2 diabetes: the SCALE obesity and prediabetes trial</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2014</span>;<span class="volume">57</span>(1):S358. <a class="crsref citation-link central-link" data-crsref="5606881" href="" ref="info:x-wiley/crsRef/5606881" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+3.0+mg+improves+insulin+secretion+and+action+in+overweight/+obese+adults+without+type+2+diabetes:+the+SCALE+obesity+and+prediabetes+trial+&author=DCW+Lau&author=JPH+Wilding&author=A+Astrup&author=K+Fujioka&author=F+Greenway&author=A+Halpern&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0036"> <div class="citation-journal">Roux C, Lau DCW, Astrup A, Fujioka K, Greenway F, Halpern A, et al. <span class="citation-title">Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2014</span>;<span class="volume">57</span>(1):S338. <a class="crsref citation-link central-link" data-crsref="5606882" href="" ref="info:x-wiley/crsRef/5606882" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Safety+and+tolerability+of+liraglutide+3.0+mg+in+overweight+and+obese+adults:+the+SCALE+obesity+and+prediabetes+randomised+trial+&author=C+Roux&author=DCW+Lau&author=A+Astrup&author=K+Fujioka&author=F+Greenway&author=A+Halpern&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0037"> <div class="citation-journal">Roux C, Lau DCW, Fujioka K, Caterson ID, Cancino AP, Jensen CB, et al. <span class="citation-title">The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2015</span>;<span class="volume">58</span>(1):S311. <a class="crsref citation-link central-link" data-crsref="5606883" href="" ref="info:x-wiley/crsRef/5606883" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+impact+of+gastrointestinal+adverse+events+on+weight+loss+with+liraglutide+3.0+mg+as+adjunct+to+a+diet+and+exercise+programme+&author=C+Roux&author=DCW+Lau&author=K+Fujioka&author=ID+Caterson&author=AP+Cancino&author=CB+Jensen&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0038"> <div class="citation-journal">Roux CW, Astrup A, Fujioka K, Greenway F, Lau DC, Gaal L, et al. <span class="citation-title">3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial</span>. <span class="citation"> Lancet </span><span class="pubYear">2017</span>;<span class="volume">389</span>(10077):1399‐409. [PUBMED: 28237263]<a class="crsref citation-link central-link" data-crsref="5606884" href="" ref="info:x-wiley/crsRef/5606884" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28237263" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=3+years+of+liraglutide+versus+placebo+for+type+2+diabetes+risk+reduction+and+weight+management+in+individuals+with+prediabetes:+a+randomised,+double%E2%80%90blind+trial+&author=CW+Roux&author=A+Astrup&author=K+Fujioka&author=F+Greenway&author=DC+Lau&author=L+Gaal&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0039"> <div class="citation-journal">Liutkus JF, Fujioka K, Astrup A, Greenway F, Halpern A, Krempf M, et al. <span class="citation-title">Liraglutide 3.0 mg reduces body weight and improves health‐related quality of life (HRQoL) in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomized, double‐blind, placebo‐controlled, 56‐week trial</span>. <span class="citation"> Canadian Journal of Diabetes </span><span class="pubYear">2015</span>;<span class="volume">39</span>(0):S36. <a class="crsref citation-link central-link" data-crsref="5606885" href="" ref="info:x-wiley/crsRef/5606885" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+3.0+mg+reduces+body+weight+and+improves+health%E2%80%90related+quality+of+life+(HRQoL)+in+overweight+or+obese+adults+without+diabetes:+the+SCALE+obesity+and+prediabetes+randomized,+double%E2%80%90blind,+placebo%E2%80%90controlled,+56%E2%80%90week+trial+&author=JF+Liutkus&author=K+Fujioka&author=A+Astrup&author=F+Greenway&author=A+Halpern&author=M+Krempf&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0040"> <div class="citation-other">Madsbad S, Lieberman G, Skjoth TV, Lilleore SK, Fronzo RA. <span class="citation-title">Comparable efficacy and safety of liraglutide 3.0 mg for weight management across baseline BMI subgroups: results from the SCALE obesity and prediabetes trial</span>. Diabetologia<span class="pubYear">2016</span>; Vol. 59, issue 0:540‐1. <a class="crsref citation-link central-link" data-crsref="5606886" href="" ref="info:x-wiley/crsRef/5606886" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparable+efficacy+and+safety+of+liraglutide+3.0+mg+for+weight+management+across+baseline+BMI+subgroups:+results+from+the+SCALE+obesity+and+prediabetes+trial+&author=S+Madsbad&author=G+Lieberman&author=TV+Skjoth&author=SK+Lilleore&author=RA+Fronzo&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0041"> <div class="citation-other">NCT01272219. <span class="citation-title">Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes</span>. clinicaltrials.gov/ct2/show/NCT01272219 Date first received: 6 January 2011. <a class="crsref citation-link central-link" data-crsref="5606887" href="" ref="info:x-wiley/crsRef/5606887" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0042"> <div class="citation-other">NN8022‐1839. <span class="citation-title">Effect of liraglutide on body weight in non‐diabetic obese subjects or overweight subjects with co‐morbidities: SCALE™ ‐ obesity and pre‐diabetes</span>. www.novonordisk‐trials.com/Website/pdf/registry/nn80221839.pdf (assessed 22 September 2016). <a class="crsref citation-link central-link" data-crsref="5606888" href="" ref="info:x-wiley/crsRef/5606888" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0043"> <div class="citation-journal">Pi‐Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. <span class="citation-title">A randomized, controlled trial of 3.0 mg of liraglutide in weight management</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2015</span>;<span class="volume">373</span>(1):11‐22. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1056/NEJMoa1411892" target="_blank"><span>10.1056/NEJMoa1411892</span></a>]<a class="crsref citation-link central-link" data-crsref="5606889" href="" ref="info:x-wiley/crsRef/5606889" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26132939" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+randomized,+controlled+trial+of+3.0+mg+of+liraglutide+in+weight+management&author=X+Pi%E2%80%90Sunyer&author=A+Astrup&author=K+Fujioka&author=F+Greenway&author=A+Halpern&author=M+Krempf&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0044"> <div class="citation-journal">Pi‐Sunyer X, Fujioka K, Roux C, Astrup A, Greenway F, Halpern A, et al. <span class="citation-title">Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2014</span>;<span class="volume">57</span>(1):S37. <a class="crsref citation-link central-link" data-crsref="5606890" href="" ref="info:x-wiley/crsRef/5606890" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+3.0+mg+reduces+the+prevalence+of+prediabetes+and+delays+onset+of+type+2+diabetes+in+overweight/obese+adults:+the+SCALE+obesity+and+prediabetes+trial+&author=X+Pi%E2%80%90Sunyer&author=K+Fujioka&author=C+Roux&author=A+Astrup&author=F+Greenway&author=A+Halpern&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0045"> <div class="citation-journal">Proietto J, Roux CW, Pi‐Sunyer X, Astrup A, Fujioka K, Greenway F, et al. <span class="citation-title">Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE obesity and prediabetes, a randomised, double‐blind and placebo‐controlled trial</span>. <span class="citation"> Obesity Research and Clinical Practice </span><span class="pubYear">2014</span>;<span class="volume">8</span>(0):117. <a class="crsref citation-link central-link" data-crsref="5606891" href="" ref="info:x-wiley/crsRef/5606891" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+liraglutide+3.0+mg+for+weight+management+in+overweight+and+obese+adults:+the+SCALE+obesity+and+prediabetes,+a+randomised,+double%E2%80%90blind+and+placebo%E2%80%90controlled+trial+&author=J+Proietto&author=CW+Roux&author=X+Pi%E2%80%90Sunyer&author=A+Astrup&author=K+Fujioka&author=F+Greenway&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0046"> <div class="citation-journal">Wilding J, Astrup A, Fujioka K, Greenway F, Krempf M, Lau D, et al. <span class="citation-title">In overweight and obese adults, liraglutide 3.0mg reduces the prevalence of prediabetes and delays the onset of type 2 diabetes: SCALE obesity and pre‐diabetes trial</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2015</span>;<span class="volume">32</span>(0):71. <a class="crsref citation-link central-link" data-crsref="5606892" href="" ref="info:x-wiley/crsRef/5606892" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=In+overweight+and+obese+adults,+liraglutide+3.0mg+reduces+the+prevalence+of+prediabetes+and+delays+the+onset+of+type+2+diabetes:+SCALE+obesity+and+pre%E2%80%90diabetes+trial+&author=J+Wilding&author=A+Astrup&author=K+Fujioka&author=F+Greenway&author=M+Krempf&author=D+Lau&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0047"> <div class="citation-journal">Wilding J, Lau D, Astrup A, Fujioka K, Greenway F, Krempf M, et al. <span class="citation-title">Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre‐diabetes trial</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2015</span>;<span class="volume">32</span>:70. <a class="crsref citation-link central-link" data-crsref="5606893" href="" ref="info:x-wiley/crsRef/5606893" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Safety+and+tolerability+of+liraglutide+3.0mg+following+56+weeks+of+randomised+treatment+in+overweight+and+obese+adults:+SCALE+obesity+and+pre%E2%80%90diabetes+trial+&author=J+Wilding&author=D+Lau&author=A+Astrup&author=K+Fujioka&author=F+Greenway&author=M+Krempf&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0048"> <div class="citation-journal">Wilding JP, Overgaard RV, Jacobsen LV, Jensen CB, Roux CW. <span class="citation-title">Exposure‐response analyses of liraglutide 3.0 mg for weight management</span>. <span class="citation"> Diabetes, Obesity &amp; Metabolism </span><span class="pubYear">2016</span>;<span class="volume">18</span>(5):491‐9. <a class="crsref citation-link central-link" data-crsref="5606894" href="" ref="info:x-wiley/crsRef/5606894" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26833744" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Exposure%E2%80%90response+analyses+of+liraglutide+3.0+mg+for+weight+management&author=JP+Wilding&author=RV+Overgaard&author=LV+Jacobsen&author=CB+Jensen&author=CW+Roux&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0049"> <div class="citation-journal">Wilding JPH, Bluher M, Hermansen K, Greenway F, Fujioka K, Claudius B, et al. <span class="citation-title">Early weight loss responders to liraglutide 3.0 mg in the scale obesity and prediabetes trial achieve greater reversal of prediabetes than placebo</span>. <span class="citation"> Diabetes </span><span class="pubYear">2015</span>;<span class="volume">64</span>:A568. <a class="crsref citation-link central-link" data-crsref="5606895" href="" ref="info:x-wiley/crsRef/5606895" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Early+weight+loss+responders+to+liraglutide+3.0+mg+in+the+scale+obesity+and+prediabetes+trial+achieve+greater+reversal+of+prediabetes+than+placebo+&author=JPH+Wilding&author=M+Bluher&author=K+Hermansen&author=F+Greenway&author=K+Fujioka&author=B+Claudius&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0050"> <div class="citation-journal">Wittert G, Roux CW, Astrup A, Fujioka K, Greenway F, Halpern A, et al. <span class="citation-title">Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the SCALE obesity and prediabetes randomised, double‐blind, placebo‐controlled 56‐week trial</span>. <span class="citation"> Obesity Research and Clinical Practice </span><span class="pubYear">2014</span>;<span class="volume">8</span>:118. <a class="crsref citation-link central-link" data-crsref="5606896" href="" ref="info:x-wiley/crsRef/5606896" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+3.0mg+improves+body+weight+and+cardiometabolic+risk+factors+in+overweight+or+obese+adults+without+diabetes:+the+SCALE+obesity+and+prediabetes+randomised,+double%E2%80%90blind,+placebo%E2%80%90controlled+56%E2%80%90week+trial+&author=G+Wittert&author=CW+Roux&author=A+Astrup&author=K+Fujioka&author=F+Greenway&author=A+Halpern&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD012204-bbs1-0002"> <h3 class="title">References to studies excluded from this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD012204-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD012204-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD012204-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD012204-bbs1-0005">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0008"> <div class="reference-title-banner"> <h4 class="title">Acosta 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0051"> <div class="citation-journal">Acosta A, Camilleri M, Burton D, O'Neill J, Eckert D, Carlson P, et al. <span class="citation-title">Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study</span>. <span class="citation"> Physiological Reports </span><span class="pubYear">2015</span>;<span class="volume">3</span>(11):e12610. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.14814/phy2.12610" target="_blank"><span>10.14814/phy2.12610</span></a>]<a class="crsref citation-link central-link" data-crsref="5606898" href="" ref="info:x-wiley/crsRef/5606898" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26542264" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Exenatide+in+obesity+with+accelerated+gastric+emptying:+a+randomized,+pharmacodynamics+study+&author=A+Acosta&author=M+Camilleri&author=D+Burton&author=J+O'Neill&author=D+Eckert&author=P+Carlson&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0009"> <div class="reference-title-banner"> <h4 class="title">ACTRN12615001029583 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0052"> <div class="citation-other">ACTRN12615001029583. <span class="citation-title">Does exenatide improve post prandial glycaemic control in young people with cystic fibrosis related diabetes or impaired glucose tolerance?</span>. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369121 Date first registered: 1 October 2015. <a class="crsref citation-link central-link" data-crsref="5606900" href="" ref="info:x-wiley/crsRef/5606900" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0010"> <div class="reference-title-banner"> <h4 class="title">Almeda‐Valdes 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0053"> <div class="citation-other">Almeda‐Valdes P, Cuevas‐Ramos D, Brito‐Cordova G, Gomez‐Perez FJ. <span class="citation-title">Treatment with sitagliptin phosphate in patients with symptomatic reactive hypoglycemia. A randomized, placebo‐controlled, double‐blinded, clinical trial</span>. 94th Annual Meeting and Expo; 2012 23‐26 Jun; Houston (TX)<span class="pubYear">2012</span>:SUN‐209. <a class="crsref citation-link central-link" data-crsref="5606902" href="" ref="info:x-wiley/crsRef/5606902" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Treatment+with+sitagliptin+phosphate+in+patients+with+symptomatic+reactive+hypoglycemia.+A+randomized,+placebo%E2%80%90controlled,+double%E2%80%90blinded,+clinical+trial+&author=P+Almeda%E2%80%90Valdes&author=D+Cuevas%E2%80%90Ramos&author=G+Brito%E2%80%90Cordova&author=FJ+Gomez%E2%80%90Perez&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0054"> <div class="citation-other">NCT00847080. <span class="citation-title">Treatment with sitagliptin for reactive hypoglycemia secondary to dysinsulinism</span>. clinicaltrials.gov/ct2/show/NCT00847080 Date first received: 18 February 2009. <a class="crsref citation-link central-link" data-crsref="5606903" href="" ref="info:x-wiley/crsRef/5606903" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0011"> <div class="reference-title-banner"> <h4 class="title">Aoki 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0055"> <div class="citation-journal">Aoki K, Kamiyama H, Masuda K, Kamiko K, Noguchi Y, Tajima K, et al. <span class="citation-title">Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels</span>. <span class="citation"> Endocrine Journal </span><span class="pubYear">2014</span>;<span class="volume">61</span>(3):249‐56. [PUBMED: 24389993]<a class="crsref citation-link central-link" data-crsref="5606905" href="" ref="info:x-wiley/crsRef/5606905" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24389993" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+miglitol,+vildagliptin,+or+their+combination+on+serum+insulin+and+peptide+YY+levels+and+plasma+glucose,+cholecystokinin,+ghrelin,+and+obestatin+levels+&author=K+Aoki&author=H+Kamiyama&author=K+Masuda&author=K+Kamiko&author=Y+Noguchi&author=K+Tajima&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0056"> <div class="citation-journal">Aoki K, Masuda K, Miyazaki T, Togashi Y, Terauchi Y. <span class="citation-title">Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non‐diabetic men</span>. <span class="citation"> Endocrine Journal </span><span class="pubYear">2010</span>;<span class="volume">57</span>(8):667‐72. [PUBMED: 20519806]<a class="crsref citation-link central-link" data-crsref="5606906" href="" ref="info:x-wiley/crsRef/5606906" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20519806" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+miglitol,+sitagliptin+or+their+combination+on+plasma+glucose,+insulin+and+incretin+levels+in+non%E2%80%90diabetic+men+&author=K+Aoki&author=K+Masuda&author=T+Miyazaki&author=Y+Togashi&author=Y+Terauchi&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0057"> <div class="citation-other">UMIN000010481. <span class="citation-title">Effect of miglitol and vildagliptin on gastrointestinal hormone</span>. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000012252&amp;language=E Date first registered: 13 April 2013. <a class="crsref citation-link central-link" data-crsref="5606907" href="" ref="info:x-wiley/crsRef/5606907" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0012"> <div class="reference-title-banner"> <h4 class="title">Armato 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0058"> <div class="citation-journal">Armato J, DeFronzo RA, Abdul‐Ghani M, Ruby R. <span class="citation-title">Successful treatment of prediabetes in clinical practice: targeting insulin resistance and beta‐cell dysfunction</span>. <span class="citation"> Endocrine Practice </span><span class="pubYear">2012</span>;<span class="volume">18</span>(3):342‐50. [PUBMED: 22068250]<a class="crsref citation-link central-link" data-crsref="5606909" href="" ref="info:x-wiley/crsRef/5606909" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22068250" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Successful+treatment+of+prediabetes+in+clinical+practice:+targeting+insulin+resistance+and+beta%E2%80%90cell+dysfunction+&author=J+Armato&author=RA+DeFronzo&author=M+Abdul%E2%80%90Ghani&author=R+Ruby&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0013"> <div class="reference-title-banner"> <h4 class="title">BEGAMI 2013 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0059"> <div class="citation-other">EUCTR2007‐003963‐31‐SE. <span class="citation-title">BEGAMI</span>. www.clinicaltrialsregister.eu/ctr‐search/trial/2007‐003963‐31/SE Date first registered: 29 August 2007. <a class="crsref citation-link central-link" data-crsref="5606911" href="" ref="info:x-wiley/crsRef/5606911" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0060"> <div class="citation-journal">Hage C, Brismar K, Efendic S, Lundman P, Ryden L, Mellbin L. <span class="citation-title">Sitagliptin improves beta‐cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities ‐ the BEGAMI study</span>. <span class="citation"> Journal of Internal Medicine </span><span class="pubYear">2013</span>;<span class="volume">273</span>(4):410‐21. [PUBMED: 23331339]<a class="crsref citation-link central-link" data-crsref="5606912" href="" ref="info:x-wiley/crsRef/5606912" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23331339" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sitagliptin+improves+beta%E2%80%90cell+function+in+patients+with+acute+coronary+syndromes+and+newly+diagnosed+glucose+abnormalities+%E2%80%90+the+BEGAMI+study+&author=C+Hage&author=K+Brismar&author=S+Efendic&author=P+Lundman&author=L+Ryden&author=L+Mellbin&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0061"> <div class="citation-journal">Hage C, Brismar K, Lundman P, Mellbin L, Ryden L. <span class="citation-title">The DPP‐4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations</span>. <span class="citation"> European Heart Journal </span><span class="pubYear">2013</span>;<span class="volume">34</span>(0):793. <a class="crsref citation-link central-link" data-crsref="5606913" href="" ref="info:x-wiley/crsRef/5606913" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23614138" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+DPP%E2%80%904+inhibitor+sitagliptin+and+endothelial+function+in+patients+with+acute+coronary+syndromes+and+newly+detected+glucose+perturbations+&author=C+Hage&author=K+Brismar&author=P+Lundman&author=L+Mellbin&author=L+Ryden&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0062"> <div class="citation-journal">Hage C, Brismar K, Lundman P, Norhammar A, Ryden L, Mellbin L. <span class="citation-title">The DPP‐4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: a report from the BEGAMI study</span>. <span class="citation"> Diabetes &amp; Vascular Disease Research </span><span class="pubYear">2014</span>;<span class="volume">11</span>(4):290‐3. [PUBMED: 24845072]<a class="crsref citation-link central-link" data-crsref="5606914" href="" ref="info:x-wiley/crsRef/5606914" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24845072" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+DPP%E2%80%904+inhibitor+sitagliptin+and+endothelial+function+in+patients+with+acute+coronary+syndromes+and+newly+detected+glucose+perturbations:+a+report+from+the+BEGAMI+study+&author=C+Hage&author=K+Brismar&author=P+Lundman&author=A+Norhammar&author=L+Ryden&author=L+Mellbin&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0063"> <div class="citation-other">NCT00627744. <span class="citation-title">Beta‐cell function in glucose abnormalities and acute myocardial infarction (BEGAMI)</span>. clinicaltrials.gov/ct2/show/NCT00627744 Date first received: 22 February 2008. <a class="crsref citation-link central-link" data-crsref="5606915" href="" ref="info:x-wiley/crsRef/5606915" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0014"> <div class="reference-title-banner"> <h4 class="title">Best 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0064"> <div class="citation-journal">Best C, Struthers H, Laciny E, Royal M, Reeds DN, Yarasheski KE. <span class="citation-title">Sitagliptin reduces inflammation and chronic immune cell activation in HIV+ adults with impaired glucose tolerance</span>. <span class="citation"> Journal of Clinical Endocrinology and Metabolism </span><span class="pubYear">2015</span>;<span class="volume">100</span>(7):2621‐9. [PUBMED: 25938633]<a class="crsref citation-link central-link" data-crsref="5606917" href="" ref="info:x-wiley/crsRef/5606917" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25938633" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sitagliptin+reduces+inflammation+and+chronic+immune+cell+activation+in+HIV++adults+with+impaired+glucose+tolerance+&author=C+Best&author=H+Struthers&author=E+Laciny&author=M+Royal&author=DN+Reeds&author=KE+Yarasheski&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0015"> <div class="reference-title-banner"> <h4 class="title">Bock 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0065"> <div class="citation-journal">Bock G, Dalla Man C, Micheletto F, Basu R, Giesler PD, Laugen J, et al. <span class="citation-title">The effect of DPP‐4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose</span>. <span class="citation"> Clinical Endocrinology </span><span class="pubYear">2010</span>;<span class="volume">73</span>(2):189‐96. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1111/j.1365-2265.2009.03764.x" target="_blank"><span>10.1111/j.1365‐2265.2009.03764.x</span></a>]<a class="crsref citation-link central-link" data-crsref="5606919" href="" ref="info:x-wiley/crsRef/5606919" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20039889" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effect+of+DPP%E2%80%904+inhibition+with+sitagliptin+on+incretin+secretion+and+on+fasting+and+postprandial+glucose+turnover+in+subjects+with+impaired+fasting+glucose+&author=G+Bock&author=C+DallaMan&author=F+Micheletto&author=R+Basu&author=PD+Giesler&author=J+Laugen&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0066"> <div class="citation-journal">Micheletto F, Dalla Man C, Vella A, Cobelli C. <span class="citation-title">Estimation of GLP‐1 induced potentiation of insulin secretion from an oral model</span>. <span class="citation"> Diabetes </span><span class="pubYear">2011</span>;<span class="volume">60</span>(0):A447. <a class="crsref citation-link central-link" data-crsref="5606920" href="" ref="info:x-wiley/crsRef/5606920" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Estimation+of+GLP%E2%80%901+induced+potentiation+of+insulin+secretion+from+an+oral+model&author=F+Micheletto&author=C+DallaMan&author=A+Vella&author=C+Cobelli&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0067"> <div class="citation-other">NCT00364377. <span class="citation-title">Incretins in impaired fasting glucose</span>. clinicaltrials.gov/ct2/show/NCT00364377 Date first received: 14 August 2006. <a class="crsref citation-link central-link" data-crsref="5606921" href="" ref="info:x-wiley/crsRef/5606921" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0068"> <div class="citation-journal">Nelson RH, Miles JM, Vella A. <span class="citation-title">Sitagliptin effects on triglyceride and free fatty acid metabolism</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2009</span>;<span class="volume">52</span>:S313. <a class="crsref citation-link central-link" data-crsref="5606922" href="" ref="info:x-wiley/crsRef/5606922" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sitagliptin+effects+on+triglyceride+and+free+fatty+acid+metabolism&author=RH+Nelson&author=JM+Miles&author=A+Vella&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0016"> <div class="reference-title-banner"> <h4 class="title">Cui 2016 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0069"> <div class="citation-journal">Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, et al. <span class="citation-title">Sitagliptin vs. placebo for non‐alcoholic fatty liver disease: a randomized controlled trial</span>. <span class="citation"> Journal of Hepatology </span><span class="pubYear">2016</span>;<span class="volume">65</span>(2):369‐76. [PUBMED: 27151177]<a class="crsref citation-link central-link" data-crsref="5606924" href="" ref="info:x-wiley/crsRef/5606924" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27151177" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sitagliptin+vs.+placebo+for+non%E2%80%90alcoholic+fatty+liver+disease:+a+randomized+controlled+trial+&author=J+Cui&author=L+Philo&author=P+Nguyen&author=H+Hofflich&author=C+Hernandez&author=R+Bettencourt&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0017"> <div class="reference-title-banner"> <h4 class="title">Daniele 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0070"> <div class="citation-journal">Daniele G, Iozzo P, Molina‐Carrion M, Lancaster J, Ciociaro D, Cersosimo E, et al. <span class="citation-title">Exenatide regulates cerebral glucose metabolism in brain areas associated with glucose homeostasis and reward system</span>. <span class="citation"> Diabetes </span><span class="pubYear">2015</span>;<span class="volume">64</span>(10):3406‐12. [PUBMED: 26116695]<a class="crsref citation-link central-link" data-crsref="5606926" href="" ref="info:x-wiley/crsRef/5606926" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26116695" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Exenatide+regulates+cerebral+glucose+metabolism+in+brain+areas+associated+with+glucose+homeostasis+and+reward+system+&author=G+Daniele&author=P+Iozzo&author=M+Molina%E2%80%90Carrion&author=J+Lancaster&author=D+Ciociaro&author=E+Cersosimo&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0071"> <div class="citation-journal">Daniele G, Iozzo P, Molina‐Wilkins M, Lancaster J, Ciociaro D, Triplitt C, et al. <span class="citation-title">Effect of exenatide on postprandial cerebral and liver glucose metabolism: a double‐blind randomised clinical trial</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2014</span>;<span class="volume">57</span>(1):S37‐8. <a class="crsref citation-link central-link" data-crsref="5606927" href="" ref="info:x-wiley/crsRef/5606927" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+exenatide+on+postprandial+cerebral+and+liver+glucose+metabolism:+a+double%E2%80%90blind+randomised+clinical+trial+&author=G+Daniele&author=P+Iozzo&author=M+Molina%E2%80%90Wilkins&author=J+Lancaster&author=D+Ciociaro&author=C+Triplitt&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0072"> <div class="citation-journal">Daniele G, Molina‐Wilkins M, Lancaster J, Ciociaro D, Triplitt C, Cersosimo E, et al. <span class="citation-title">Exenatide affects the distribution of cerebral postprandial glucose uptake: a double‐blind, randomized clinical trial</span>. <span class="citation"> Diabetes </span><span class="pubYear">2014</span>;<span class="volume">63</span>:A85. <a class="crsref citation-link central-link" data-crsref="5606928" href="" ref="info:x-wiley/crsRef/5606928" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Exenatide+affects+the+distribution+of+cerebral+postprandial+glucose+uptake:+a+double%E2%80%90blind,+randomized+clinical+trial+&author=G+Daniele&author=M+Molina%E2%80%90Wilkins&author=J+Lancaster&author=D+Ciociaro&author=C+Triplitt&author=E+Cersosimo&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0073"> <div class="citation-other">NCT01588418. <span class="citation-title">Effect of exenatide on brain, adipose tissue, pancreas, and liver function</span>. clinicaltrials.gov/ct2/show/NCT01588418 Date first received: 19 March 2012. <a class="crsref citation-link central-link" data-crsref="5606929" href="" ref="info:x-wiley/crsRef/5606929" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0018"> <div class="reference-title-banner"> <h4 class="title">Dushay 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0074"> <div class="citation-journal">Dushay J, Gao C, Gopalakrishnan GS, Crawley M, Mitten EK, Wilker E, et al. <span class="citation-title">Short‐term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2012</span>;<span class="volume">35</span>(1):4‐11. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.2337/dc11-0931" target="_blank"><span>10.2337/dc11‐0931</span></a>]<a class="crsref citation-link central-link" data-crsref="5606931" href="" ref="info:x-wiley/crsRef/5606931" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22040840" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Short%E2%80%90term+exenatide+treatment+leads+to+significant+weight+loss+in+a+subset+of+obese+women+without+diabetes+&author=J+Dushay&author=C+Gao&author=GS+Gopalakrishnan&author=M+Crawley&author=EK+Mitten&author=E+Wilker&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0075"> <div class="citation-other">NCT00456885. <span class="citation-title">The effect of exenatide on weight and hunger in obese, healthy women</span>. clinicaltrials.gov/ct2/show/NCT00456885 Date first received: 4 April 2007. <a class="crsref citation-link central-link" data-crsref="5606932" href="" ref="info:x-wiley/crsRef/5606932" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0019"> <div class="reference-title-banner"> <h4 class="title">EudraCT 2011‐005980‐26 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0076"> <div class="citation-other">EudraCT 2011‐005980‐26. <span class="citation-title">Metformin and sitagliptin in patients with impaired glucose tolerance and a recent TIA or minor ischemic stroke ‐ a multicenter, randomized, open‐label phase II trial</span>. www.clinicaltrialsregister.eu/ctr‐search/trial/2011‐005980‐26/NL Date first registered: 13 February 2012. <a class="crsref citation-link central-link" data-crsref="5606934" href="" ref="info:x-wiley/crsRef/5606934" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0077"> <div class="citation-journal">Osei E, Fonville S, Zandbergen AA, Brouwers PJ, Mulder LJ, Lingsma HF, et al. <span class="citation-title">Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial</span>. <span class="citation"> Trials </span><span class="pubYear">2015</span>;<span class="volume">16</span>:332. [PUBMED: 26242578]<a class="crsref citation-link central-link" data-crsref="5606935" href="" ref="info:x-wiley/crsRef/5606935" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26242578" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Metformin+and+sitAgliptin+in+patients+with+impAired+glucose+tolerance+and+a+recent+TIA+or+minor+ischemic+Stroke+(MAAS):+study+protocol+for+a+randomized+controlled+trial+&author=E+Osei&author=S+Fonville&author=AA+Zandbergen&author=PJ+Brouwers&author=LJ+Mulder&author=HF+Lingsma&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0020"> <div class="reference-title-banner"> <h4 class="title">EudraCT 2013‐001240‐64 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0078"> <div class="citation-other">EudraCT 2013‐001240‐64. <span class="citation-title">Effect of intact GLP‐1 (7‐36) and GLP‐1 metabolite (9‐36) on coronary microvascular function in adults with prediabetes</span>. www.clinicaltrialsregister.eu/ctr‐search/search?query=2013‐001240‐64 (accessed 5 April 2016). <a class="crsref citation-link central-link" data-crsref="5606937" href="" ref="info:x-wiley/crsRef/5606937" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0021"> <div class="reference-title-banner"> <h4 class="title">Gonzalez‐Ortiz 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0079"> <div class="citation-other">Gonzalez‐Ortiz M, Perez‐Rubio KG, Martinezabundis E. <span class="citation-title">Lixisenatide vs. exenatide on metabolic control, insulin secretion, and insulin sensitivity in impaired glucose tolerance patients</span>. Diabetes<span class="pubYear">2015</span>; Vol. 64:A297. <a class="crsref citation-link central-link" data-crsref="5606939" href="" ref="info:x-wiley/crsRef/5606939" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Lixisenatide+vs.+exenatide+on+metabolic+control,+insulin+secretion,+and+insulin+sensitivity+in+impaired+glucose+tolerance+patients+&author=M+Gonzalez%E2%80%90Ortiz&author=KG+Perez%E2%80%90Rubio&author=E+Martinezabundis&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0022"> <div class="reference-title-banner"> <h4 class="title">Gudipaty 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0080"> <div class="citation-other"><span class="citation-title">Effect of exenatide, sitagliptin or glimepiride on functional β‐cell mass</span>. clinicaltrials.gov/ct2/show/NCT00775684 Date first received: 17 October 2008. <a class="crsref citation-link central-link" data-crsref="5606941" href="" ref="info:x-wiley/crsRef/5606941" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0081"> <div class="citation-other">Gudipaty L, Fuller C, Rosenfeld N, Rickels MR. <span class="citation-title">No effect of exenatide or sitagliptin therapy on beta‐cell secretory capacity in early type 2 diabetes</span>. Diabetes<span class="pubYear">2013</span>; Vol. 62:A288. <a class="crsref citation-link central-link" data-crsref="5606942" href="" ref="info:x-wiley/crsRef/5606942" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=No+effect+of+exenatide+or+sitagliptin+therapy+on+beta%E2%80%90cell+secretory+capacity+in+early+type+2+diabetes+&author=L+Gudipaty&author=C+Fuller&author=N+Rosenfeld&author=MR+Rickels&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0082"> <div class="citation-journal">Gudipaty L, Rosenfeld NK, Fuller CS, Gallop R, Schutta MH, Rickels MR. <span class="citation-title">Effect of exenatide, sitagliptin, or glimepiride on beta‐cell secretory capacity in early type 2 diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2014</span>;<span class="volume">37</span>(9):2451‐8. [PUBMED: 24969577]<a class="crsref citation-link central-link" data-crsref="5606943" href="" ref="info:x-wiley/crsRef/5606943" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24969577" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+exenatide,+sitagliptin,+or+glimepiride+on+beta%E2%80%90cell+secretory+capacity+in+early+type+2+diabetes+&author=L+Gudipaty&author=NK+Rosenfeld&author=CS+Fuller&author=R+Gallop&author=MH+Schutta&author=MR+Rickels&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0023"> <div class="reference-title-banner"> <h4 class="title">Ishikawa 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0083"> <div class="citation-journal">Ishikawa S, Shimano M, Watarai M, Koyasu M, Uchikawa T, Ishii H, et al. <span class="citation-title">Impact of sitagliptin on carotid intima‐media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus</span>. <span class="citation"> American Journal of Cardiology </span><span class="pubYear">2014</span>;<span class="volume">114</span>(3):384‐8. [PUBMED: 24929624]<a class="crsref citation-link central-link" data-crsref="5606945" href="" ref="info:x-wiley/crsRef/5606945" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24929624" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Impact+of+sitagliptin+on+carotid+intima%E2%80%90media+thickness+in+patients+with+coronary+artery+disease+and+impaired+glucose+tolerance+or+mild+diabetes+mellitus+&author=S+Ishikawa&author=M+Shimano&author=M+Watarai&author=M+Koyasu&author=T+Uchikawa&author=H+Ishii&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0024"> <div class="reference-title-banner"> <h4 class="title">Kaku 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0084"> <div class="citation-journal">Kaku K, Kadowaki T, Terauchi Y, Okamoto T, Sato A, Okuyama K, et al. <span class="citation-title">Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance</span>. <span class="citation"> Diabetes, Obesity &amp; Metabolism </span><span class="pubYear">2015</span>;<span class="volume">17</span>(11):1033‐41. [PUBMED: 26094974]<a class="crsref citation-link central-link" data-crsref="5606947" href="" ref="info:x-wiley/crsRef/5606947" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26094974" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sitagliptin+improves+glycaemic+excursion+after+a+meal+or+after+an+oral+glucose+load+in+Japanese+subjects+with+impaired+glucose+tolerance+&author=K+Kaku&author=T+Kadowaki&author=Y+Terauchi&author=T+Okamoto&author=A+Sato&author=K+Okuyama&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0085"> <div class="citation-other">NCT01405911. <span class="citation-title">Dose response finding study of MK‐0431/ONO‐5435 in Japanese subjects with impaired glucose tolerance (MK‐0431‐105)</span>. clinicaltrials.gov/ct2/show/NCT01405911 Date first received: 28 July 2011. <a class="crsref citation-link central-link" data-crsref="5606948" href="" ref="info:x-wiley/crsRef/5606948" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0025"> <div class="reference-title-banner"> <h4 class="title">Koska 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0086"> <div class="citation-journal">Koska J, Sands M, Burciu C, D'Souza KM, Raravikar K, Liu J, et al. <span class="citation-title">Exenatide protects against glucose‐ and lipid‐induced endothelial dysfunction: evidence for direct vasodilation effect of GLP‐1 receptor agonists in humans</span>. <span class="citation"> Diabetes </span><span class="pubYear">2015</span>;<span class="volume">64</span>(7):2624‐35. [PUBMED: 25720388]<a class="crsref citation-link central-link" data-crsref="5606950" href="" ref="info:x-wiley/crsRef/5606950" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25720388" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Exenatide+protects+against+glucose%E2%80%90+and+lipid%E2%80%90induced+endothelial+dysfunction:+evidence+for+direct+vasodilation+effect+of+GLP%E2%80%901+receptor+agonists+in+humans+&author=J+Koska&author=M+Sands&author=C+Burciu&author=KM+D'Souza&author=K+Raravikar&author=J+Liu&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0087"> <div class="citation-other">NCT01181986. <span class="citation-title">The study of exenatide action on vessel function in type 2 diabetes and prediabetes</span>. clinicaltrials.gov/ct2/show/NCT01181986 Date first received: 13 August 2010. <a class="crsref citation-link central-link" data-crsref="5606951" href="" ref="info:x-wiley/crsRef/5606951" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0026"> <div class="reference-title-banner"> <h4 class="title">Larsen 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0088"> <div class="citation-journal">Larsen JR, Vedtofte L, Holst JJ, Oturai P, Kjaer A, Correll CU, et al. <span class="citation-title">Does a GLP‐1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double‐blinded, placebo‐controlled clinical trial</span>. <span class="citation"> BMJ Open </span><span class="pubYear">2014</span>;<span class="volume">4</span>(3):e004227. [PUBMED: 24667381]<a class="crsref citation-link central-link" data-crsref="5606953" href="" ref="info:x-wiley/crsRef/5606953" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24667381" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Does+a+GLP%E2%80%901+receptor+agonist+change+glucose+tolerance+in+patients+treated+with+antipsychotic+medications?+Design+of+a+randomised,+double%E2%80%90blinded,+placebo%E2%80%90controlled+clinical+trial+&author=JR+Larsen&author=L+Vedtofte&author=JJ+Holst&author=P+Oturai&author=A+Kjaer&author=CU+Correll&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0027"> <div class="reference-title-banner"> <h4 class="title">NCT00101712 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0089"> <div class="citation-other">NCT00101712. <span class="citation-title">Efficacy and safety of vildagliptin compared to placebo in patients with type 2 diabetes and mild hyperglycemia</span>. clinicaltrials.gov/ct2/show/NCT00101712 Date first received: 12 January 2005. <a class="crsref citation-link central-link" data-crsref="5606955" href="" ref="info:x-wiley/crsRef/5606955" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0028"> <div class="reference-title-banner"> <h4 class="title">NCT00198146 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0090"> <div class="citation-other">NCT00198146. <span class="citation-title">Prevention of Diabetes Progression Trial (PDPT)</span>. clinicaltrials.gov/ct2/show/NCT00198146 Date first received: 12 September 2005. <a class="crsref citation-link central-link" data-crsref="5606957" href="" ref="info:x-wiley/crsRef/5606957" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0029"> <div class="reference-title-banner"> <h4 class="title">NCT00721552 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0091"> <div class="citation-other">NCT00721552. <span class="citation-title">Sitagliptin prophylaxis for glucocorticoid‐induced impairment of glucose metabolism in males with the metabolic syndrome (SPHINX)</span>. clinicaltrials.gov/ct2/show/NCT00721552 Date first received: 22 July 2008. <a class="crsref citation-link central-link" data-crsref="5606959" href="" ref="info:x-wiley/crsRef/5606959" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0030"> <div class="reference-title-banner"> <h4 class="title">NCT00845182 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0092"> <div class="citation-other">NCT00845182. <span class="citation-title">Effect of pioglitazone and exenatide on body weight and beta cell function (PIO‐EX)</span>. clinicaltrials.gov/ct2/show/study/NCT00845182 Date first received: 17 February 2009. <a class="crsref citation-link central-link" data-crsref="5606961" href="" ref="info:x-wiley/crsRef/5606961" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0031"> <div class="reference-title-banner"> <h4 class="title">NCT00845559 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0093"> <div class="citation-other">NCT00845559. <span class="citation-title">The effects of exenatide on post‐meal sugar peaks and vascular health in obese/pre‐diabetic young adults</span>. clinicaltrials.gov/ct2/show/NCT00845559 Date first received: 16 February 2009. <a class="crsref citation-link central-link" data-crsref="5606963" href="" ref="info:x-wiley/crsRef/5606963" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0032"> <div class="reference-title-banner"> <h4 class="title">NCT00886626 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0094"> <div class="citation-other">NCT00886626. <span class="citation-title">GLP‐1 therapy for weight loss and improved glucose tolerance in obese children</span>. clinicaltrials.gov/ct2/show/NCT00886626 Date first received: 22 April 2009. <a class="crsref citation-link central-link" data-crsref="5606965" href="" ref="info:x-wiley/crsRef/5606965" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0033"> <div class="reference-title-banner"> <h4 class="title">NCT00961363 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0095"> <div class="citation-other">NCT00961363. <span class="citation-title">Effect of sitagliptin in impaired glucose tolerance</span>. clinicaltrials.gov/ct2/show/NCT00961363 Date first received: 11 August 2009. <a class="crsref citation-link central-link" data-crsref="5606967" href="" ref="info:x-wiley/crsRef/5606967" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0034"> <div class="reference-title-banner"> <h4 class="title">NCT01006018 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0096"> <div class="citation-other">NCT01006018. <span class="citation-title">DPP‐4 Inhibition and TZD for DM Prevention (DInT DM)</span>. clinicaltrials.gov/ct2/show/NCT01006018 Date first received: 27 October 2009. <a class="crsref citation-link central-link" data-crsref="5606969" href="" ref="info:x-wiley/crsRef/5606969" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0035"> <div class="reference-title-banner"> <h4 class="title">NCT01018602 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0097"> <div class="citation-other">NCT01018602. <span class="citation-title">PINGUIN (Postpartum Intervention in Women with Gestational Diabetes Using Insulin)</span>. clinicaltrials.gov/ct2/show/NCT01018602 Date first received: 20 November 2009. <a class="crsref citation-link central-link" data-crsref="5606971" href="" ref="info:x-wiley/crsRef/5606971" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0036"> <div class="reference-title-banner"> <h4 class="title">NCT01038648 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0098"> <div class="citation-other">NCT01038648. <span class="citation-title">Sitagliptin in Prevention of Type 2 Diabetes Mellitus (SITAGLIPTIN)</span>. clinicaltrials.gov/ct2/show/NCT01038648 Date first received: 22 December 2009. <a class="crsref citation-link central-link" data-crsref="5606973" href="" ref="info:x-wiley/crsRef/5606973" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0037"> <div class="reference-title-banner"> <h4 class="title">NCT01054118 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0099"> <div class="citation-other">NCT01054118. <span class="citation-title">A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of JNJ‐38431055, sitagliptin, and co‐administration of JNJ‐38431055 and sitagliptin</span>. clinicaltrials.gov/ct2/show/NCT01054118 Date first received: 15 January 2010. <a class="crsref citation-link central-link" data-crsref="5606975" href="" ref="info:x-wiley/crsRef/5606975" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0038"> <div class="reference-title-banner"> <h4 class="title">NCT01122641 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0100"> <div class="citation-other">NCT01122641. <span class="citation-title">The vascular effects of vildagliptin in insulin resistant individuals</span>. clinicaltrials.gov/ct2/show/NCT01122641 Date first received: 12 May 2010. <a class="crsref citation-link central-link" data-crsref="5606977" href="" ref="info:x-wiley/crsRef/5606977" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0039"> <div class="reference-title-banner"> <h4 class="title">NCT01346254 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0101"> <div class="citation-other">NCT01346254. <span class="citation-title">Glucose control in pre‐diabetic renal transplant patients (GCPD)</span>. clinicaltrials.gov/ct2/show/NCT01346254 Date first received: 29 April 2011. <a class="crsref citation-link central-link" data-crsref="5606979" href="" ref="info:x-wiley/crsRef/5606979" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0040"> <div class="reference-title-banner"> <h4 class="title">NCT01472640 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0102"> <div class="citation-other">NCT01472640. <span class="citation-title">The effect of liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes mellitus</span>. clinicaltrials.gov/ct2/show/NCT01472640 Date first received: 11 November 2011. <a class="crsref citation-link central-link" data-crsref="5606981" href="" ref="info:x-wiley/crsRef/5606981" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0041"> <div class="reference-title-banner"> <h4 class="title">NCT01845259 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0103"> <div class="citation-other">NCT01845259. <span class="citation-title">Does a GLP‐1 receptor agonist change glucose tolerance in antipsychotic‐treated patients? (GREAT)</span>. clinicaltrials.gov/ct2/show/NCT01845259 Date first received: 14 April 2013. <a class="crsref citation-link central-link" data-crsref="5606983" href="" ref="info:x-wiley/crsRef/5606983" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0042"> <div class="reference-title-banner"> <h4 class="title">NCT01970462 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0104"> <div class="citation-other">NCT01970462. <span class="citation-title">Use of sitagliptin for stress hyperglycemia or mild diabetes following cardiac surgery</span>. clinicaltrials.gov/ct2/show/NCT01970462 Date first received: 22 October 2013. <a class="crsref citation-link central-link" data-crsref="5606985" href="" ref="info:x-wiley/crsRef/5606985" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0043"> <div class="reference-title-banner"> <h4 class="title">NCT02016846 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0105"> <div class="citation-other">NCT02016846. <span class="citation-title">Liraglutide efficacy on glucocorticoid induced hyperglycemia in patients high risk for diabetes</span>. clinicaltrials.gov/ct2/show/NCT02016846 Date first received: 15 December 2013. <a class="crsref citation-link central-link" data-crsref="5606987" href="" ref="info:x-wiley/crsRef/5606987" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0044"> <div class="reference-title-banner"> <h4 class="title">NCT02022007 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0106"> <div class="citation-other">NCT02022007. <span class="citation-title">Saxagliptin + metformin compared to saxagliptin or metformin monotherapy in PCOS women Wwith impaired glucose homeostasis (BMS‐AZPCOS)</span>. clinicaltrials.gov/ct2/show/NCT02022007 Date first received: 17 December 2013. [NCT02022007]<a class="crsref citation-link central-link" data-crsref="5606989" href="" ref="info:x-wiley/crsRef/5606989" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0045"> <div class="reference-title-banner"> <h4 class="title">NCT02284230 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0107"> <div class="citation-other">2014‐001778‐32/DK. <span class="citation-title">The LiRA2 study</span>. www.clinicaltrialsregister.eu/ctr‐search/trial/2014‐001778‐32/DK Date first registered: 17 June 2014. <a class="crsref citation-link central-link" data-crsref="5606991" href="" ref="info:x-wiley/crsRef/5606991" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0108"> <div class="citation-other">NCT02284230. <span class="citation-title">The effect of liraglutide in patients with prediabetes and kidney failure (LiRA2)</span>. clinicaltrials.gov/ct2/show/NCT02284230 Date first received: 3 November 2014. <a class="crsref citation-link central-link" data-crsref="5606992" href="" ref="info:x-wiley/crsRef/5606992" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0046"> <div class="reference-title-banner"> <h4 class="title">NCT02446834 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0109"> <div class="citation-other">NCT02446834. <span class="citation-title">Research of intensive lifestyle Intervention for PCOS patients with IGT</span>. clinicaltrials.gov/ct2/show/NCT02446834 Date first received: 6 May 2015. <a class="crsref citation-link central-link" data-crsref="5606994" href="" ref="info:x-wiley/crsRef/5606994" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0047"> <div class="reference-title-banner"> <h4 class="title">Schwartz 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0110"> <div class="citation-journal">Koska J, Sands M, Burciu C, D'Souza KM, Raravikar K, Liu J, et al. <span class="citation-title">Exenatide protects against glucose‐ and lipid‐induced endothelial dysfunction: evidence for direct vasodilation effect of GLP‐1 receptor agonists in humans</span>. <span class="citation"> Diabetes </span><span class="pubYear">2015</span>;<span class="volume">64</span>(7):2624‐35. [PUBMED: 25720388]<a class="crsref citation-link central-link" data-crsref="5606996" href="" ref="info:x-wiley/crsRef/5606996" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25720388" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Exenatide+protects+against+glucose%E2%80%90+and+lipid%E2%80%90induced+endothelial+dysfunction:+evidence+for+direct+vasodilation+effect+of+GLP%E2%80%901+receptor+agonists+in+humans+&author=J+Koska&author=M+Sands&author=C+Burciu&author=KM+D'Souza&author=K+Raravikar&author=J+Liu&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0111"> <div class="citation-journal">Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD. <span class="citation-title">Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent‐onset type 2 diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2010</span>;<span class="volume">33</span>(5):1028‐30. [PUBMED: 20200309]<a class="crsref citation-link central-link" data-crsref="5606997" href="" ref="info:x-wiley/crsRef/5606997" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20200309" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Improvement+of+postprandial+endothelial+function+after+a+single+dose+of+exenatide+in+individuals+with+impaired+glucose+tolerance+and+recent%E2%80%90onset+type+2+diabetes+&author=J+Koska&author=EA+Schwartz&author=MP+Mullin&author=DC+Schwenke&author=PD+Reaven&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0112"> <div class="citation-journal">Mullin MP, Koska J, Schwartz EA, Schwenke DC, Reaven PD. <span class="citation-title">Acute administration of exenatide improves endothelial function following a high‐fat meal</span>. <span class="citation"> Diabetes </span><span class="pubYear">2009</span>;<span class="volume">58</span>:P‐640. <a class="crsref citation-link central-link" data-crsref="5606998" href="" ref="info:x-wiley/crsRef/5606998" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Acute+administration+of+exenatide+improves+endothelial+function+following+a+high%E2%80%90fat+meal+&author=MP+Mullin&author=J+Koska&author=EA+Schwartz&author=DC+Schwenke&author=PD+Reaven&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0113"> <div class="citation-other">Schwartz EA, Koska J, Mullin MP, Schwenke DC, Reaven PD. <span class="citation-title">Effects of acute exenatide administration on postprandial lipids and lipoproteins in individuals with impaired glucose metabolism</span>. Diabetes<span class="pubYear">2009</span>; Vol. 58:375‐OR. <a class="crsref citation-link central-link" data-crsref="5606999" href="" ref="info:x-wiley/crsRef/5606999" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+acute+exenatide+administration+on+postprandial+lipids+and+lipoproteins+in+individuals+with+impaired+glucose+metabolism+&author=EA+Schwartz&author=J+Koska&author=MP+Mullin&author=DC+Schwenke&author=PD+Reaven&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0114"> <div class="citation-journal">Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD. <span class="citation-title">Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus</span>. <span class="citation"> Atherosclerosis </span><span class="pubYear">2010</span>;<span class="volume">212</span>(1):217‐22. [PUBMED: 20557887]<a class="crsref citation-link central-link" data-crsref="5607000" href="" ref="info:x-wiley/crsRef/5607000" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20557887" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Exenatide+suppresses+postprandial+elevations+in+lipids+and+lipoproteins+in+individuals+with+impaired+glucose+tolerance+and+recent+onset+type+2+diabetes+mellitus+&author=EA+Schwartz&author=J+Koska&author=MP+Mullin&author=I+Syoufi&author=DC+Schwenke&author=PD+Reaven&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0048"> <div class="reference-title-banner"> <h4 class="title">Tsuchiya 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0115"> <div class="citation-journal">Aramaki M. <span class="citation-title">Alogliptin, but not voglibose, ameliorates dyslipidemia and LDL particle size in patients with impaired glucose tolerance or Type 2 diabetes</span>. <span class="citation"> Clinical Lipidology </span><span class="pubYear">2013</span>;<span class="volume">8</span>(5):533‐40. <a class="crsref citation-link central-link" data-crsref="5607002" href="" ref="info:x-wiley/crsRef/5607002" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Alogliptin,+but+not+voglibose,+ameliorates+dyslipidemia+and+LDL+particle+size+in+patients+with+impaired+glucose+tolerance+or+Type+2+diabetes+&author=M+Aramaki&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0117"> <div class="citation-journal">Tsuchiya M. <span class="citation-title">Alogliptin ameliorates dyslipidemia and LDL‐size in patients with IGT or type 2 diabetes: comparing alogliptin and voglibose</span>. <span class="citation"> Diabetes </span><span class="pubYear">2011</span>;<span class="volume">60</span>:A280. <a class="crsref citation-link central-link" data-crsref="5607004" href="" ref="info:x-wiley/crsRef/5607004" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Alogliptin+ameliorates+dyslipidemia+and+LDL%E2%80%90size+in+patients+with+IGT+or+type+2+diabetes:+comparing+alogliptin+and+voglibose+&author=M+Tsuchiya&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0118"> <div class="citation-journal">Tsuchiya M. <span class="citation-title">Alogliptin decreases liver fat content in patients with IGT or type Q2 DM: comparing alogliptin and voglibose</span>. <span class="citation"> Diabetes </span><span class="pubYear">2011</span>;<span class="volume">60</span>:A595. <a class="crsref citation-link central-link" data-crsref="5607005" href="" ref="info:x-wiley/crsRef/5607005" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Alogliptin+decreases+liver+fat+content+in+patients+with+IGT+or+type+Q2+DM:+comparing+alogliptin+and+voglibose+&author=M+Tsuchiya&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0116"> <div class="citation-journal">Tsuchiya M, Maegawa H. <span class="citation-title">DPP4 inhibition ameliorates intramuscular fat content in patients with IGT or type 2 DM: comparing alogliptin and voglibose</span>. <span class="citation"> Diabetes </span><span class="pubYear">2013</span>;<span class="volume">62</span>:A297. <a class="crsref citation-link central-link" data-crsref="5607003" href="" ref="info:x-wiley/crsRef/5607003" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=DPP4+inhibition+ameliorates+intramuscular+fat+content+in+patients+with+IGT+or+type+2+DM:+comparing+alogliptin+and+voglibose+&author=M+Tsuchiya&author=H+Maegawa&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0049"> <div class="reference-title-banner"> <h4 class="title">UMIN000006197 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0119"> <div class="citation-other">UMIN000006197. <span class="citation-title">Therapeutic efficacy of sitagliptin in patients with nonalcoholic fatty liver disease (NAFLD) in impaired glucose tolerance (IGT): a pilot study</span>. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;recptno=R000007311&amp;type=summary&amp;language=E Date first registered: 1 September 2011. <a class="crsref citation-link central-link" data-crsref="5607007" href="" ref="info:x-wiley/crsRef/5607007" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0050"> <div class="reference-title-banner"> <h4 class="title">UMIN000014249 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0120"> <div class="citation-other">UMIN000014249. <span class="citation-title">Efficacy and safety of combination therapy with GLP‐1 analog lixisenatide and long‐acting insulin glargine in patients with glucose intolerance or diabetes caused by hyposecretion of endogenous insulin who underwent partial pancreatectomy</span>. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000016598&amp;language=E Date first registered: 12 June 2014. <a class="crsref citation-link central-link" data-crsref="5607009" href="" ref="info:x-wiley/crsRef/5607009" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0051"> <div class="reference-title-banner"> <h4 class="title">Utzschneider 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0121"> <div class="citation-other">NCT00312130. <span class="citation-title">A study to evaluate the effects of vildagliptin on the insulin response to glucose in subjects with pre‐diabetes</span>. clinicaltrials.gov/ct2/show/NCT00312130 Date first received: 6 April 2006. <a class="crsref citation-link central-link" data-crsref="5607011" href="" ref="info:x-wiley/crsRef/5607011" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0122"> <div class="citation-journal">Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, et al. <span class="citation-title">The dipeptidyl peptidase‐4 inhibitor vildagliptin improves beta‐cell function and insulin sensitivity in subjects with impaired fasting glucose</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2008</span>;<span class="volume">31</span>(1):108‐13. [PUBMED: 17909087]<a class="crsref citation-link central-link" data-crsref="5607012" href="" ref="info:x-wiley/crsRef/5607012" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17909087" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+dipeptidyl+peptidase%E2%80%904+inhibitor+vildagliptin+improves+beta%E2%80%90cell+function+and+insulin+sensitivity+in+subjects+with+impaired+fasting+glucose+&author=KM+Utzschneider&author=J+Tong&author=B+Montgomery&author=J+Udayasankar&author=F+Gerchman&author=SM+Marcovina&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD012204-bbs2-0052"> <div class="reference-title-banner"> <h4 class="title">Werzowa 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0123"> <div class="citation-journal">Werzowa J, Hecking M, Haidinger M, Lechner F, Doller D, Pacini G, et al. <span class="citation-title">Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo‐controlled clinical trial</span>. <span class="citation"> Transplantation </span><span class="pubYear">2013</span>;<span class="volume">95</span>(3):456‐62. [PUBMED: 23380864]<a class="crsref citation-link central-link" data-crsref="5607014" href="" ref="info:x-wiley/crsRef/5607014" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23380864" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Vildagliptin+and+pioglitazone+in+patients+with+impaired+glucose+tolerance+after+kidney+transplantation:+a+randomized,+placebo%E2%80%90controlled+clinical+trial+&author=J+Werzowa&author=M+Hecking&author=M+Haidinger&author=F+Lechner&author=D+Doller&author=G+Pacini&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD012204-bbs1-0003"> <h3 class="title">References to studies awaiting assessment</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD012204-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD012204-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD012204-bbs1-0004">ongoing studies</a></li> <li><a class="jump-to" href="#CD012204-bbs1-0005">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD012204-bbs2-0053"> <div class="reference-title-banner"> <h4 class="title">Astrup 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0124"> <div class="citation-journal">Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, et al. <span class="citation-title">Safety, tolerability and sustained weight loss over 2 years with the once‐daily human GLP‐1 analog, liraglutide</span>. <span class="citation"> International Journal of Obesity (2005) </span><span class="pubYear">2012</span>;<span class="volume">36</span>(6):843‐54. [PUBMED: 21844879]<a class="crsref citation-link central-link" data-crsref="5607016" href="" ref="info:x-wiley/crsRef/5607016" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21844879" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Safety,+tolerability+and+sustained+weight+loss+over+2+years+with+the+once%E2%80%90daily+human+GLP%E2%80%901+analog,+liraglutide+&author=A+Astrup&author=R+Carraro&author=N+Finer&author=A+Harper&author=M+Kunesova&author=ME+Lean&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0125"> <div class="citation-journal">Astrup A, Rossner S, Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. <span class="citation-title">Effects of liraglutide in the treatment of obesity: a randomised, double‐blind, placebo‐controlled study</span>. <span class="citation"> Lancet </span><span class="pubYear">2009</span>;<span class="volume">374</span>(9701):1606‐16. [PUBMED: 19853906]<a class="crsref citation-link central-link" data-crsref="5607017" href="" ref="info:x-wiley/crsRef/5607017" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19853906" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+liraglutide+in+the+treatment+of+obesity:+a+randomised,+double%E2%80%90blind,+placebo%E2%80%90controlled+study+&author=A+Astrup&author=S+Rossner&author=L+Gaal&author=A+Rissanen&author=L+Niskanen&author=M+AlHakim&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0126"> <div class="citation-other">EudraCT 2006‐004481‐13. <span class="citation-title">Effect of liraglutide on body weight in obese subjects without diabetes. A 20‐week randomised, double‐blind, placebo‐controlled, six armed parallel group, multi‐centre, multinational trial with an open label orlistat comparator arm with an 84 week extension period</span>. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004481‐13/DK Date first received: 3 October 2006. <a class="crsref citation-link central-link" data-crsref="5607018" href="" ref="info:x-wiley/crsRef/5607018" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0127"> <div class="citation-journal">Finer N, Astrup A, Carraro R, Hartvig H, Kunesova M, Lean ME, et al. <span class="citation-title">Liraglutide once daily reduces the prevalence of prediabetes and metabolic syndrome in obese non‐diabetic adults over two years</span>. <span class="citation"> Journal of Diabetes </span><span class="pubYear">2011</span>;<span class="volume">3</span>:30. <a class="crsref citation-link central-link" data-crsref="5607019" href="" ref="info:x-wiley/crsRef/5607019" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+once+daily+reduces+the+prevalence+of+prediabetes+and+metabolic+syndrome+in+obese+non%E2%80%90diabetic+adults+over+two+years+&author=N+Finer&author=A+Astrup&author=R+Carraro&author=H+Hartvig&author=M+Kunesova&author=ME+Lean&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0128"> <div class="citation-journal">Finer N, Hakim MA, Astrup A, Harper A, Lean M, Niskanen L, et al. <span class="citation-title">Liraglutide, a once‐daily human GLP‐1 analog, reverses indices of prediabetes in obese subjects: a randomized placebo‐controlled 20‐week trial</span>. <span class="citation"> Diabetes </span><span class="pubYear">2009</span>;<span class="volume">58</span>. <a class="crsref citation-link central-link" data-crsref="5607020" href="" ref="info:x-wiley/crsRef/5607020" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide,+a+once%E2%80%90daily+human+GLP%E2%80%901+analog,+reverses+indices+of+prediabetes+in+obese+subjects:+a+randomized+placebo%E2%80%90controlled+20%E2%80%90week+trial+&author=N+Finer&author=MA+Hakim&author=A+Astrup&author=A+Harper&author=M+Lean&author=L+Niskanen&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0129"> <div class="citation-journal">Finer N, Hakim MA, Astrup A, Harper A, Lean M, Niskanen, L, et al. <span class="citation-title">Liraglutide, a once‐daily human GLP‐1 analogue, reduces the prevalence of prediabetes in obese subjects over 20 weeks: a randomized placebo‐controlled trial</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2009</span>;<span class="volume">52</span>(0):S11‐2. <a class="crsref citation-link central-link" data-crsref="5607021" href="" ref="info:x-wiley/crsRef/5607021" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide,+a+once%E2%80%90daily+human+GLP%E2%80%901+analogue,+reduces+the+prevalence+of+prediabetes+in+obese+subjects+over+20+weeks:+a+randomized+placebo%E2%80%90controlled+trial+&author=N+Finer&author=MA+Hakim&author=A+Astrup&author=A+Harper&author=M+Lean&author=+Niskanen&author=+L&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0130"> <div class="citation-journal">Lean ME, Carraro R, Finer N, Hartvig H, Lindegaard ML, Rossner S, et al. <span class="citation-title">Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non‐diabetic adults</span>. <span class="citation"> International Journal of Obesity </span><span class="pubYear">2014</span>;<span class="volume">38</span>(5):689‐97. [PUBMED: 23942319]<a class="crsref citation-link central-link" data-crsref="5607022" href="" ref="info:x-wiley/crsRef/5607022" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23942319" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Tolerability+of+nausea+and+vomiting+and+associations+with+weight+loss+in+a+randomized+trial+of+liraglutide+in+obese,+non%E2%80%90diabetic+adults+&author=ME+Lean&author=R+Carraro&author=N+Finer&author=H+Hartvig&author=ML+Lindegaard&author=S+Rossner&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0131"> <div class="citation-other">NCT00422058. <span class="citation-title">The effect of liraglutide on body weight in obese subjects without diabetes</span>. clinicaltrials.gov/ct2/show/NCT00422058 Date first received: 12 January 2007. <a class="crsref citation-link central-link" data-crsref="5607023" href="" ref="info:x-wiley/crsRef/5607023" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0132"> <div class="citation-other">NN8022‐1807. <span class="citation-title">The effect of liraglutide on body weight in obese subjects without diabetes</span>. www.novonordisk‐trials.com/Website/pdf/registry/nn80221807.pdf (assessed 3 July 2016). <a class="crsref citation-link central-link" data-crsref="5607024" href="" ref="info:x-wiley/crsRef/5607024" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0133"> <div class="citation-journal">Niskanen L, Astrup A, Hakim MA, Carraro R, Finer N, Hartvig H, et al. <span class="citation-title">Liraglutide once daily reduces the prevalence of prediabetes and metabolic syndrome in obese non‐diabetic adults: a 2‐year randomized trial</span>. <span class="citation"> Obesity </span><span class="pubYear">2010</span>;<span class="volume">18</span>:S56. <a class="crsref citation-link central-link" data-crsref="5607025" href="" ref="info:x-wiley/crsRef/5607025" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+once+daily+reduces+the+prevalence+of+prediabetes+and+metabolic+syndrome+in+obese+non%E2%80%90diabetic+adults:+a+2%E2%80%90year+randomized+trial+&author=L+Niskanen&author=A+Astrup&author=MA+Hakim&author=R+Carraro&author=N+Finer&author=H+Hartvig&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0134"> <div class="citation-other">Synopsis NN8022‐1807. <span class="citation-title">Effect of liraglutide on body weight in obese subjects without diabetes. A 20‐week randomised, double‐blind, placebo‐controlled, six armed parallel group, multi‐centre, multinational trial with an open label orlistat comparator arm with an 84 week extension period</span>. novonordisk‐trials.com/website/pdf/registry/bin_20110928‐123116‐617.pdf (assessed 3 July 2016). <a class="crsref citation-link central-link" data-crsref="5607026" href="" ref="info:x-wiley/crsRef/5607026" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD012204-bbs2-0054"> <div class="reference-title-banner"> <h4 class="title">NCT01521312 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0135"> <div class="citation-other">NCT01521312. <span class="citation-title">Acute and chronic effects of saxagliptin (ACCES)</span>. clinicaltrials.gov/ct2/show/NCT01521312 Date first received: 22 November 2011. <a class="crsref citation-link central-link" data-crsref="5607028" href="" ref="info:x-wiley/crsRef/5607028" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD012204-bbs2-0055"> <div class="reference-title-banner"> <h4 class="title">NCT01960205 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0136"> <div class="citation-other">NCT01960205. <span class="citation-title">Effect of saxagliptin on pre‐diabetes mellitus and obesity</span>. clinicaltrials.gov/ct2/show/NCT01960205 Date first received: 7 October 2013. <a class="crsref citation-link central-link" data-crsref="5607030" href="" ref="info:x-wiley/crsRef/5607030" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD012204-bbs2-0056"> <div class="reference-title-banner"> <h4 class="title">NCT02294084 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0137"> <div class="citation-other">EudraCT: 2014‐003532‐39. <span class="citation-title">The effect of the diabetes medication sitagliptin on brown fat and whole‐body metabolism in men with overweight and impaired glucose tolerance (or 'pre‐diabetes')</span>. www.clinicaltrialsregister.eu/ctr‐search/trial/2014‐003532‐39/NL Date first registered: 15 October 2014. <a class="crsref citation-link central-link" data-crsref="5607032" href="" ref="info:x-wiley/crsRef/5607032" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0138"> <div class="citation-other">NCT02294084. <span class="citation-title">Sitagliptin and brown adipose tissue (Sita01)</span>. clinicaltrials.gov/ct2/show/NCT02294084 Date first received: 17 November 2014. <a class="crsref citation-link central-link" data-crsref="5607033" href="" ref="info:x-wiley/crsRef/5607033" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD012204-bbs2-0057"> <div class="reference-title-banner"> <h4 class="title">Santilli 2015 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0139"> <div class="citation-journal">Santilli F, Guagnano M, Tartaro A, Simeone PG, Liani R, Tripaldi R, et al. <span class="citation-title">Effects of liraglutide vs lifestyle changes on subcutaneous and visceral fat, liver steatosis, insulin sensitivity and beta cell function after comparable weight loss</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2015</span>;<span class="volume">58</span>(1):S375. <a class="crsref citation-link central-link" data-crsref="5607035" href="" ref="info:x-wiley/crsRef/5607035" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+liraglutide+vs+lifestyle+changes+on+subcutaneous+and+visceral+fat,+liver+steatosis,+insulin+sensitivity+and+beta+cell+function+after+comparable+weight+loss+&author=F+Santilli&author=M+Guagnano&author=A+Tartaro&author=PG+Simeone&author=R+Liani&author=R+Tripaldi&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0140"> <div class="citation-journal">Santilli F, Guagnano MT, Tartaro A, Angelucci E, Simeone PG, Laronga G, et al. <span class="citation-title">Liraglutide is more effective than lifestyle changes in modulating subcutaneous and visceral fat distribution, liver steatosis, insulin sensitivity and beta‐cell function after comparable weight loss</span>. <span class="citation"> European Heart Journal </span><span class="pubYear">2015</span>;<span class="volume">36</span>(0):473. <a class="crsref citation-link central-link" data-crsref="5607036" href="" ref="info:x-wiley/crsRef/5607036" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Liraglutide+is+more+effective+than+lifestyle+changes+in+modulating+subcutaneous+and+visceral+fat+distribution,+liver+steatosis,+insulin+sensitivity+and+beta%E2%80%90cell+function+after+comparable+weight+loss+&author=F+Santilli&author=MT+Guagnano&author=A+Tartaro&author=E+Angelucci&author=PG+Simeone&author=G+Laronga&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0141"> <div class="citation-journal">Santilli F, Tartaro A, Guagnano MT, Simeone PG, Laronga G, Sborgia C, et al. <span class="citation-title">Effects of liraglutide or lifestyle counseling on subcutaneous and visceral fat distribution, liver fat content, insulin sensitivity, and beta‐cell performance</span>. <span class="citation"> Diabetes </span><span class="pubYear">2015</span>;<span class="volume">64</span>:A287. <a class="crsref citation-link central-link" data-crsref="5607037" href="" ref="info:x-wiley/crsRef/5607037" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+liraglutide+or+lifestyle+counseling+on+subcutaneous+and+visceral+fat+distribution,+liver+fat+content,+insulin+sensitivity,+and+beta%E2%80%90cell+performance+&author=F+Santilli&author=A+Tartaro&author=MT+Guagnano&author=PG+Simeone&author=G+Laronga&author=C+Sborgia&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD012204-bbs2-0058"> <div class="reference-title-banner"> <h4 class="title">SCALE 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0142"> <div class="citation-journal">Hollander P, Aronne L, Klein S, Niswender K, Jensen CB, Woo V, et al. <span class="citation-title">Diet‐induced weight loss and subsequent addition of liraglutide 3.0 mg reduces impaired fasting glucose in overweight/obese adults in the SCALE<sup>tm</sup> maintenance 56‐week randomised trial</span>. <span class="citation"> Journal of Diabetes </span><span class="pubYear">2013</span>;<span class="volume">5</span>:124. <a class="crsref citation-link central-link" data-crsref="5607039" href="" ref="info:x-wiley/crsRef/5607039" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diet%E2%80%90induced+weight+loss+and+subsequent+addition+of+liraglutide+3.0+mg+reduces+impaired+fasting+glucose+in+overweight/obese+adults+in+the+SCALEtm+maintenance+56%E2%80%90week+randomised+trial+&author=P+Hollander&author=L+Aronne&author=S+Klein&author=K+Niswender&author=CB+Jensen&author=V+Woo&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0143"> <div class="citation-journal">Klein S, Aronne L, Hollander P, Niswender K, Bjorn Jensen C, Lindegaard M, et al. <span class="citation-title">Effect of diet‐induced weight loss and subsequent addition of liraglutide 3.0 MG on impaired fasting glucose in overweight/obese adults in the SCALE<sup>tm</sup> maintenance 56‐week phase 3 randomised trial</span>. <span class="citation"> Obesity Facts </span><span class="pubYear">2012</span>;<span class="volume">5</span>:206. <a class="crsref citation-link central-link" data-crsref="5607040" href="" ref="info:x-wiley/crsRef/5607040" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+diet%E2%80%90induced+weight+loss+and+subsequent+addition+of+liraglutide+3.0+MG+on+impaired+fasting+glucose+in+overweight/obese+adults+in+the+SCALEtm+maintenance+56%E2%80%90week+phase+3+randomised+trial+&author=S+Klein&author=L+Aronne&author=P+Hollander&author=K+Niswender&author=C+BjornJensen&author=M+Lindegaard&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0144"> <div class="citation-other">Klein S, Aronne LJ, Hollander P, Niswender K, Woo V, Hale PM, et al. <span class="citation-title">Effect of liraglutide on cardiovascular (CV) risk factors in adults without diabetes after diet‐induced weight loss: the SCALE 56‐week randomized study</span>. Obesity (Silver Spring, Md.)<span class="pubYear">2011</span>; Vol. 19:S177. <a class="crsref citation-link central-link" data-crsref="5607041" href="" ref="info:x-wiley/crsRef/5607041" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+liraglutide+on+cardiovascular+(CV)+risk+factors+in+adults+without+diabetes+after+diet%E2%80%90induced+weight+loss:+the+SCALE+56%E2%80%90week+randomized+study+&author=S+Klein&author=LJ+Aronne&author=P+Hollander&author=K+Niswender&author=V+Woo&author=PM+Hale&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0145"> <div class="citation-other">NCT00781937. <span class="citation-title">Comparison of liraglutide versus placebo in weight loss maintenance in obese subjects: SCALE ‐ maintenance</span>. clinicaltrials.gov/show/NCT00781937 Date first received: 28 October 2008. <a class="crsref citation-link central-link" data-crsref="5607042" href="" ref="info:x-wiley/crsRef/5607042" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0146"> <div class="citation-journal">Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. NN8022‐1923 Investigators. <span class="citation-title">Weight maintenance and additional weight loss with liraglutide after low‐calorie‐diet‐induced weight loss: the SCALE maintenance randomized study</span>. <span class="citation"> International Journal of Obesity </span><span class="pubYear">2013</span>;<span class="volume">37</span>(11):1443‐51. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1038/ijo.2013.120" target="_blank"><span>10.1038/ijo.2013.120</span></a>]<a class="crsref citation-link central-link" data-crsref="5607043" href="" ref="info:x-wiley/crsRef/5607043" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23812094" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Weight+maintenance+and+additional+weight+loss+with+liraglutide+after+low%E2%80%90calorie%E2%80%90diet%E2%80%90induced+weight+loss:+the+SCALE+maintenance+randomized+study+&author=TA+Wadden&author=P+Hollander&author=S+Klein&author=K+Niswender&author=V+Woo&author=PM+Hale&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_awaitingAssessmentStudies" id="CD012204-bbs2-0059"> <div class="reference-title-banner"> <h4 class="title">SCALE‐SLEEP {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0147"> <div class="citation-journal">Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, et al. <span class="citation-title">Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial</span>. <span class="citation"> International Journal of Obesity </span><span class="pubYear">2016</span>;<span class="volume">40</span>(8):1310‐9. [PUBMED: 27005405]<a class="crsref citation-link central-link" data-crsref="5607045" href="" ref="info:x-wiley/crsRef/5607045" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27005405" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+liraglutide+3.0+mg+in+individuals+with+obesity+and+moderate+or+severe+obstructive+sleep+apnea:+the+SCALE+sleep+apnea+randomized+clinical+trial+&author=A+Blackman&author=GD+Foster&author=G+Zammit&author=R+Rosenberg&author=L+Aronne&author=T+Wadden&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0148"> <div class="citation-other">NCT01557166. <span class="citation-title">Effect of liraglutide in obese subjects with moderate or severe obstructive sleep apnoea: SCALE™ ‐ sleep apnoea</span>. clinicaltrials.gov/ct2/show/NCT01272232 Date first received: 6 January 2011. <a class="crsref citation-link central-link" data-crsref="5607046" href="" ref="info:x-wiley/crsRef/5607046" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0149"> <div class="citation-other">NN8022‐3970. <span class="citation-title">Effect of liraglutide in obese subjects with moderate or severe obstructive sleep apnoea: SCALE™ ‐ sleep apnoea</span>. novonordisk‐trials.com/Website/pdf/registry/nn80223970.pdf (accessed 30 September 2016). <a class="crsref citation-link central-link" data-crsref="5607047" href="" ref="info:x-wiley/crsRef/5607047" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD012204-bbs1-0004"> <h3 class="title">References to ongoing studies</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD012204-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD012204-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD012204-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD012204-bbs1-0005">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD012204-bbs2-0060"> <div class="reference-title-banner"> <h4 class="title">EudraCT 2013‐000418‐39 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0152"> <div class="citation-other"><span class="citation-title">Unpublished protocol</span>. Provided by the investigators. <a class="crsref citation-link central-link" data-crsref="5607051" href="" ref="info:x-wiley/crsRef/5607051" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0150"> <div class="citation-other">EUCTR2013‐000418‐39‐AT. <span class="citation-title">Early prevention of diabetes complications in people with hyperglycaemia in Europe ‐ e‐PREDICE</span>. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013‐000418‐39‐AT (accessed 8 April 2016). <a class="crsref citation-link central-link" data-crsref="5607049" href="" ref="info:x-wiley/crsRef/5607049" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0151"> <div class="citation-other">EudraCT 2013‐000418‐39. <span class="citation-title">Early prevention of diabetes complications in people with hyperglycaemia in Europe</span>. www.clinicaltrialsregister.eu/ctr‐search/search?query=2013‐000418‐39 (accessed 17 March 2016). <a class="crsref citation-link central-link" data-crsref="5607050" href="" ref="info:x-wiley/crsRef/5607050" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0153"> <div class="citation-other">ePRECIDE. <span class="citation-title">The project</span>. www.epredice.eu/en/the‐project (accessed 17 March 2016). <a class="crsref citation-link central-link" data-crsref="5607052" href="" ref="info:x-wiley/crsRef/5607052" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD012204-bbs2-0061"> <div class="reference-title-banner"> <h4 class="title">Naidoo 2016 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0154"> <div class="citation-journal">Naidoo P, Wing J, Rambiritch V. <span class="citation-title">Effect of sitagliptin and metformin on prediabetes progression to type 2 diabetes ‐ a randomized, double‐blind, double‐arm, multicenter clinical trial: protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) study</span>. <span class="citation"> JMIR Research Protocols </span><span class="pubYear">2016</span>;<span class="volume">5</span>(3):e145. [PUBMED: 27491324]<a class="crsref citation-link central-link" data-crsref="5607054" href="" ref="info:x-wiley/crsRef/5607054" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27491324" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+sitagliptin+and+metformin+on+prediabetes+progression+to+type+2+diabetes+%E2%80%90+a+randomized,+double%E2%80%90blind,+double%E2%80%90arm,+multicenter+clinical+trial:+protocol+for+the+Sitagliptin+and+Metformin+in+PreDiabetes+(SiMePreD)+study+&author=P+Naidoo&author=J+Wing&author=V+Rambiritch&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD012204-bbs2-0062"> <div class="reference-title-banner"> <h4 class="title">NCT01234649 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0155"> <div class="citation-other">NCT01234649. <span class="citation-title">Combined liraglutide and metformin therapy in women with previous gestational diabetes mellitus (GDM)</span>. clinicaltrials.gov/ct2/show/NCT01234649 Date first received: 3 November 2010. <a class="crsref citation-link central-link" data-crsref="5607056" href="" ref="info:x-wiley/crsRef/5607056" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD012204-bbs2-0063"> <div class="reference-title-banner"> <h4 class="title">NCT01336322 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0156"> <div class="citation-other">NCT01336322. <span class="citation-title">Metformin and sitagliptin in women with previous gestational diabetes</span>. clinicaltrials.gov/ct2/show/NCT01336322 Date first received: 13 April 2011. <a class="crsref citation-link central-link" data-crsref="5607058" href="" ref="info:x-wiley/crsRef/5607058" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD012204-bbs2-0064"> <div class="reference-title-banner"> <h4 class="title">NCT01548651 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0157"> <div class="citation-other">NCT01548651. <span class="citation-title">Effect of saxagliptin treatment on myocardial fat content, and monocyte inflammation</span>. clinicaltrials.gov/ct2/show/NCT01548651 Date first received: 6 February 2012. <a class="crsref citation-link central-link" data-crsref="5607060" href="" ref="info:x-wiley/crsRef/5607060" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD012204-bbs2-0065"> <div class="reference-title-banner"> <h4 class="title">NCT01779362 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0158"> <div class="citation-other">NCT01779362. <span class="citation-title">RISE adult medication study (RISE Adult)</span>. clinicaltrials.gov/ct2/show/NCT01779362 Date first received: 28 January 2013. <a class="crsref citation-link central-link" data-crsref="5607062" href="" ref="info:x-wiley/crsRef/5607062" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0159"> <div class="citation-journal">RISE Consortium. <span class="citation-title">Restoring Insulin Secretion (RISE): design of studies of beta‐cell preservation in prediabetes and early type 2 diabetes across the life span</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2014</span>;<span class="volume">37</span>(3):780‐8. [PUBMED: 24194506]<a class="crsref citation-link central-link" data-crsref="5607063" href="" ref="info:x-wiley/crsRef/5607063" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24194506" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD012204-bbs2-0066"> <div class="reference-title-banner"> <h4 class="title">NCT01795248 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0160"> <div class="citation-other">EudraCT 2012‐001371‐37. <span class="citation-title">GDM‐TREAT</span>. www.clinicaltrialsregister.eu/ctr‐search/trial/2012‐001371‐37/DK Date first registered: 9 July 2012. <a class="crsref citation-link central-link" data-crsref="5607065" href="" ref="info:x-wiley/crsRef/5607065" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0161"> <div class="citation-journal">Foghsgaard S, Vedtofte L, Mathiesen ER, Svare JA, Gluud LL, Holst JJ, et al. <span class="citation-title">The effect of a glucagon‐like peptide‐1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator‐initiated, randomised, placebo‐controlled, double‐blinded, parallel intervention trial</span>. <span class="citation"> BMJ Open </span><span class="pubYear">2013</span>;<span class="volume">3</span>(10):e003834. [PUBMED: 24176797]<a class="crsref citation-link central-link" data-crsref="5607066" href="" ref="info:x-wiley/crsRef/5607066" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24176797" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effect+of+a+glucagon%E2%80%90like+peptide%E2%80%901+receptor+agonist+on+glucose+tolerance+in+women+with+previous+gestational+diabetes+mellitus:+protocol+for+an+investigator%E2%80%90initiated,+randomised,+placebo%E2%80%90controlled,+double%E2%80%90blinded,+parallel+intervention+trial+&author=S+Foghsgaard&author=L+Vedtofte&author=ER+Mathiesen&author=JA+Svare&author=LL+Gluud&author=JJ+Holst&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD012204-bib-0162"> <div class="citation-other">NCT01795248. <span class="citation-title">The impact of liraglutide on glucose tolerance and the risk of type 2 diabetes in women with previous pregnancy‐induced diabetes</span>. clinicaltrials.gov/ct2/show/NCT01795248 Date first received: 18 February 2013. <a class="crsref citation-link central-link" data-crsref="5607067" href="" ref="info:x-wiley/crsRef/5607067" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD012204-bbs2-0067"> <div class="reference-title-banner"> <h4 class="title">NCT01856907 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0163"> <div class="citation-other">NCT01856907. <span class="citation-title">Sitagliptin + metformin compared to metformin monotherapy and placebo in women with a recent GDM</span>. clinicaltrials.gov/ct2/show/NCT01856907 Date first received: 14 May 2013. <a class="crsref citation-link central-link" data-crsref="5607069" href="" ref="info:x-wiley/crsRef/5607069" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD012204-bbs2-0068"> <div class="reference-title-banner"> <h4 class="title">NCT02104739 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0164"> <div class="citation-other">NCT02104739. <span class="citation-title">Effects of antidiabetic medications on the postprandial state in prediabetes</span>. clinicaltrials.gov/ct2/show/NCT02104739 Date first received: 1 April 2014. <a class="crsref citation-link central-link" data-crsref="5607071" href="" ref="info:x-wiley/crsRef/5607071" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD012204-bbs2-0069"> <div class="reference-title-banner"> <h4 class="title">NCT02140983 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0165"> <div class="citation-other">NCT02140983. <span class="citation-title">Effects of liraglutide on hippocampal structure and function in aging adults with prediabetes (LGT)</span>. clinicaltrials.gov/ct2/show/NCT02140983 Date first received: 27 January 2014. <a class="crsref citation-link central-link" data-crsref="5607073" href="" ref="info:x-wiley/crsRef/5607073" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD012204-bbs2-0070"> <div class="reference-title-banner"> <h4 class="title">NCT02488057 {published and unpublished data} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0166"> <div class="citation-other">NCT02488057. <span class="citation-title">Improving beta cell function in Mexican American women with prediabetes</span>. clinicaltrials.gov/ct2/show/NCT02488057 Date first received: 11 June 2015. <a class="crsref citation-link central-link" data-crsref="5607075" href="" ref="info:x-wiley/crsRef/5607075" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD012204-bbs2-0071"> <div class="reference-title-banner"> <h4 class="title">NCT02576288 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0167"> <div class="citation-other">NCT02576288. <span class="citation-title">Sitagliptin effects on arterial vasculature and inflammation in obesity (SAVORO)</span>. clinicaltrials.gov/ct2/show/NCT02576288 Date first received: 12 October 2015. <a class="crsref citation-link central-link" data-crsref="5607077" href="" ref="info:x-wiley/crsRef/5607077" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD012204-bbs2-0072"> <div class="reference-title-banner"> <h4 class="title">NCT02847403 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0168"> <div class="citation-other">NCT02847403. <span class="citation-title">Long‐acting exenatide and cognitive decline in dysglycemic patients (DRINN)</span>. clinicaltrials.gov/show/NCT02847403 Date first received: 21 July 2016. <a class="crsref citation-link central-link" data-crsref="5607079" href="" ref="info:x-wiley/crsRef/5607079" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD012204-bbs2-0073"> <div class="reference-title-banner"> <h4 class="title">NCT02969798 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0169"> <div class="citation-other">NCT02969798. <span class="citation-title">Pre‐diabetes in subject with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)</span>. clinicaltrials.gov/show/NCT02969798 Date first received: 16 March 2016. <a class="crsref citation-link central-link" data-crsref="5607081" href="" ref="info:x-wiley/crsRef/5607081" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD012204-bbs2-0074"> <div class="reference-title-banner"> <h4 class="title">NCT03004612 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0170"> <div class="citation-other">NCT03004612. <span class="citation-title">Effect of linagliptin + metformin vs metformin alone in patients with prediabetes (PRELLIM)</span>. clinicaltrials.gov/show/NCT03004612 Date first received: 21 December 2016. <a class="crsref citation-link central-link" data-crsref="5607083" href="" ref="info:x-wiley/crsRef/5607083" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD012204-bbs2-0075"> <div class="reference-title-banner"> <h4 class="title">UMIN000008620 {published data only} </h4> </div> <div class="bibliography-section" id="CD012204-bib-0171"> <div class="citation-other">UMIN000008620. <span class="citation-title">The impact of DPP‐4 inhibitor on daily glucose profile and coronary plaque character in impaired glucose tolerance patients with coronary artery disease</span>. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;recptno=R000010058&amp;type=summary&amp;language=E Date first received: 6 August 2012. <a class="crsref citation-link central-link" data-crsref="5607085" href="" ref="info:x-wiley/crsRef/5607085" target="_blank"><span style="display: none;">CENTRAL</span></a> <ul class="citation-link-group"> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD012204-bbs1-0005"> <h3 class="title">Additional references</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD012204-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD012204-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD012204-bbs1-0003">studies awaiting assessment</a></li> <li><a class="jump-to" href="#CD012204-bbs1-0004">ongoing studies</a></li> </ul> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0076"> <div class="reference-title-banner"> <h4 class="title">Abdul‐Ghani 2006</h4> </div> <div class="bibliography-section" id="CD012204-bib-0172"> <div class="citation-journal">Abdul‐Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. <span class="citation-title">Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study</span>. <span class="citation"> Diabetes </span><span class="pubYear">2006</span>;<span class="volume">55</span>(5):1430‐5. [PUBMED: 16644701] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16644701" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Insulin+secretion+and+action+in+subjects+with+impaired+fasting+glucose+and+impaired+glucose+tolerance:+results+from+the+Veterans+Administration+Genetic+Epidemiology+Study+&author=MA+Abdul%E2%80%90Ghani&author=CP+Jenkinson&author=DK+Richardson&author=D+Tripathy&author=RA+DeFronzo&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0077"> <div class="reference-title-banner"> <h4 class="title">ADA 1997</h4> </div> <div class="bibliography-section" id="CD012204-bib-0173"> <div class="citation-journal">The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. <span class="citation-title">Report of the expert committee on the diagnosis and classification of diabetes mellitus</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1997</span>;<span class="volume">20</span>(7):1183‐97. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9203460" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0078"> <div class="reference-title-banner"> <h4 class="title">ADA 2003</h4> </div> <div class="bibliography-section" id="CD012204-bib-0174"> <div class="citation-journal">Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. <span class="citation-title">Report of the expert committee on the diagnosis and classification of diabetes mellitus</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2003</span>;<span class="volume">26</span>(Suppl 1):S5‐20. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12502614" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0079"> <div class="reference-title-banner"> <h4 class="title">ADA 2008</h4> </div> <div class="bibliography-section" id="CD012204-bib-0175"> <div class="citation-journal">American Diabetes Association. <span class="citation-title">Standards of medical care in diabetes ‐ 2008</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2008</span>;<span class="volume">31</span>(Suppl 1):S12‐54. [PUBMED: 18165335] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18165335" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0080"> <div class="reference-title-banner"> <h4 class="title">ADA 2010</h4> </div> <div class="bibliography-section" id="CD012204-bib-0176"> <div class="citation-journal">American Diabetes Association. <span class="citation-title">Diagnosis and classification of diabetes mellitus</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2010</span>;<span class="volume">33</span>(Suppl 1):S62‐9. [PUBMED: 20042775] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20042775" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0081"> <div class="reference-title-banner"> <h4 class="title">ADA 2014</h4> </div> <div class="bibliography-section" id="CD012204-bib-0177"> <div class="citation-journal">American Diabetes Association. <span class="citation-title">Standards of medical care in diabetes ‐ 2014</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2014</span>;<span class="volume">37 Suppl 1</span>:S14‐80. [PUBMED: 24357209] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24357209" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0082"> <div class="reference-title-banner"> <h4 class="title">ADA 2015</h4> </div> <div class="bibliography-section" id="CD012204-bib-0178"> <div class="citation-journal">American Diabetes Association. <span class="citation-title">Standards of medical care in diabetes ‐ 2015</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2015</span>;<span class="volume">38</span>(Suppl 1):S1‐93. [PUBMED: 24357209] <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0083"> <div class="reference-title-banner"> <h4 class="title">ADA 2017</h4> </div> <div class="bibliography-section" id="CD012204-bib-0179"> <div class="citation-journal">American Diabetes Association. <span class="citation-title">Standards of medical care in diabetes ‐ 2017</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2017</span>;<span class="volume">40</span>(Suppl 1):S4‐S5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27979887" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0084"> <div class="reference-title-banner"> <h4 class="title">Anderson 2005</h4> </div> <div class="bibliography-section" id="CD012204-bib-0180"> <div class="citation-journal">Anderson DC. <span class="citation-title">Pharmacologic prevention or delay of type 2 diabetes mellitus</span>. <span class="citation"> Annals of Pharmacotherapy </span><span class="pubYear">2005</span>;<span class="volume">39</span>(1):102‐9. [PUBMED: 15562143] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15562143" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pharmacologic+prevention+or+delay+of+type+2+diabetes+mellitus&author=DC+Anderson&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0085"> <div class="reference-title-banner"> <h4 class="title">Bell 2013</h4> </div> <div class="bibliography-section" id="CD012204-bib-0181"> <div class="citation-journal">Bell ML, McKenzie JE. <span class="citation-title">Designing psycho‐oncology randomised trials and cluster randomised trials: variance components and intra‐cluster correlation of commonly used psychosocial measures</span>. <span class="citation"> Psycho‐oncology </span><span class="pubYear">2013</span>;<span class="volume">22</span>:1738‐47. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23080401" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Designing+psycho%E2%80%90oncology+randomised+trials+and+cluster+randomised+trials:+variance+components+and+intra%E2%80%90cluster+correlation+of+commonly+used+psychosocial+measures+&author=ML+Bell&author=JE+McKenzie&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0086"> <div class="reference-title-banner"> <h4 class="title">Bhardwaj 2010</h4> </div> <div class="bibliography-section" id="CD012204-bib-0182"> <div class="citation-other">Bhardwaj A, Agarwal V, Phung OJ, Baker WL, Tongbram V, Coleman CI. <span class="citation-title">Can oral hypoglycemic agents restore normoglycemia in individuals with insulin resistance?</span>. 70th Scientific Sessions of the American Diabetes Association; 2010 25‐29 June; Orlando (FL). <span class="pubYear">2010</span>. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Can+oral+hypoglycemic+agents+restore+normoglycemia+in+individuals+with+insulin+resistance?&author=A+Bhardwaj&author=V+Agarwal&author=OJ+Phung&author=WL+Baker&author=V+Tongbram&author=CI+Coleman&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0087"> <div class="reference-title-banner"> <h4 class="title">Bjorner 2013</h4> </div> <div class="bibliography-section" id="CD012204-bib-0183"> <div class="citation-journal">Bjorner JB, Lyng WM, Gundgaard J, Miller KA. <span class="citation-title">Benchmarks for interpretation of score differences on the SF‐36 health survey for patients with diabetes</span>. <span class="citation"> Value in Health </span><span class="pubYear">2013</span>;<span class="volume">16</span>(6):993‐1000. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24041349" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Benchmarks+for+interpretation+of+score+differences+on+the+SF%E2%80%9036+health+survey+for+patients+with+diabetes+&author=JB+Bjorner&author=WM+Lyng&author=J+Gundgaard&author=KA+Miller&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0088"> <div class="reference-title-banner"> <h4 class="title">Boutron 2014</h4> </div> <div class="bibliography-section" id="CD012204-bib-0184"> <div class="citation-journal">Boutron I, Altman DG, Hopewell S, Vera‐Badillo F, Tannock I, Ravaud P. <span class="citation-title">Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial</span>. <span class="citation"> Journal of Clinical Oncology </span><span class="pubYear">2014</span>;<span class="volume">32</span>:4120‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25403215" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Impact+of+spin+in+the+abstracts+of+articles+reporting+results+of+randomized+controlled+trials+in+the+field+of+cancer:+the+SPIIN+randomized+controlled+trial+&author=I+Boutron&author=DG+Altman&author=S+Hopewell&author=F+Vera%E2%80%90Badillo&author=I+Tannock&author=P+Ravaud&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0089"> <div class="reference-title-banner"> <h4 class="title">Brok 2009</h4> </div> <div class="bibliography-section" id="CD012204-bib-0185"> <div class="citation-journal">Brok J, Thorlund K, Wetterslev J, Gluud C. <span class="citation-title">Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses</span>. <span class="citation"> International Journal of Epidemiology </span><span class="pubYear">2009</span>;<span class="volume">38</span>(1):287‐98. [PUBMED: 18824466] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18824466" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Apparently+conclusive+meta%E2%80%90analyses+may+be+inconclusive+%E2%80%90+trial+sequential+analysis+adjustment+of+random+error+risk+due+to+repetitive+testing+of+accumulating+data+in+apparently+conclusive+neonatal+meta%E2%80%90analyses+&author=J+Brok&author=K+Thorlund&author=J+Wetterslev&author=C+Gluud&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0090"> <div class="reference-title-banner"> <h4 class="title">Calanna 2013</h4> </div> <div class="bibliography-section" id="CD012204-bib-0186"> <div class="citation-journal">Calanna S, Christensen M, Holst JJ, Laferrere B, Gluud LL, Vilsboll T, et al. <span class="citation-title">Secretion of glucagon‐like peptide‐1 in patients with type 2 diabetes mellitus: systematic review and meta‐analyses of clinical studies</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2013</span>;<span class="volume">56</span>(5):965‐72. [PUBMED: 23377698] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23377698" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Secretion+of+glucagon%E2%80%90like+peptide%E2%80%901+in+patients+with+type+2+diabetes+mellitus:+systematic+review+and+meta%E2%80%90analyses+of+clinical+studies+&author=S+Calanna&author=M+Christensen&author=JJ+Holst&author=B+Laferrere&author=LL+Gluud&author=T+Vilsboll&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0091"> <div class="reference-title-banner"> <h4 class="title">CDC 2015</h4> </div> <div class="bibliography-section" id="CD012204-bib-0187"> <div class="citation-other">Centers for Disease Control and Prevention. <span class="citation-title">2014 National Diabetes Statistics Report</span>. www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html (accessed 15 October 2015). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0092"> <div class="reference-title-banner"> <h4 class="title">Cheng 2006</h4> </div> <div class="bibliography-section" id="CD012204-bib-0188"> <div class="citation-journal">Cheng C, Kushner H, Falkner BE. <span class="citation-title">The utility of fasting glucose for detection of prediabetes</span>. <span class="citation"> Metabolism: Clinical and Experimental </span><span class="pubYear">2006</span>;<span class="volume">55</span>(4):434‐8. [PUBMED: 16546472] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16546472" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+utility+of+fasting+glucose+for+detection+of+prediabetes&author=C+Cheng&author=H+Kushner&author=BE+Falkner&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0093"> <div class="reference-title-banner"> <h4 class="title">ClinicalTrials.gov</h4> </div> <div class="bibliography-section" id="CD012204-bib-0189"> <div class="citation-other"><span class="citation-title">Search terms: prediabetes drugs</span>. clinicaltrials.gov/ct2/results?term=prediabetes+drugs&amp;Search=Search (accessed 12 February 2016). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0094"> <div class="reference-title-banner"> <h4 class="title">Corbett 2014</h4> </div> <div class="bibliography-section" id="CD012204-bib-0190"> <div class="citation-journal">Corbett MS, Higgins JP, Woolacott NF. <span class="citation-title">Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool</span>. <span class="citation"> Research Synthesis Methods </span><span class="pubYear">2014</span>;<span class="volume">5</span>:79‐85. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/26054027" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Assessing+baseline+imbalance+in+randomised+trials:+implications+for+the+Cochrane+risk+of+bias+tool+&author=MS+Corbett&author=JP+Higgins&author=NF+Woolacott&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0095"> <div class="reference-title-banner"> <h4 class="title">Creutzfeldt 1979</h4> </div> <div class="bibliography-section" id="CD012204-bib-0191"> <div class="citation-journal">Creutzfeldt W. <span class="citation-title">The incretin concept today</span>. <span class="citation"> Diabetologia </span><span class="pubYear">1979</span>;<span class="volume">16</span>(2):75‐85. [PUBMED: 32119] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/32119" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+incretin+concept+today&author=W+Creutzfeldt&publication_year=1979&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0096"> <div class="reference-title-banner"> <h4 class="title">De Heer 2014</h4> </div> <div class="bibliography-section" id="CD012204-bib-0192"> <div class="citation-journal">Heer J, Göke B. <span class="citation-title">Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?</span>. <span class="citation"> Expert Opinion on Drug Safety </span><span class="pubYear">2014</span>;<span class="volume">13</span>(11):1469‐81. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25270593" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Are+incretin+mimetics+and+enhancers+linked+to+pancreatitis+and+malignant+transformations+in+pancreas?+&author=J+Heer&author=B+G%C3%B6ke&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0097"> <div class="reference-title-banner"> <h4 class="title">DeFronzo 1989</h4> </div> <div class="bibliography-section" id="CD012204-bib-0193"> <div class="citation-journal">DeFronzo RA, Ferrannini E, Simonson DC. <span class="citation-title">Fasting hyperglycemia in non‐insulin‐dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake</span>. <span class="citation"> Metabolism: Clinical and Experimental </span><span class="pubYear">1989</span>;<span class="volume">38</span>(4):387‐95. [PUBMED: 2657323] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2657323" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Fasting+hyperglycemia+in+non%E2%80%90insulin%E2%80%90dependent+diabetes+mellitus:+contributions+of+excessive+hepatic+glucose+production+and+impaired+tissue+glucose+uptake+&author=RA+DeFronzo&author=E+Ferrannini&author=DC+Simonson&publication_year=1989&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0098"> <div class="reference-title-banner"> <h4 class="title">DeFronzo 2011</h4> </div> <div class="bibliography-section" id="CD012204-bib-0194"> <div class="citation-journal">DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. <span class="citation-title">Pioglitazone for diabetes prevention in impaired glucose tolerance</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2011</span>;<span class="volume">364</span>(12):1104‐15. [PUBMED: 21428766] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21428766" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pioglitazone+for+diabetes+prevention+in+impaired+glucose+tolerance&author=RA+DeFronzo&author=D+Tripathy&author=DC+Schwenke&author=M+Banerji&author=GA+Bray&author=TA+Buchanan&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0099"> <div class="reference-title-banner"> <h4 class="title">Diabetes Prevention Program 2009</h4> </div> <div class="bibliography-section" id="CD012204-bib-0195"> <div class="citation-journal">Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. <span class="citation-title">10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study</span>. <span class="citation"> Lancet </span><span class="pubYear">2009</span>;<span class="volume">374</span>(9702):1677‐86. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1016/S0140-6736(09)61457-4" target="_blank"><span>10.1016/S0140‐6736(09)61457‐4</span></a>; PUBMED: 19878986] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19878986" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=10%E2%80%90year+follow%E2%80%90up+of+diabetes+incidence+and+weight+loss+in+the+Diabetes+Prevention+Program+Outcomes+Study+&author=WC+Knowler&author=SE+Fowler&author=RF+Hamman&author=CA+Christophi&author=HJ+Hoffman&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0100"> <div class="reference-title-banner"> <h4 class="title">Dunkley 2014</h4> </div> <div class="bibliography-section" id="CD012204-bib-0196"> <div class="citation-journal">Dunkley AJ, Bodicoat DH, Greaves CJ, Russell C, Yates T, Davies MJ, et al. <span class="citation-title">Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta‐analysis</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2014</span>;<span class="volume">37</span>(4):922‐33. [PUBMED: 24652723] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24652723" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Diabetes+prevention+in+the+real+world:+effectiveness+of+pragmatic+lifestyle+interventions+for+the+prevention+of+type+2+diabetes+and+of+the+impact+of+adherence+to+guideline+recommendations:+a+systematic+review+and+meta%E2%80%90analysis+&author=AJ+Dunkley&author=DH+Bodicoat&author=CJ+Greaves&author=C+Russell&author=T+Yates&author=MJ+Davies&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0101"> <div class="reference-title-banner"> <h4 class="title">Egan 2014</h4> </div> <div class="bibliography-section" id="CD012204-bib-0197"> <div class="citation-journal">Egan AG, Blind E, Dunder K, Graeff PA, Hummer BT, Bourcier T, et al. <span class="citation-title">Pancreatic safety of incretin‐based drugs ‐ FDA and EMA assessment</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2014</span>;<span class="volume">370</span>(9):794‐7. [PUBMED: 24571751] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24571751" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pancreatic+safety+of+incretin%E2%80%90based+drugs+%E2%80%90+FDA+and+EMA+assessment&author=AG+Egan&author=E+Blind&author=K+Dunder&author=PA+Graeff&author=BT+Hummer&author=T+Bourcier&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0102"> <div class="reference-title-banner"> <h4 class="title">Egbewale 2014</h4> </div> <div class="bibliography-section" id="CD012204-bib-0198"> <div class="citation-journal">Egbewale BE, Lewis M, Sim J. <span class="citation-title">Bias, precision and statistical power of analysis of covariance in the analysis of randomized trials with baseline imbalance: a simulation study</span>. <span class="citation"> BMC Medical Research Methodology </span><span class="pubYear">2014</span>;<span class="volume">14</span>:49. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1186/1471-2288-14-49" target="_blank"><span>10.1186/1471‐2288‐14‐49</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24712304" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Bias,+precision+and+statistical+power+of+analysis+of+covariance+in+the+analysis+of+randomized+trials+with+baseline+imbalance:+a+simulation+study+&author=BE+Egbewale&author=M+Lewis&author=J+Sim&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0103"> <div class="reference-title-banner"> <h4 class="title">Elgendy 2017</h4> </div> <div class="bibliography-section" id="CD012204-bib-0199"> <div class="citation-journal">Elgendy IY, Mahmoud AN, Barakat AF, Elgendy AY, Saad M, Abuzaid A, et al. <span class="citation-title">Cardiovascular safety of dipeptidyl‐peptidase IV inhibitors: a meta‐analysis of placebo‐controlled randomized trials</span>. <span class="citation"> American Journal of Cardiovascular Drugs </span><span class="pubYear">2017</span>;<span class="volume">17</span>(2):143‐55. [PUBMED: 27873238] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27873238" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cardiovascular+safety+of+dipeptidyl%E2%80%90peptidase+IV+inhibitors:+a+meta%E2%80%90analysis+of+placebo%E2%80%90controlled+randomized+trials+&author=IY+Elgendy&author=AN+Mahmoud&author=AF+Barakat&author=AY+Elgendy&author=M+Saad&author=A+Abuzaid&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0104"> <div class="reference-title-banner"> <h4 class="title">EMA/143005/2015</h4> </div> <div class="bibliography-section" id="CD012204-bib-0200"> <div class="citation-other">European Medicines Agency. <span class="citation-title">Assessment Report. Saxenda. International non‐proprietary name: liraglutide</span>. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_report/human/003780/WC500185788.pdf (accessed 21 September 2016). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0105"> <div class="reference-title-banner"> <h4 class="title">FDA 2005</h4> </div> <div class="bibliography-section" id="CD012204-bib-0201"> <div class="citation-other">US Food, Drug Administration. <span class="citation-title">Drug approval package: Byetta (exenatide) injection</span>. www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_ByettaTOC.cfm (accessed 26 February 2016). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0106"> <div class="reference-title-banner"> <h4 class="title">FDA 2006</h4> </div> <div class="bibliography-section" id="CD012204-bib-0202"> <div class="citation-other">US Food, Drug Administration. <span class="citation-title">FDA approves new treatment for diabetes</span>. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108770 (assessed 26 February 2016). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0107"> <div class="reference-title-banner"> <h4 class="title">FDA 2014</h4> </div> <div class="bibliography-section" id="CD012204-bib-0203"> <div class="citation-other">US Food, Drug Administration. <span class="citation-title">Saxenda Injection (Liraglutide [rDNA origin])</span>. www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206321Orig1s000TOC.cfm (assessed 22 September 2016). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0108"> <div class="reference-title-banner"> <h4 class="title">Gosmanov 2014</h4> </div> <div class="bibliography-section" id="CD012204-bib-0204"> <div class="citation-journal">Gosmanov AR, Wan J. <span class="citation-title">Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice</span>. <span class="citation"> American Journal of the Medical Sciences </span><span class="pubYear">2014</span>;<span class="volume">348</span>(3):191‐4. [PUBMED: 24556928] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24556928" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Low+positive+predictive+value+of+hemoglobin+A1c+for+diagnosis+of+prediabetes+in+clinical+practice+&author=AR+Gosmanov&author=J+Wan&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0109"> <div class="reference-title-banner"> <h4 class="title">GRADEpro GDT 2015 [Computer program]</h4> </div> <div class="bibliography-section" id="CD012204-bib-0205"> <div class="citation-other">GRADE Working Group, McMaster University. <span class="citation-title">GRADEpro GDT</span>. Hamilton (ON): GRADE Working Group, McMaster University, <span class="pubYear">2015</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0110"> <div class="reference-title-banner"> <h4 class="title">Hemmingsen 2016a</h4> </div> <div class="bibliography-section" id="CD012204-bib-0206"> <div class="citation-journal">Hemmingsen B, Krogh J, Metzendorf MI, Richter B. <span class="citation-title">Sodium‐glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2016</span>, Issue 4. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD012106.pub2" target="_blank"><span>10.1002/14651858.CD012106.pub2</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sodium%E2%80%90glucose+cotransporter+(SGLT)+2+inhibitors+for+prevention+or+delay+of+type+2+diabetes+mellitus+and+its+associated+complications+in+people+at+risk+for+the+development+of+type+2+diabetes+mellitus+&author=B+Hemmingsen&author=J+Krogh&author=MI+Metzendorf&author=B+Richter&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0111"> <div class="reference-title-banner"> <h4 class="title">Hemmingsen 2016b</h4> </div> <div class="bibliography-section" id="CD012204-bib-0207"> <div class="citation-journal">Hemmingsen B, Krogh J, Metzendorf MI, Richter B. <span class="citation-title">Dipeptidyl‐peptidase (DPP)‐4 inhibitors or glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2016</span>, Issue 5. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD012204" target="_blank"><span>10.1002/14651858.CD012204</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Dipeptidyl%E2%80%90peptidase+(DPP)%E2%80%904+inhibitors+or+glucagon%E2%80%90like+peptide+(GLP)%E2%80%901+analogues+for+prevention+or+delay+of+type+2+diabetes+mellitus+and+its+associated+complications+in+persons+at+increased+risk+for+the+development+of+type+2+diabetes+mellitus+&author=B+Hemmingsen&author=J+Krogh&author=MI+Metzendorf&author=B+Richter&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0112"> <div class="reference-title-banner"> <h4 class="title">Hemmingsen 2016c</h4> </div> <div class="bibliography-section" id="CD012204-bib-0208"> <div class="citation-journal">Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. <span class="citation-title">Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2016</span>, Issue 10. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD012151.pub2" target="_blank"><span>10.1002/14651858.CD012151.pub2</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Insulin+secretagogues+for+prevention+or+delay+of+type+2+diabetes+mellitus+and+its+associated+complications+in+persons+at+increased+risk+for+the+development+of+type+2+diabetes+mellitus+&author=B+Hemmingsen&author=DP+Sonne&author=MI+Metzendorf&author=B+Richter&publication_year=2016&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0113"> <div class="reference-title-banner"> <h4 class="title">Higgins 2002</h4> </div> <div class="bibliography-section" id="CD012204-bib-0209"> <div class="citation-journal">Higgins JPT, Thompson SG. <span class="citation-title">Quantifying heterogeneity in a meta‐analysis</span>. <span class="citation"> Statistics in Medicine </span><span class="pubYear">2002</span>;<span class="volume">21</span>:1539‐58. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12111919" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Quantifying+heterogeneity+in+a+meta%E2%80%90analysis&author=JPT+Higgins&author=SG+Thompson&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0114"> <div class="reference-title-banner"> <h4 class="title">Higgins 2003</h4> </div> <div class="bibliography-section" id="CD012204-bib-0210"> <div class="citation-journal">Higgins JPT, Thompson SG, Deeks JJ, Altman DG. <span class="citation-title">Measuring inconsistency in meta‐analysis</span>. <span class="citation"> BMJ </span><span class="pubYear">2003</span>;<span class="volume">327</span>(7414):557‐60. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12958120" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Measuring+inconsistency+in+meta%E2%80%90analysis&author=JPT+Higgins&author=SG+Thompson&author=JJ+Deeks&author=DG+Altman&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0115"> <div class="reference-title-banner"> <h4 class="title">Higgins 2009</h4> </div> <div class="bibliography-section" id="CD012204-bib-0211"> <div class="citation-journal">Higgins JPT, Thompson SG, Spiegelhalter DJ. <span class="citation-title">A re‐evaluation of random‐effects meta‐analysis</span>. <span class="citation"> Journal of the Royal Statistical Society. Series A, (Statistics in Society) </span><span class="pubYear">2009</span>;<span class="volume">172</span>(1):137‐59. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19381330" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+re%E2%80%90evaluation+of+random%E2%80%90effects+meta%E2%80%90analysis&author=JPT+Higgins&author=SG+Thompson&author=DJ+Spiegelhalter&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0116"> <div class="reference-title-banner"> <h4 class="title">Higgins 2011a</h4> </div> <div class="bibliography-section" id="CD012204-bib-0212"> <div class="citation-other">Higgins JPT, Green S, editor(s). <span class="citation-title">Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</span>. Available from handbook.cochrane.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0117"> <div class="reference-title-banner"> <h4 class="title">Higgins 2011b</h4> </div> <div class="bibliography-section" id="CD012204-bib-0213"> <div class="citation-journal">Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. <span class="citation-title">The Cochrane Collaboration's tool for assessing risk of bias in randomised trials</span>. <span class="citation"> BMJ </span><span class="pubYear">2011</span>;<span class="volume">343</span>:d5928. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22008217" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+Cochrane+Collaboration's+tool+for+assessing+risk+of+bias+in+randomised+trials&author=JPT+Higgins&author=DG+Altman&author=PC+Gøtzsche&author=P+Jüni&author=D+Moher&author=AD+Oxman&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0118"> <div class="reference-title-banner"> <h4 class="title">Higgins 2011c</h4> </div> <div class="bibliography-section" id="CD012204-bib-0214"> <div class="citation-journal">Higgins JP, Whitehead A, Simmonds M. <span class="citation-title">Sequential methods for random‐effects meta‐analysis</span>. <span class="citation"> Statistics in Medicine </span><span class="pubYear">2011</span>;<span class="volume">30</span>(9):903‐21. [PUBMED: 21190240] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21472757" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Sequential+methods+for+random%E2%80%90effects+meta%E2%80%90analysis&author=JP+Higgins&author=A+Whitehead&author=M+Simmonds&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0119"> <div class="reference-title-banner"> <h4 class="title">Holst 2007</h4> </div> <div class="bibliography-section" id="CD012204-bib-0215"> <div class="citation-journal">Holst JJ. <span class="citation-title">The physiology of glucagon‐like peptide 1</span>. <span class="citation"> Physiological Reviews </span><span class="pubYear">2007</span>;<span class="volume">87</span>(4):1409‐39. [PUBMED: 17928588] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17928588" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+physiology+of+glucagon%E2%80%90like+peptide+1&author=JJ+Holst&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0120"> <div class="reference-title-banner"> <h4 class="title">Holz 1993</h4> </div> <div class="bibliography-section" id="CD012204-bib-0216"> <div class="citation-journal">Holz GG, Kuhtreiber WM, Habener JF. <span class="citation-title">Pancreatic beta‐cells are rendered glucose‐competent by the insulinotropic hormone glucagon‐like peptide‐1(7‐37)</span>. <span class="citation"> Nature </span><span class="pubYear">1993</span>;<span class="volume">361</span>(6410):362‐5. [PUBMED: 8381211] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8381211" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pancreatic+beta%E2%80%90cells+are+rendered+glucose%E2%80%90competent+by+the+insulinotropic+hormone+glucagon%E2%80%90like+peptide%E2%80%901(7%E2%80%9037)+&author=GG+Holz&author=WM+Kuhtreiber&author=JF+Habener&publication_year=1993&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0121"> <div class="reference-title-banner"> <h4 class="title">Hopper 2011</h4> </div> <div class="bibliography-section" id="CD012204-bib-0217"> <div class="citation-journal">Hopper I, Billah B, Skiba M, Krum H. <span class="citation-title">Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta‐analysis of randomised controlled clinical trials</span>. <span class="citation"> European Journal of Cardiovascular Prevention and Rehabilitation </span><span class="pubYear">2011</span>;<span class="volume">18</span>(6):813‐23. [PUBMED: 21878448] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21878448" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prevention+of+diabetes+and+reduction+in+major+cardiovascular+events+in+studies+of+subjects+with+prediabetes:+meta%E2%80%90analysis+of+randomised+controlled+clinical+trials+&author=I+Hopper&author=B+Billah&author=M+Skiba&author=H+Krum&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0122"> <div class="reference-title-banner"> <h4 class="title">Hróbjartsson 2013</h4> </div> <div class="bibliography-section" id="CD012204-bib-0218"> <div class="citation-journal">Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. <span class="citation-title">Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors</span>. <span class="citation"> Canadian Medical Association Journal </span><span class="pubYear">2013</span>;<span class="volume">185</span>(4):E201‐11. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23359047" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Observer+bias+in+randomized+clinical+trials+with+measurement+scale+outcomes:+a+systematic+review+of+trials+with+both+blinded+and+nonblinded+assessors+&author=A+Hr%C3%B3bjartsson&author=AS+Thomsen&author=F+Emanuelsson&author=B+Tendal&author=J+Hilden&author=I+Boutron&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0123"> <div class="reference-title-banner"> <h4 class="title">ICH 1997</h4> </div> <div class="bibliography-section" id="CD012204-bib-0219"> <div class="citation-book">International Conference on Harmonisation Expert Working Group. <span class="citation">International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice 1997 CFR &amp; ICH Guidelines</span>. Philadelphia (PA): Barnett International/PAREXEL, <span class="pubYear">1997</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0124"> <div class="reference-title-banner"> <h4 class="title">IDF 2015</h4> </div> <div class="bibliography-section" id="CD012204-bib-0220"> <div class="citation-book">International Diabetes Federation. <span class="citation">IDF Diabetes Atlas</span>. 7th Edition. Brussels: International Diabetes Federation, <span class="pubYear">2015</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0125"> <div class="reference-title-banner"> <h4 class="title">IEC 2009</h4> </div> <div class="bibliography-section" id="CD012204-bib-0221"> <div class="citation-journal">International Expert Committee. <span class="citation-title">International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2009</span>;<span class="volume">32</span>(7):1327‐34. [PUBMED: 19502545] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19502545" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0126"> <div class="reference-title-banner"> <h4 class="title">Inzucchi 2012</h4> </div> <div class="bibliography-section" id="CD012204-bib-0222"> <div class="citation-journal">Inzucchi SE. <span class="citation-title">Clinical practice. Diagnosis of diabetes</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2012</span>;<span class="volume">367</span>(6):542‐50. [PUBMED: 22873534] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22873534" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Clinical+practice.+Diagnosis+of+diabetes&author=SE+Inzucchi&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0127"> <div class="reference-title-banner"> <h4 class="title">Jensen 2002</h4> </div> <div class="bibliography-section" id="CD012204-bib-0223"> <div class="citation-journal">Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE. <span class="citation-title">Beta‐cell function is a major contributor to oral glucose tolerance in high‐risk relatives of four ethnic groups in the U.S</span>. <span class="citation"> Diabetes </span><span class="pubYear">2002</span>;<span class="volume">51</span>(7):2170‐8. [PUBMED: 12086947] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12086947" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Beta%E2%80%90cell+function+is+a+major+contributor+to+oral+glucose+tolerance+in+high%E2%80%90risk+relatives+of+four+ethnic+groups+in+the+U.S+&author=CC+Jensen&author=M+Cnop&author=RL+Hull&author=WY+Fujimoto&author=SE+Kahn&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0128"> <div class="reference-title-banner"> <h4 class="title">Kirkham 2010</h4> </div> <div class="bibliography-section" id="CD012204-bib-0224"> <div class="citation-journal">Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. <span class="citation-title">The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews</span>. <span class="citation"> BMJ </span><span class="pubYear">2010</span>;<span class="volume">340</span>:c365. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1136/bmj.c365" target="_blank"><span>10.1136/bmj.c365</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20156912" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+impact+of+outcome+reporting+bias+in+randomised+controlled+trials+on+a+cohort+of+systematic+reviews+&author=JJ+Kirkham&author=KM+Dwan&author=DG+Altman&author=C+Gamble&author=S+Dodd&author=R+Smyth&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0129"> <div class="reference-title-banner"> <h4 class="title">Knowler 2002</h4> </div> <div class="bibliography-section" id="CD012204-bib-0225"> <div class="citation-journal">Knowler WC, Barrett‐Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. <span class="citation-title">Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2002</span>;<span class="volume">346</span>(6):393‐403. [PUBMED: 11832527] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11832527" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Reduction+in+the+incidence+of+type+2+diabetes+with+lifestyle+intervention+or+metformin&author=WC+Knowler&author=E+Barrett%E2%80%90Connor&author=SE+Fowler&author=RF+Hamman&author=JM+Lachin&author=EA+Walker&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0130"> <div class="reference-title-banner"> <h4 class="title">Lan 1983</h4> </div> <div class="bibliography-section" id="CD012204-bib-0226"> <div class="citation-journal">Lan KKG, DeMets DL. <span class="citation-title">Discrete sequential boundaries for clinical trials</span>. <span class="citation"> Biometrika </span><span class="pubYear">1983</span>;<span class="volume">70</span>:659‐63. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Discrete+sequential+boundaries+for+clinical+trials&author=KKG+Lan&author=DL+DeMets&publication_year=1983&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0131"> <div class="reference-title-banner"> <h4 class="title">Le Roux 2017</h4> </div> <div class="bibliography-section" id="CD012204-bib-0227"> <div class="citation-journal">Lle Roux CW, Astrup A, Fujioka K, Greenway F, Lau DC, Gaal L, et al. <span class="citation-title">3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial</span>. <span class="citation"> Lancet </span><span class="pubYear">2017</span>;<span class="volume">389</span>(10077):1399‐409. [PUBMED: 28237263] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28237263" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=3+years+of+liraglutide+versus+placebo+for+type+2+diabetes+risk+reduction+and+weight+management+in+individuals+with+prediabetes:+a+randomised,+double%E2%80%90blind+trial+&author=CW+LleRoux&author=A+Astrup&author=K+Fujioka&author=F+Greenway&author=DC+Lau&author=L+Gaal&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0132"> <div class="reference-title-banner"> <h4 class="title">Liberati 2009</h4> </div> <div class="bibliography-section" id="CD012204-bib-0228"> <div class="citation-journal">Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. <span class="citation-title">The PRISMA statement for reporting systematic and meta‐analyses of studies that evaluate interventions: explanation and elaboration</span>. <span class="citation"> PLoS Medicine </span><span class="pubYear">2009</span>;<span class="volume">6</span>(7):1‐28. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1371/journal.pmed.1000100" target="_blank"><span>10.1371/journal.pmed.1000100</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+PRISMA+statement+for+reporting+systematic+and+meta%E2%80%90analyses+of+studies+that+evaluate+interventions:+explanation+and+elaboration+&author=A+Liberati&author=DG+Altman&author=J+Tetzlaff&author=C+Mulrow&author=PC+G%C3%B8tzsche&author=JPA+Ioannidis&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0133"> <div class="reference-title-banner"> <h4 class="title">Lundh 2017</h4> </div> <div class="bibliography-section" id="CD012204-bib-0229"> <div class="citation-journal">Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. <span class="citation-title">Industry sponsorship and research outcome</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2017</span>, Issue 2. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.MR000033.pub3" target="_blank"><span>10.1002/14651858.MR000033.pub3</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/28207928" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Industry+sponsorship+and+research+outcome&author=A+Lundh&author=J+Lexchin&author=B+Mintzes&author=JB+Schroll&author=L+Bero&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0134"> <div class="reference-title-banner"> <h4 class="title">Mathieu 2009</h4> </div> <div class="bibliography-section" id="CD012204-bib-0230"> <div class="citation-journal">Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. <span class="citation-title">Comparison of registered and published primary outcomes in randomized controlled trials</span>. <span class="citation"> JAMA </span><span class="pubYear">2009</span>;<span class="volume">302</span>:977‐84. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19724045" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparison+of+registered+and+published+primary+outcomes+in+randomized+controlled+trials&author=S+Mathieu&author=I+Boutron&author=D+Moher&author=DG+Altman&author=P+Ravaud&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0135"> <div class="reference-title-banner"> <h4 class="title">Meader 2014</h4> </div> <div class="bibliography-section" id="CD012204-bib-0231"> <div class="citation-journal">Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. <span class="citation-title">A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation</span>. <span class="citation"> Systematic Reviews </span><span class="pubYear">2014</span>;<span class="volume">3</span>:82. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25056145" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+checklist+designed+to+aid+consistency+and+reproducibility+of+GRADE+assessments:+development+and+pilot+validation+&author=N+Meader&author=K+King&author=A+Llewellyn&author=G+Norman&author=J+Brown&author=M+Rodgers&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0136"> <div class="reference-title-banner"> <h4 class="title">Morris 2013</h4> </div> <div class="bibliography-section" id="CD012204-bib-0232"> <div class="citation-journal">Morris DH, Khunti K, Achana F, Srinivasan B, Gray LJ, Davies MJ, et al. <span class="citation-title">Progression rates from HbA1c 6.0‐6.4% and other prediabetes definitions to type 2 diabetes: a meta‐analysis</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2013</span>;<span class="volume">56</span>(7):1489‐93. [PUBMED: 23584433] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23584433" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Progression+rates+from+HbA1c+6.0%E2%80%906.4%+and+other+prediabetes+definitions+to+type+2+diabetes:+a+meta%E2%80%90analysis+&author=DH+Morris&author=K+Khunti&author=F+Achana&author=B+Srinivasan&author=LJ+Gray&author=MJ+Davies&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0137"> <div class="reference-title-banner"> <h4 class="title">Nagel 2015</h4> </div> <div class="bibliography-section" id="CD012204-bib-0233"> <div class="citation-other">Nagel AK, Ahmed‐Sarwar N, Werner PM, Cipriano GC, Manen RP, Brown JE. <span class="citation-title">Dipeptidyl peptidase‐4 inhibitor‐associated pancreatic carcinoma: a review of the FAERS database</span>. Annals of Pharmacotherapy<span class="pubYear">2015</span>; Vol. 50, issue 1:27‐31. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Dipeptidyl+peptidase%E2%80%904+inhibitor%E2%80%90associated+pancreatic+carcinoma:+a+review+of+the+FAERS+database+&author=AK+Nagel&author=N+Ahmed%E2%80%90Sarwar&author=PM+Werner&author=GC+Cipriano&author=RP+Manen&author=JE+Brown&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0138"> <div class="reference-title-banner"> <h4 class="title">Nauck 1986</h4> </div> <div class="bibliography-section" id="CD012204-bib-0234"> <div class="citation-journal">Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, et al. <span class="citation-title">Incretin effects of increasing glucose loads in man calculated from venous insulin and C‐peptide responses</span>. <span class="citation"> Journal of Clinical Endocrinology and Metabolism </span><span class="pubYear">1986</span>;<span class="volume">63</span>(2):492‐8. [PUBMED: 3522621] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/3522621" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Incretin+effects+of+increasing+glucose+loads+in+man+calculated+from+venous+insulin+and+C%E2%80%90peptide+responses+&author=MA+Nauck&author=E+Homberger&author=EG+Siegel&author=RC+Allen&author=RP+Eaton&author=R+Ebert&publication_year=1986&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0139"> <div class="reference-title-banner"> <h4 class="title">NCT02161588</h4> </div> <div class="bibliography-section" id="CD012204-bib-0235"> <div class="citation-other">NCT02161588. <span class="citation-title">A trial to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy male Japanese and Caucasian subjects</span>. clinicaltrials.gov/ct2/show/NCT02161588 Date first received: 10 June 2014. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0140"> <div class="reference-title-banner"> <h4 class="title">NDDG 1979</h4> </div> <div class="bibliography-section" id="CD012204-bib-0236"> <div class="citation-journal">National Diabetes Data Group. <span class="citation-title">Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group</span>. <span class="citation"> Diabetes </span><span class="pubYear">1979</span>;<span class="volume">28</span>(12):1039‐57. [PUBMED: 510803] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/510803" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0141"> <div class="reference-title-banner"> <h4 class="title">Orskov 1988</h4> </div> <div class="bibliography-section" id="CD012204-bib-0237"> <div class="citation-journal">Orskov C, Holst JJ, Nielsen OV. <span class="citation-title">Effect of truncated glucagon‐like peptide‐1 [proglucagon‐(78‐107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach</span>. <span class="citation"> Endocrinology </span><span class="pubYear">1988</span>;<span class="volume">123</span>(4):2009‐13. [PUBMED: 2901341] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2901341" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+truncated+glucagon%E2%80%90like+peptide%E2%80%901+[proglucagon%E2%80%90(78%E2%80%90107)+amide]+on+endocrine+secretion+from+pig+pancreas,+antrum,+and+nonantral+stomach+&author=C+Orskov&author=JJ+Holst&author=OV+Nielsen&publication_year=1988&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0142"> <div class="reference-title-banner"> <h4 class="title">Phung 2012</h4> </div> <div class="bibliography-section" id="CD012204-bib-0238"> <div class="citation-journal">Phung OJ, Baker WL, Tongbram V, Bhardwaj A, Coleman CI. <span class="citation-title">Oral antidiabetic drugs and regression from prediabetes to normoglycemia: a meta‐analysis</span>. <span class="citation"> Annals of Pharmacotherapy </span><span class="pubYear">2012</span>;<span class="volume">46</span>(4):469‐76. [PUBMED: 22474136] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22474136" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Oral+antidiabetic+drugs+and+regression+from+prediabetes+to+normoglycemia:+a+meta%E2%80%90analysis&author=OJ+Phung&author=WL+Baker&author=V+Tongbram&author=A+Bhardwaj&author=CI+Coleman&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0143"> <div class="reference-title-banner"> <h4 class="title">Pogue 1997</h4> </div> <div class="bibliography-section" id="CD012204-bib-0239"> <div class="citation-journal">Pogue JM, Yusuf S. <span class="citation-title">Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta‐analysis</span>. <span class="citation"> Controlled Clinical Trials </span><span class="pubYear">1997</span>;<span class="volume">18</span>(6):580‐93; discussion 661‐6. [PUBMED: 9408720] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9408720" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cumulating+evidence+from+randomized+trials:+utilizing+sequential+monitoring+boundaries+for+cumulative+meta%E2%80%90analysis+&author=JM+Pogue&author=S+Yusuf&publication_year=1997&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0144"> <div class="reference-title-banner"> <h4 class="title">Rask 2004</h4> </div> <div class="bibliography-section" id="CD012204-bib-0240"> <div class="citation-journal">Rask E, Olsson T, Soderberg S, Holst JJ, Tura A, Pacini G, et al. <span class="citation-title">Insulin secretion and incretin hormones after oral glucose in non‐obese subjects with impaired glucose tolerance</span>. <span class="citation"> Metabolism: Clinical and Experimental </span><span class="pubYear">2004</span>;<span class="volume">53</span>(5):624‐31. [PUBMED: 15131768] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15131768" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Insulin+secretion+and+incretin+hormones+after+oral+glucose+in+non%E2%80%90obese+subjects+with+impaired+glucose+tolerance+&author=E+Rask&author=T+Olsson&author=S+Soderberg&author=JJ+Holst&author=A+Tura&author=G+Pacini&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0145"> <div class="reference-title-banner"> <h4 class="title">Rehman 2017</h4> </div> <div class="bibliography-section" id="CD012204-bib-0241"> <div class="citation-journal">Rehman MB, Tudrej BV, Soustre J, Buisson M, Archambault P, Pouchain D, et al. <span class="citation-title">Efficacy and safety of DPP‐4 inhibitors in patients with type 2 diabetes: Meta‐analysis of placebo‐controlled randomized clinical trials</span>. <span class="citation"> Diabetes &amp; Metabolism </span><span class="pubYear">2017</span>;<span class="volume">43</span>(1):48‐58. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/27745828" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Efficacy+and+safety+of+DPP%E2%80%904+inhibitors+in+patients+with+type+2+diabetes:+Meta%E2%80%90analysis+of+placebo%E2%80%90controlled+randomized+clinical+trials+&author=MB+Rehman&author=BV+Tudrej&author=J+Soustre&author=M+Buisson&author=P+Archambault&author=D+Pouchain&publication_year=2017&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0146"> <div class="reference-title-banner"> <h4 class="title">Reid 2014</h4> </div> <div class="bibliography-section" id="CD012204-bib-0242"> <div class="citation-journal">Reid TS. <span class="citation-title">Practical use of glucagon‐like peptide‐1 receptor agonist therapy in primary care</span>. <span class="citation"> Clinical Diabetes </span><span class="pubYear">2014</span>;<span class="volume">31</span>(4):148‐57. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Practical+use+of+glucagon%E2%80%90like+peptide%E2%80%901+receptor+agonist+therapy+in+primary+care&author=TS+Reid&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0147"> <div class="reference-title-banner"> <h4 class="title">RevMan 2014 [Computer program]</h4> </div> <div class="bibliography-section" id="CD012204-bib-0243"> <div class="citation-other">The Nordic Cochrane Centre, The Cochrane Collaboration. <span class="citation-title">Review Manager (RevMan)</span>. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, <span class="pubYear">2014</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0148"> <div class="reference-title-banner"> <h4 class="title">Riley 2011</h4> </div> <div class="bibliography-section" id="CD012204-bib-0244"> <div class="citation-journal">Riley RD, Higgins JP, Deeks JJ. <span class="citation-title">Interpretation of random effects meta‐analyses</span>. <span class="citation"> BMJ </span><span class="pubYear">2011</span>;<span class="volume">342</span>:d549. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21310794" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Interpretation+of+random+effects+meta%E2%80%90analyses&author=RD+Riley&author=JP+Higgins&author=JJ+Deeks&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0149"> <div class="reference-title-banner"> <h4 class="title">Riley 2013</h4> </div> <div class="bibliography-section" id="CD012204-bib-0245"> <div class="citation-journal">Riley RD, Kauser I, Bland M, Thijs L, Staessen JA, Wang J, et al. <span class="citation-title">Meta‐analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data</span>. <span class="citation"> Statistics in Medicine </span><span class="pubYear">2013</span>;<span class="volume">32</span>(16):2747‐66. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23303608" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Meta%E2%80%90analysis+of+randomised+trials+with+a+continuous+outcome+according+to+baseline+imbalance+and+availability+of+individual+participant+data+&author=RD+Riley&author=I+Kauser&author=M+Bland&author=L+Thijs&author=JA+Staessen&author=J+Wang&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0150"> <div class="reference-title-banner"> <h4 class="title">Scirica 2013</h4> </div> <div class="bibliography-section" id="CD012204-bib-0246"> <div class="citation-journal">Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. <span class="citation-title">Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2013</span>;<span class="volume">369</span>(14):1317‐26. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1056" target="_blank"><span>10.1056</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23992601" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Saxagliptin+and+cardiovascular+outcomes+in+patients+with+type+2+diabetes+mellitus&author=BM+Scirica&author=DL+Bhatt&author=E+Braunwald&author=PG+Steg&author=J+Davidson&author=B+Hirshberg&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0151"> <div class="reference-title-banner"> <h4 class="title">Selvin 2011</h4> </div> <div class="bibliography-section" id="CD012204-bib-0247"> <div class="citation-journal">Selvin E, Steffes MW, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL. <span class="citation-title">Racial differences in glycemic markers: a cross‐sectional analysis of community‐based data</span>. <span class="citation"> Annals of Internal Medicine </span><span class="pubYear">2011</span>;<span class="volume">154</span>(5):303‐9. [PUBMED: 21357907] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21357907" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Racial+differences+in+glycemic+markers:+a+cross%E2%80%90sectional+analysis+of+community%E2%80%90based+data+&author=E+Selvin&author=MW+Steffes&author=CM+Ballantyne&author=RC+Hoogeveen&author=J+Coresh&author=FL+Brancati&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0152"> <div class="reference-title-banner"> <h4 class="title">Siddiqui 2009</h4> </div> <div class="bibliography-section" id="CD012204-bib-0248"> <div class="citation-journal">Siddiqui O, Hung HM, O'Neill R. <span class="citation-title">MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets</span>. <span class="citation"> Journal of Biopharmaceutical Statistics </span><span class="pubYear">2009</span>;<span class="volume">19</span>(2):227‐46. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19212876" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=MMRM+vs.+LOCF:+a+comprehensive+comparison+based+on+simulation+study+and+25+NDA+datasets&author=O+Siddiqui&author=HM+Hung&author=R+O'Neill&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0153"> <div class="reference-title-banner"> <h4 class="title">Sterne 2011</h4> </div> <div class="bibliography-section" id="CD012204-bib-0249"> <div class="citation-journal">Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. <span class="citation-title">Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials</span>. <span class="citation"> BMJ </span><span class="pubYear">2011</span>;<span class="volume">343</span>:d4002. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21784880" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Recommendations+for+examining+and+interpreting+funnel+plot+asymmetry+in+meta%E2%80%90analyses+of+randomised+controlled+trials+&author=JA+Sterne&author=AJ+Sutton&author=JP+Ioannidis&author=N+Terrin&author=DR+Jones&author=J+Lau&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0154"> <div class="reference-title-banner"> <h4 class="title">Toft‐Nielsen 2001</h4> </div> <div class="bibliography-section" id="CD012204-bib-0250"> <div class="citation-journal">Toft‐Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. <span class="citation-title">Determinants of the impaired secretion of glucagon‐like peptide‐1 in type 2 diabetic patients</span>. <span class="citation"> Journal of Clinical Endocrinology and Metabolism </span><span class="pubYear">2001</span>;<span class="volume">86</span>(8):3717‐23. [PUBMED: 11502801] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11502801" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Determinants+of+the+impaired+secretion+of+glucagon%E2%80%90like+peptide%E2%80%901+in+type+2+diabetic+patients+&author=MB+Toft%E2%80%90Nielsen&author=MB+Damholt&author=S+Madsbad&author=LM+Hilsted&author=TE+Hughes&author=BK+Michelsen&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0155"> <div class="reference-title-banner"> <h4 class="title">Tuomilehto 2001</h4> </div> <div class="bibliography-section" id="CD012204-bib-0251"> <div class="citation-journal">Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne‐Parikka P, et al. <span class="citation-title">Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance</span>. <span class="citation"> New England Journal of Medicine </span><span class="pubYear">2001</span>;<span class="volume">344</span>(18):1343‐50. [PUBMED: 11333990] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11333990" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prevention+of+type+2+diabetes+mellitus+by+changes+in+lifestyle+among+subjects+with+impaired+glucose+tolerance+&author=J+Tuomilehto&author=J+Lindstrom&author=JG+Eriksson&author=TT+Valle&author=H+Hamalainen&author=P+Ilanne%E2%80%90Parikka&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0156"> <div class="reference-title-banner"> <h4 class="title">Van de Laar 2006</h4> </div> <div class="bibliography-section" id="CD012204-bib-0252"> <div class="citation-journal">Laar FA, Lucassen PL, Akkermans RP, Lisdonk EH, Grauw WJ. <span class="citation-title">Alpha‐glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2006</span>, Issue 4. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD005061.pub2" target="_blank"><span>10.1002/14651858.CD005061.pub2</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17054235" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Alpha%E2%80%90glucosidase+inhibitors+for+people+with+impaired+glucose+tolerance+or+impaired+fasting+blood+glucose+&author=FA+Laar&author=PL+Lucassen&author=RP+Akkermans&author=EH+Lisdonk&author=WJ+Grauw&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0157"> <div class="reference-title-banner"> <h4 class="title">Viera 2011</h4> </div> <div class="bibliography-section" id="CD012204-bib-0253"> <div class="citation-journal">Viera AJ. <span class="citation-title">Predisease: when does it make sense?</span>. <span class="citation"> Epidemiologic Reviews </span><span class="pubYear">2011</span>;<span class="volume">33</span>:122‐34. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21624963" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Predisease:+when+does+it+make+sense?&author=AJ+Viera&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0158"> <div class="reference-title-banner"> <h4 class="title">Vist 2008</h4> </div> <div class="bibliography-section" id="CD012204-bib-0254"> <div class="citation-journal">Vist GE, Bryant D, Somerville L, Birminghem T, Oxman AD. <span class="citation-title">Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2008</span>, Issue 3. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.MR000009.pub4" target="_blank"><span>10.1002/14651858.MR000009.pub4</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Outcomes+of+patients+who+participate+in+randomized+controlled+trials+compared+to+similar+patients+receiving+similar+interventions+who+do+not+participate+&author=GE+Vist&author=D+Bryant&author=L+Somerville&author=T+Birminghem&author=AD+Oxman&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0159"> <div class="reference-title-banner"> <h4 class="title">Wetterslev 2008</h4> </div> <div class="bibliography-section" id="CD012204-bib-0255"> <div class="citation-journal">Wetterslev J, Thorlund K, Brok J, Gluud C. <span class="citation-title">Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis</span>. <span class="citation"> Journal of Clinical Epidemiology </span><span class="pubYear">2008</span>;<span class="volume">61</span>(1):64‐75. [PUBMED: 18083463] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18083463" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Trial+sequential+analysis+may+establish+when+firm+evidence+is+reached+in+cumulative+meta%E2%80%90analysis+&author=J+Wetterslev&author=K+Thorlund&author=J+Brok&author=C+Gluud&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0160"> <div class="reference-title-banner"> <h4 class="title">WHO 1998</h4> </div> <div class="bibliography-section" id="CD012204-bib-0256"> <div class="citation-journal">Alberti KM, Zimmet PZ. <span class="citation-title">Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">1998</span>;<span class="volume">15</span>(7):539‐53. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9686693" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Definition,+diagnosis+and+classification+of+diabetes+mellitus+and+its+complications.+Part+I:+diagnosis+and+classification+of+diabetes+mellitus.+Provisional+report+of+a+WHO+consultation+&author=KM+Alberti&author=PZ+Zimmet&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0161"> <div class="reference-title-banner"> <h4 class="title">WHO 1999</h4> </div> <div class="bibliography-section" id="CD012204-bib-0257"> <div class="citation-book">World Health Organization. <span class="citation">Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus</span>. Geneva: WHO, <span class="pubYear">1999</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0162"> <div class="reference-title-banner"> <h4 class="title">WHO/IDF 2006</h4> </div> <div class="bibliography-section" id="CD012204-bib-0258"> <div class="citation-other">World Health Organization/International Diabetes Federation. <span class="citation-title">Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation</span>. www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf<span class="pubYear">2006</span>; Vol. (assessed 7 May 2017). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0163"> <div class="reference-title-banner"> <h4 class="title">Wong 2006a</h4> </div> <div class="bibliography-section" id="CD012204-bib-0259"> <div class="citation-journal">Wong SS, Wilczynski NL, Haynes RB. <span class="citation-title">Comparison of top‐performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE</span>. <span class="citation"> Journal of the Medical Library Association </span><span class="pubYear">2006</span>;<span class="volume">94</span>(4):451‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17082841" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparison+of+top%E2%80%90performing+search+strategies+for+detecting+clinically+sound+treatment+studies+and+systematic+reviews+in+MEDLINE+and+EMBASE+&author=SS+Wong&author=NL+Wilczynski&author=RB+Haynes&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0164"> <div class="reference-title-banner"> <h4 class="title">Wong 2006b</h4> </div> <div class="bibliography-section" id="CD012204-bib-0260"> <div class="citation-journal">Wong SSL, Wilczynski NL, Haynes RB. <span class="citation-title">Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE</span>. <span class="citation"> Journal of the Medical Library Association </span><span class="pubYear">2006</span>;<span class="volume">94</span>(1):41‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16404468" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Developing+optimal+search+strategies+for+detecting+clinically+sound+treatment+studies+in+EMBASE+&author=SSL+Wong&author=NL+Wilczynski&author=RB+Haynes&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0165"> <div class="reference-title-banner"> <h4 class="title">Wood 2008</h4> </div> <div class="bibliography-section" id="CD012204-bib-0261"> <div class="citation-journal">Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. <span class="citation-title">Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study</span>. <span class="citation"> BMJ </span><span class="pubYear">2008</span>;<span class="volume">336</span>(7644):601‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18316340" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Empirical+evidence+of+bias+in+treatment+effect+estimates+in+controlled+trials+with+different+interventions+and+outcomes:+meta%E2%80%90epidemiological+study+&author=L+Wood&author=M+Egger&author=LL+Gluud&author=KF+Schulz&author=P+J%C3%BCni&author=DG+Altman&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0166"> <div class="reference-title-banner"> <h4 class="title">Yudkin 2014</h4> </div> <div class="bibliography-section" id="CD012204-bib-0262"> <div class="citation-journal">Yudkin JS, Montori VM. <span class="citation-title">The epidemic of pre‐diabetes: the medicine and the politics</span>. <span class="citation"> BMJ </span><span class="pubYear">2014</span>;<span class="volume">349</span>:g4485. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25028385" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+epidemic+of+pre%E2%80%90diabetes:+the+medicine+and+the+politics&author=JS+Yudkin&author=VM+Montori&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD012204-bbs2-0167"> <div class="reference-title-banner"> <h4 class="title">Zannad 2015</h4> </div> <div class="bibliography-section" id="CD012204-bib-0263"> <div class="citation-journal">Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. <span class="citation-title">Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double‐blind trial</span>. <span class="citation"> Lancet </span><span class="pubYear">2015</span>;<span class="volume">385</span>(9982):2067‐76. [PUBMED: 25765696] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/25765696" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Heart+failure+and+mortality+outcomes+in+patients+with+type+2+diabetes+taking+alogliptin+versus+placebo+in+EXAMINE:+a+multicentre,+randomised,+double%E2%80%90blind+trial+&author=F+Zannad&author=CP+Cannon&author=WC+Cushman&author=GL+Bakris&author=V+Menon&author=AT+Perez&publication_year=2015&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> </section> <section class="characteristicStudies" id="characteristicStudies"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title"> Characteristics of studies <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="characteristicIncludedStudiesContent" lang=""> <div class="section-header" id="CD012204-sec2-0036"> <h3 class="title">Characteristics of included studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD012204-sec2-0037" class="jump-to">excluded studies</a></li> <li><a href="#CD012204-sec2-0038" class="jump-to">awaiting classification</a></li> <li><a href="#CD012204-sec2-0039" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Ariel 2014 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Design</b>: parallel RCT </p> <p><b>Randomisation ratio</b>: 1:1 </p> <p><b>Number of study centres</b>: 1 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Inclusion criteria</b>: aged 40‐70 years; IFG or IGT; BMI 27.0‐37.0 kg/m²; stable weight (&lt; 5% reported change) in the previous 3 months </p> <p><b>Exclusion criteria</b>: T2DM; use of medications that can affect carbohydrate metabolism or promote weight loss; gallstones; history of pancreatitis; medullary carcinoma; family history of medullary carcinoma or multiple endocrine neoplasia type 2; and known cardiac, liver or kidney disease </p> <p><b>Diagnostic criteria</b>: criteria for intermediate hyperglycaemia as defined by ADA: intermediate hyperglycaemia defined as elevated fasting glucose (5.6‐6.9 mmol/L) or elevated 2‐h glucose (7.8‐11.0 mmol/L) concentration after OGTT with 75‐g glucose, or both; 1 of the publications defined intermediate hyperglycaemia as elevated fasting glucose (5.6‐6.9 mmol/L) or elevated 2‐h glucose (7.8‐10.5 mmol/L) concentration after OGTT with 75‐g glucose, or both </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: liraglutide 1.8 mg subcutaneous </p> <p><b>Comparator</b>: placebo subcutaneous </p> <p><b>Run‐in period</b>: none </p> <p><b>Study drug administration free period before glucose testing during trial</b>: fasting glucose measured on the days of the insulin suppression test. On these days, the trial medication was given after the testing </p> <p><b>Extension period</b>: none </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Composite outcome measures reported</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: English </p> <p><b>Funding</b>: commercial funding (liraglutide and matching placebo were provided by Novo Nordisk); non‐commercial funding (ADA) </p> <p><b>Publication status</b>: peer‐reviewed journal/full article </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim for study</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "To evaluate the effects of 14 weeks of liraglutide plus modest caloric restriction on lipid/lipoprotein metabolism in overweight/obese persons with prediabetes." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>The participants visited a dietitian weekly for the first 4 weeks, and then every 2 weeks. They were advised to eat a moderate‐carbohydrate diet (43% carbohydrate, 42% fat and 15% protein) and to decrease total caloric intake by 500 kcal/day. Individualised meal plan was provided </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "This was a double‐blind, randomised, placebo controlled, parallel‐group study. Participants were randomised to receive either liraglutide (n =35) or matching placebo (n =33) by block randomisation by sex and BMI (&lt;31 vs ≥31 kg/m²) via a computerised randomisation system." </p> <p><b>Comment</b>: method of random sequence generation adequately described </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "This was a double‐blind, randomised, placebo controlled, parallel‐group study. Participants were randomised to receive either liraglutide (n =35) or matching placebo (n =33) by block randomisation by sex and BMI (&lt;31 vs ≥31 kg/m²) via a computerised randomisation system." </p> <p><b>Comment</b>: method of allocation concealment adequately described </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "We conducted a double‐blind ..." </p> <p><b>Comment</b>: investigator‐assessed </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "We conducted a double‐blind ..." </p> <p><b>Comment</b>: investigator‐assessed </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Only subjects who had end‐of‐study testing were included in the analyses." </p> <p><b>Comment</b>: 31% (n = 11) in liraglutide group and 18% (n = 6) in placebo group dropped out during the trial and were not included in the final analysis of fasting blood glucose </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: no selective outcome reporting bias </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "funding was received by a pharmaceutical company." </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Kelly 2012 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Design</b>: parallel RCT </p> <p><b>Randomisation ratio</b>: 1:1 </p> <p><b>Number of study centres</b>: 2 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Inclusion criteria</b>: aged ≥ 18 years; IGT or IFG or moderately elevated HbA1c; abdominal obesity: waist circumference &gt; 102 cm (men) and &gt; 88 cm (women); stable cardiovascular medication regimen (or other medications known to affect endothelial function) at least 1 month prior to enrolment and throughout the study </p> <p><b>Exclusion criteria</b>: T2DM; current use of glycaemic control medications within 1 month of randomisation; fasting glucose &gt; 126 mg/dL (7.0 mmol/L); current use of weight loss medication; previous weight loss surgery; history of severe gastrointestinal disease; standard clinical contraindications to exenatide or metformin; unstable angina; heart failure; stroke or coronary artery bypass graft within 3 months of screening; women who were currently pregnant or planning to become pregnant; breastfeeding women; clinically significant liver disease; creatinine &gt; 1.5 mg/dL; hepatic function &gt; 3 times upper limit of normal; mentally incompetent and cannot sign a patient informed consent form </p> <p><b>Diagnostic criteria</b>: criteria for intermediate hyperglycaemia as defined by ADA: IGT: 2‐h OGTT plasma glucose &gt; 140 mg/dL (7.8 mmol/L); IFG: fasting glucose ≥ 100 mg/dL (5.6 mmol/L); moderately elevated HbA1c ≥ 5.7% </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: exenatide 10 μg twice daily </p> <p><b>Comparator</b>: metformin 1000 mg twice daily </p> <p><b>Run‐in period</b>: none </p> <p><b>Study drug administration free period before glucose testing during trial</b>: all testing was performed in the morning after fasting. The study drugs were withheld on these mornings </p> <p><b>Extension period</b>: none </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Composite outcome measures reported</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: English </p> <p><b>Funding</b>: commercial funding (funding was provided by an investigator‐initiated grant from Amylin Pharmaceuticals and Eli Lilly and Company) </p> <p><b>Publication status</b>: peer‐reviewed journal/full article </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim for study</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "The purpose of this study is to compare the effects of exenatide versus metformin on vascular health with chronic (3‐month) therapy and during a 2‐hour period following a meal in patients with pre‐diabetes. It is predicted that exenatide will improve vascular health to a greater degree compared to metformin." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "We performed a 3‐month, randomized (1:1), open‐label, head‐to‐head (exenatide vs. metformin) clinical trial." </p> <p><b>Comment</b>: method of random sequence generation not adequately described </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "We performed a 3‐month, randomized (1:1), open‐label, head‐to‐head (exenatide vs. metformin) clinical trial." </p> <p><b>Comment</b>: method of allocation concealment not adequately described </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "We performed a randomized, open‐label ..." </p> <p><b>Comment</b>: investigator‐assessed outcome measurement, outcome unlikely to be influenced by lack of blinding </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> non‐serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "We performed a randomized, open‐label ..." </p> <p><b>Comment</b>: self‐reported and investigator‐assessed outcome measurement. Trial observed no non‐serious adverse events </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "We performed a randomized, open‐label ..." </p> <p><b>Comment</b>: investigator‐assessed outcome measurement, outcome unlikely to be influenced by lack of blinding </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "We performed a randomized, open‐label ..." </p> <p><b>Comment</b>: investigator‐assessed outcome measurement, outcome unlikely to be influenced by lack of blinding </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> non‐serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "We performed a randomized, open‐label ..." </p> <p><b>Comment</b>: self‐reported and investigator‐assessed outcome measurement. Trial observed no non‐serious adverse events. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "We performed a randomized, open‐label ..." </p> <p><b>Comment</b>: investigator‐assessed outcome measurement, outcome unlikely to be influenced by lack of blinding </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: all randomised participants completed study and were included in analysis </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> non‐serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: all randomised participants completed study and were included in analysis </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from ClinicalTrials.gov</b>: "Threshold above which other adverse events are reported 5." </p> <p><b>Comment</b>: quote referred to non‐serious adverse events, meaning that adverse events with a lower frequency were not reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: funding received from a pharmaceutical company </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Martinez‐Abundis 2015 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Design</b>: parallel RCT </p> <p><b>Randomisation ratio</b>: 1:1 </p> <p><b>Number of study centres</b>: NR, presumably 1 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Inclusion criteria</b>: IGT with overweight or obesity, no other inclusion criteria specified </p> <p><b>Exclusion criteria</b>: not specified </p> <p><b>Diagnostic criteria</b>: IGT, not further specified </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: linagliptin 5 mg + placebo. </p> <p><b>Comparator</b>: metformin 500 mg twice daily </p> <p><b>Run‐in period</b>: NR </p> <p><b>Study drug administration free period before glucose testing during trial</b>: NR </p> <p><b>Extension period</b>: none </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Composite outcome measures reported</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: English </p> <p><b>Funding</b>: NR </p> <p><b>Publication status</b>: abstract </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim for study</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "The aim of this study was to assess the effect of linagliptin on glycemic control and GV in patients with IGT." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"></td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote from internal correspondence</b>: "Yes, we used a table of random numbers for randomisation." </p> <p><b>Comment</b>: method of random sequence generation judged sufficient </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: method for allocation concealment NR </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "A randomized, double blind clinical trial with parallel groups ..." </p> <p><b>Comment</b>: measured by investigator at baseline and end of follow‐up. Blinding ensured by placebo tablet </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> non‐serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "A randomized, double blind clinical trial with parallel groups ..." </p> <p><b>Comment</b>: unclear how non‐serious adverse events were adjudicated. Blinding ensured by placebo tablet </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "A randomized, double blind clinical trial with parallel groups ..." </p> <p><b>Comment</b>: measured by investigator at baseline and end of follow‐up. Blinding ensured by placebo tablet </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> non‐serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "A randomized, double blind clinical trial with parallel groups ..." </p> <p><b>Comment</b>: unclear how non‐serious adverse events were adjudicated. Blinding ensured by placebo tablet </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: according to data provided by investigators all participants were included in analysis </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: insufficient information about selective reporting. No trial protocol available </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: funding source NR </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">McLaughlin 2011 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Design</b>: parallel RCT, superiority design, controlled clinical trial </p> <p><b>Randomisation ratio</b>: 1:1 </p> <p><b>Number of study centres</b>: NR </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Inclusion criteria</b>: aged 30‐70 years; healthy men and women, BMI 27‐37 kg/m²; FPG ≥ 100 mg/dL and ≤ 125 mg/dL or a 2‐h post OGTT ≥ 140 mg/dL or ≤ 199 mg/dL </p> <p><b>Exclusion criteria</b>: diabetes; active cardiac, kidney, liver, pulmonary or other major organ diseases that are cause for exclusion; other exclusionary criteria include: use of corticosteroids, diet medications or antipsychotic medications, history of eating disorder, history of bariatric surgery, active malignancy, recent weight change &gt; 2%, inability to attend follow‐up visits, excessive alcohol use, investigator's discretion that it is not in person's best interest. </p> <p><b>Diagnostic criteria</b>: criteria for intermediate hyperglycaemia as defined by ADA: FPG ≥ 100 mg/dL and ≤ 125 mg/dL or a 2‐h post OGTT ≥ 140 mg/dL or ≤ 199 mg/dL </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: exenatide 10 μg twice daily </p> <p><b>Comparator</b>: placebo </p> <p><b>Run‐in period</b>: none </p> <p><b>Study drug administration free period before glucose testing during trial</b>: NR </p> <p><b>Extension period</b>: none </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Composite outcome measures reported</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: English </p> <p><b>Funding</b>: NR </p> <p><b>Publication status</b>: abstract </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim for study</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "We sought to evaluate persistence of weight and metabolic benefits of exenatide in moderately‐obese prediabetics one year after discontinuing the drug." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Contacted investigator Dr Tracey, but the trial is not yet published as an article</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "In a double blinded, randomized controlled design ..." </p> <p><b>Comment</b>: method of random sequence generation not adequately described </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "In a double blinded, randomized controlled design ..." </p> <p><b>Comment</b>: method of allocation concealment not adequately described </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: stated in abstract that fasting blood glucose and 2‐h blood glucose were measured, but data not reported in a way that they could be included in review. Useable data might be available in updates </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: funding source NR </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Rosenstock 2008 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Design</b>: parallel RCT </p> <p><b>Randomisation ratio</b>: 1:1 </p> <p><b>Number of study centres</b>: 28 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Inclusion criteria</b>: aged 18‐80 years with IGT as defined as FPG &lt; 126 mg/dL (7.0 mmol/L) and 2‐h post‐challenge plasma glucose (after OGTT 75‐g glucose) 140 mg/dL (7.8 mmol/L) to &lt; 200 mg/dL (&lt; 11.1 mmol/L) and BMI 23‐45 kg/m². Agreement to maintain prior diet and exercise habits during the full course of trial. Women with childbearing potential required to use medically approved contraception </p> <p><b>Exclusion criteria</b>: pregnant or lactating women; diabetes (defined as any of: FPG ≥ 126 mg/dL (7.0 mmol/L) at visit 1 (week ‐4); 2‐h post‐challenge plasma glucose (after OGTT 75‐g glucose) ≥ 200 mg/dL (11.1 mmol/L) at visit 1 (week ‐4); diabetes diagnosed by physician and confirmed by other clinical data, other than gestational diabetes; use of insulin or any oral antidiabetic agents prior to visit 1 (week ‐4), other than during pregnancy); acute infections that may have affected blood glucose control within 4 weeks prior to visit 1 (week ‐4); history of torsades de pointes, sustained and clinically relevant ventricular tachycardia or ventricular fibrillation; percutaneous coronary intervention within the past 3 months; any of the following within the past 6 months: myocardial infarction, coronary artery bypass surgery, unstable angina or stroke; congestive heart failure NYHA class III or IV; second‐degree AV block (Mobitz 1 and 2), third degree AV block; prolonged QTc; malignancy including leukaemia and lymphoma (not including basal cell skin cancer) within last 5 years; liver disease; acromegaly or treatment with growth hormone or similar drugs; concurrent medical condition that may interfere with interpretation of efficacy and safety data during trial; donation of ≥ 1 unit (500 mL) blood, significant blood loss ≥ 1 unit of blood within past 2 weeks, or a blood transfusion within past 8 weeks; chronic insulin treatment (&gt; 4 weeks of treatment in the absence of an intercurrent illness) within past 6 months; chronic oral or parenteral corticosteroid treatment (&gt; 7 consecutive days of treatment) within 8 weeks prior to visit 1 (week ‐4); treatment with class Ia, Ib and Ic, or III anti‐arrhythmic drugs; thyroid hormone replacement allowed if dosage had been stable for ≥ 3 months; use of other investigational drugs at visit 1 (week ‐4), or within 30 days or 5 half‐lives of visit 1 (week ‐4), whichever longer, unless local health authority guidelines mandate a longer period; treatment with any drug with a known and frequent toxicity to a major organ system within the past 3 months; any of the following significant laboratory abnormalities alanine aminotransferase, aspartate aminotransferase &gt; 3 times the upper limit of the normal range, direct bilirubin &gt; 1.3 times the upper limit of the normal range at visit 2 (week ‐2), serum creatinine levels ≥ 2.5 mg/dL (220 μmol/L) at visit 2 (week ‐2), thyroid‐stimulating hormone outside normal range at visit 2 (week ‐2), clinically significant laboratory abnormalities confirmed by repeat measurement at visit 2 (week ‐2), fasting triglycerides &gt; 700 mg/dL (&gt; 7.9 mmol/L) at visit 2 (week ‐2); history of active substance abuse (including alcohol) within the past 2 years; potentially unreliable people, and people judged by investigator to be unsuitable for trial </p> <p><b>Diagnostic criteria</b>: criteria for IGT as defined by WHO: FPG &lt; 126 mg/dL (7.0 mmol/L) and 2‐h post‐challenge plasma glucose (after a OGTT 75‐g glucose) ≥ 140 mg/dL (7.8 mmol/L) to &lt; 200 mg/dL (11.1 mmol/L) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: vildagliptin 50 mg once daily </p> <p><b>Comparator</b>: placebo </p> <p><b>Run‐in period</b>: none </p> <p><b>Study drug administration free period before glucose testing during trial</b>: study drug not given before test meal at baseline but was given 15 minutes before test meal at week 12; not described if study drug provided before measurement of OGTT and fasting glucose </p> <p><b>Extension period</b>: none </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Composite outcome measures reported</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: English </p> <p><b>Funding</b>: commercial funding (Novartis Pharmaceuticals Corporation) </p> <p><b>Publication status</b>: peer‐reviewed journal. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim for study</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "This study was conducted to determine the effects of vildagliptin on incretin hormone levels, islet function, and postprandial glucose control in subjects with impaired glucose tolerance (IGT)." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Each potential relevant participant attended a prescreening visit (week ‐4) where an OGTT was performed. Possible participants with confirmed IGT then attended main screening visit (week ‐2) where all the inclusion/exclusion criteria were assessed. Eligible participants randomised at visit 3 (baseline, day 1) and completed 2 further visits over 12 weeks of treatment with vildagliptin or placebo </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "... double‐blind, randomized, placebo‐controlled, parallel‐group study conducted ..." </p> <p><b>Comment</b>: method of random sequence generation not adequately described </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "... double‐blind, randomized, placebo‐controlled, parallel‐group study conducted ..." </p> <p><b>Comment</b>: method of allocation concealment not adequately described </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: self‐reported outcome measurement. Blinding of participants ensured using placebo tablet </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> incidence of T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: listed as adverse events. Investigator assessed outcome measurement. Blinding ensured using placebo tablet </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> non‐fatal myocardial infarction/stroke, congestive heart failure </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: investigator assessed outcome measurement. Blinding ensured using placebo tablet </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> non‐serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: investigator assessed outcome measurement. Blinding ensured using placebo tablet </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: investigator assessed outcome measurement. Blinding ensured using placebo tablet </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: self‐reported outcome measurement. Blinding of participants ensured by placebo tablet </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> incidence of T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: listed as adverse events; investigator assessed outcome measurement. Blinding ensured by placebo tablet </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: measured by investigator at baseline and end of follow‐up. Blinding ensured by placebo tablet </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> non‐serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: adjudicated by investigator at baseline and end of follow‐up. Blinding ensured by placebo tablet </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: adjudicated by investigator at baseline and end of follow‐up. Blinding ensured by placebo tablet </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: 5 participants missing in each group. Reasons for vildagliptin group: adverse events (n = 3); withdrew consent (n = 1); protocol violation (n = 1); lost to follow‐up (n = 0). For placebo group: adverse events (n = 2); withdrew consent (n = 1); protocol violation (n = 2); lost to follow‐up (n = 0); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; proportion of missing outcomes not enough to have a clinically relevant impact on intervention effect estimate </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: 5 participants missing in each group. Reasons for vildagliptin group: adverse events (n = 3); withdrew consent (n = 1); protocol violation (n = 1); lost to follow‐up (n = 0). For placebo group: adverse events (n = 2); withdrew consent (n = 1); protocol violation (n = 2); lost to follow‐up (n = 0); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; proportion of missing outcomes not enough to have a clinically relevant impact on intervention effect estimate </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> non‐fatal myocardial infarction/stroke, congestive heart failure </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: 5 participants missing in each group. Reasons for vildagliptin group: adverse events (n = 3); withdrew consent (n = 1); protocol violation (n = 1); lost to follow‐up (n = 0). For placebo group: adverse events (n = 2); withdrew consent (n = 1); protocol violation (n = 2); lost to follow‐up (n = 0); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; proportion of missing outcomes not enough to have a clinically relevant impact on intervention effect estimate </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> non‐serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: 5 participants missing in each group. Reasons for vildagliptin group: adverse events (n = 3); withdrew consent (n = 1); protocol violation (n = 1); lost to follow‐up (n = 0). For placebo group: adverse events (n = 2); withdrew consent (n = 1); protocol violation (n = 2); lost to follow‐up (n = 0); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; proportion of missing outcomes not enough to have a clinically relevant impact on intervention effect estimate </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: 5 participants missing in each group. Reason for vildagliptin group: adverse events (n = 3); withdrew consent (n = 1); protocol violation (n = 1); lost to follow‐up (n = 0). For placebo group: adverse events (n = 2); withdrew consent (n = 1); protocol violation (n = 2); lost to follow‐up (n = 0); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; proportion of missing outcomes not enough to have a clinically relevant impact on the intervention effect estimate </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: trial protocol available and all the trial's prespecified outcomes that were of interest in review were reported in prespecified way </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: funding received by a pharmaceutical company </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Rosenstock 2010 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Design</b>: parallel RCT </p> <p><b>Randomisation ratio</b>: 1:1 </p> <p><b>Number of study centres</b>: 16 (identified through ClinicalTrials.gov) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Inclusion criteria</b>: BMI ≥ 30 kg/m²; aged ≥ 18 years </p> <p><b>Exclusion criteria</b>: participated in this study previously, or any other study using exenatide or GLP‐1 analogues; participated in an interventional medical, surgical or pharmaceutical study (a study in which an experimental, drug, medical or surgical treatment was given) within 30 days of study start (this criterion included drugs that had not received regulatory approval for any indication at time of study entry); diagnosis of diabetes mellitus (other than gestational diabetes), or previous use of antidiabetic medications for &gt; 3 months; change in prescribed lipid‐lowering or blood pressure agents within 4 weeks of screening; used drugs for weight loss (e.g. orlistat, sibutramine, phenylpropanolamine, rimonabant, low‐dose orlistat or other similar non‐prescription weight loss remedies or medications) within 3 months of screening; actively participating in, or have participated in a formal weight loss programme within the last 3 months; have a history of chronic use of drugs that directly affect gastrointestinal motility, including, but not limited to, metoclopramide and chronic macrolide antibiotics; treated with any antidiabetic medications within 3 months of screening; receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy or have received such therapy within the 4 weeks immediately prior to study start; have had bariatric surgery; have had an organ transplant </p> <p><b>Diagnostic criteria</b>: criteria for intermediate hyperglycaemia as defined by WHO; IGT (fasting glucose &lt; 7 mmol/L and 2‐h postprandial glucose ≥ 7.8 to &lt; 11.1 mmol/L); IFG (fasting glucose 6.1‐6.9 mmol/L and 2‐h postprandial glucose &lt; 7.8 mmol/L) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: exenatide 10 μg twice daily </p> <p><b>Comparator</b>: placebo </p> <p><b>Run‐in period</b>: prior to randomisation, a 1‐week single‐blind placebo lead‐in period was performed </p> <p><b>Study drug administration free period before glucose testing during trial</b>: study drug was withheld before OGTT assessments. Follow‐up visit conducted 4 weeks after study completion </p> <p><b>Extension period</b>: none </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Composite outcome measures reported</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: English </p> <p><b>Funding</b>: commercial funding (Eli Lilly and Company and Amylin Pharmaceuticals) </p> <p><b>Publication status</b>: peer‐reviewed journal. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim for study</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "To assess the effects of exenatide on body weight and glucose tolerance in nondiabetic obese subjects with normal or impaired glucose tolerance (IGT) or impaired fasting glucose (IFG)." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>38/152 participants had IFG or IGT at baseline</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "... were randomized to receive exenatide ..." </p> <p><b>Comment</b>: method of random sequence generation not adequately described. No separate baseline variables available for participants with IFG or IGT, or both </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "... were randomized to receive exenatide ..." </p> <p><b>Comment</b>: method of allocation concealment not adequately described. No separate baseline variables available for participants with IFG or IGT, or both </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> all‐cause/cardiovascular mortality </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "No deaths, serious adverse events, or hypoglycemia were observed during the study." Blinding was ensured by placebo injection </p> <p><b>Comment</b>: investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "No deaths, serious adverse events, or hypoglycemia were observed during the study." Blinding was ensured by placebo injection </p> <p><b>Comment</b>: investigator‐assessed outcome measurement/self‐reported (mild hypoglycaemia) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> incidence of T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Five participants (three exenatide, two placebo) developed type 2 diabetes during the study, three of which (two exenatide, one placebo) had IGT or IFG at baseline." Blinding was ensured by placebo injection </p> <p><b>Comment</b>: investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "No deaths, serious adverse events, or hypoglycemia were observed during the study." Blinding was ensured by placebo injection </p> <p><b>Comment</b>: investigator‐assessed outcome measurement/self‐reported (mild hypoglycaemia) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> all‐cause/cardiovascular mortality </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "No deaths, serious adverse events, or hypoglycemia were observed during the study." Blinding was ensured by placebo injection </p> <p><b>Comment</b>: investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "No deaths, serious adverse events, or hypoglycemia were observed during the study." Blinding was ensured by placebo injection </p> <p><b>Comment</b>: investigator‐assessed outcome measurement/self‐reported (mild hypoglycaemia) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> incidence of T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Five participants (three exenatide, two placebo) developed type 2 diabetes during the study, three of which (two exenatide, one placebo) had IGT or IFG at baseline." Blinding was ensured by placebo injection </p> <p><b>Comment</b>: investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "No deaths, serious adverse events, or hypoglycemia were observed during the study." Blinding was ensured by placebo injection </p> <p><b>Comment</b>: investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> all‐cause/cardiovascular mortality </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: 163 participants randomised. 152 participants included in analyses, 96 completed final follow‐up visit. Balanced across groups. 38 randomised with IFG or IGT, 33 included in analyses of abstract in publication, and presumably received at least 1 dose of study drug. Unknown how many participants with IFG or IGT completed final visit. Method of imputation of missing data not explained </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: 163 participants randomised. 152 participants included in analyses, 96 completed final follow‐up visit. Balanced across groups. 38 randomised with IFG or IGT, 33 included in analyses of abstract in publication, and presumably received at least 1 dose of study drug. Unknown how many participants with IFG or IGT completed final visit. Method of imputation of missing data not explained. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> incidence of T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: 163 participants randomised. 152 participants included in analyses, 96 completed final follow‐up visit. Balanced across groups. 38 randomised with IFG or IGT, 33 included in analyses of abstract in publication, and presumably received at least 1 dose of study drug. Unknown how many participants with IFG or IGT completed final visit. Method of imputation of missing data not explained </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: 163 participants randomised. 152 participants included in analyses, 96 completed final follow‐up visit. Balanced across groups. 38 randomised with IFG or IGT, 33 included in analyses of abstract in publication, and presumably received at least 1 dose of study drug. Unknown how many participants with IFG or IGT completed final visit. Method of imputation of missing data not explained </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: subgroup of participants with IFG or IGT, or both not prespecified in available protocol, except for normalisation of glycaemic levels (<a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNXGT5UJMNRXZ7DTNFRXZ63PM7YYG/ct2/show/study/NCT00500370?sect=X43m0156" target="_blank">NCT00500370</a>). Several outcomes of interest for this review reported for all participants but not separately reported for participants with IFG or IGT, or both </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: participants with IFG or IGT, or both were only a subgroup of participants; funding received from a pharmaceutical company </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">SCALE </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Design</b>: parallel RCT </p> <p><b>Randomisation ratio</b>: 2:1 </p> <p><b>Number of study centres</b>: 191 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Inclusion criteria</b>: aged ≥ 18 years; informed consent obtained before any trial‐related activity took place; obesity (BMI ≥ 30.0 kg/m²) or overweight (BMI ≥ 27.0 kg/m²) with treated or untreated comorbid dyslipidaemia (LDL ≥ 160 mg/dL, or triglycerides ≥ 150 mg/dL, or HDL &lt; 40 mg/dL for men and &lt; 50 mg/dL for women) or hypertension (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg), or both; stable body weight (&lt; 5 kg self‐reported change during the previous 3 months); preceding failed dietary effort </p> <p><b>Exclusion criteria</b>: diagnosis of T1DM or T2DM per the judgement of investigator; HbA1c ≥ 6.5% or FPG ≥ 126 mg/dL (7.0 mmol/L) or 2‐h post‐challenge plasma glucose ≥ 200 mg/dL (11.1 mmol/L) (at screening); previous treatment with glucagon‐like peptide‐1 receptor agonists (including liraglutide or exenatide) within last 3 months; untreated or uncontrolled hypothyroidism/hyperthyroidism defined as thyroid‐stimulating hormone &gt; 6 mIU/L or &lt; 0.4 mIU/L; screening calcitonin ≥ 50 ng/L; family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma; personal history of non‐familial medullary thyroid carcinoma; history of chronic pancreatitis or idiopathic acute pancreatitis; obesity induced by other endocrinological disorders (e.g. Cushing's syndrome); current or history of treatment with medications that may cause significant weight gain, within 3 months prior to screening, including systemic corticosteroids (except for a short course of treatment, i.e. 7‐10 days), tricyclic antidepressants, atypical antipsychotic and mood stabilisers (e.g. imipramine, amitriptyline, mirtazepine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid and its derivatives, and lithium); diet attempts using herbal supplements or non‐prescription medications within 3 months before screening; current participation (or within the last 3 months) in an organised weight reduction programme or currently using or used within 3 months before screening: pramlintide, sibutramine, orlistat, zonisamide, topiramate, phentermine or metformin (either by prescription or as part of a clinical trial); participation in a clinical trial within the last 3 months prior to screening; simultaneous participation in any other clinical trial of an investigational drug; previous surgical treatment for obesity (excluding liposuction if performed &gt; 1 year before trial entry); history of major depressive disorder within the last 2 years; history of other severe psychiatric disorders(e.g. schizophrenia, bipolar disorder; Patient Health Questionnaire (PHQ‐9) score ≥ 15); any lifetime history of a suicidal attempt; history of any suicidal behaviour in month prior to randomisation; any suicidal ideation of type 4 or 5 on the Columbian Suicidality Severity Rating Scale (C‐SSRS) in month prior to randomisation; surgery scheduled for the trial duration period, except for minor surgical procedures, at the discretion of investigator; uncontrolled treated/untreated hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg, or both) (if white‐coat hypertension suspected at screening, a repeated measurement prior to other trial‐related activities allowed); cancer (past or present, except basal cell skin cancer or squamous cell skin cancer), which in investigator's opinion could interfere with the results of the trial; known or suspected hypersensitivity to trial product or related products; previous participation in the randomised phase of this trial. Re‐screening allowed once within limit of recruitment period; known or suspected abuse of alcohol or narcotics; language barrier, mental incapacity, unwillingness or inability to understand and be able to complete the mental health questionnaire in the provided language; people from the same household participating in the trial; women of child‐bearing potential who were pregnant, breastfeeding or intend to become pregnant or were not using adequate contraception (adequate contraceptive measures as required by local law or practice). US: abstinence and the following methods: diaphragm with spermicide, condom with spermicide (by male partner), intrauterine device, sponge, spermicide, Norplant, Depo‐Provera or oral contraceptives. Germany: adequate contraceptive measures are implants, injectables, combined oral contraceptives, hormonal intrauterine device, sexual abstinence or vasectomised partner. UK: adequate contraceptive measures are defined as sterilisation, intrauterine device, oral contraceptives, consistent use of barrier methods, male sterilisation or true abstinence; receipt of any investigational drug within 4 weeks prior to screening for this trial (Brazil: the receipt of any investigational drug within 1 year prior to screening for this trial, unless there was direct benefit to the person at investigator's discretion; France: abnormality of the thyroid identified during the physical examination at screening) </p> <p><b>Diagnostic criteria</b>: criteria for intermediate hyperglycaemia as defined by ADA: </p> <p> <ul id="CD012204-lst1-0029"> <li> <p>HbA1c 5.7‐6.4% both inclusive or</p> </li> <li> <p>FPG measurement ≥ 100 mg/dL (5.6 mmol/L) and ≤ 125 mg/dL (6.9 mmol/L), or</p> </li> <li> <p>2‐h plasma glucose measurement post‐challenge (OGTT) ≥ 140 mg/dL (7.8 mmol/L) and ≤ 199 mg/dL (11.0 mmol/L) or </p> </li> <li> <p>a combination of these.</p> </li> </ul> </p> <p>OGTT done at screening for diagnosis of intermediate hyperglycaemia.</p> <p>Diagnosis confirmed by second repeated measurement</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: liraglutide 3.0 mg once daily </p> <p><b>Comparator</b>: placebo </p> <p><b>Run‐in period</b>: none </p> <p><b>Study drug administration free period before glucose testing during trial</b>: protocol stated that trial participants were not supposed to inject liraglutide/liraglutide placebo in morning on days where OGTT measurements were made. OGTT performed every sixth month. FPG and HbA1c measured every third month. Participants allowed to take study medication on days where FPG was measured (except if OGTT was planned to be measured at same visit). This was not written clearly in protocol, but confirmed through internal correspondence with corresponding author of main publication </p> <p><b>Extension period</b>: yes; intervention period 160 weeks, and followed by an off‐drug, observational follow‐up period of 12 weeks </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Composite outcome measures reported</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: English </p> <p><b>Funding</b>: commercial funding (pharmaceutical company) </p> <p><b>Publication status</b>: peer‐reviewed journal </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim for study</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese subjects or overweight subjects with co‐morbidities. Furthermore, the aim is to investigate the long term potential of liraglutide to delay the onset of type 2 diabetes in subjects diagnosed with pre‐diabetes at baseline." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Participants stratified based on prediabetes status and BMI at screening. Prespecified subgroup analyses performed in participants with or without prediabetes at enrolment (all endpoints) and in those with different baseline BMI categories (body weight and HbA1c endpoints). </p> <p>Trial had predefined withdrawal criteria: "6.6 Withdrawal criteria. The subject may be withdrawn from the trial at the discretion of investigator or Novo Nordisk due to a safety concern or if judged non‐compliant with trial procedures.<br> A subject must be withdrawn if the following applies:<br> 1. The subject may withdraw from the trial at will at any time<br> 2. If the target treatment dose of the randomised trial product is not tolerated by the subjects<br> 3. Pregnancy or intention of becoming pregnant<br> 4. Subjects who develop diabetes during the trial will not be withdrawn but should receive the best standard of care at the discretion of the Investigator. If the Investigator determines that insulin, GLP‐1 receptor agonist (e.g., Byetta® or Victoza®), or DPP‐4 inhibitor is the best treatment option, the subject must be withdrawn. The medication prescribed by the Investigator will not be provided by Novo Nordisk<br> 5. If the investigator suspects acute pancreatitis, all suspected drugs should be discontinued until confirmatory tests have been conducted and appropriate treatment should be initiated. Subjects that are diagnosed with acute pancreatitis (as a minimum 2 of 3: characteristic abdominal pain, amylase and/or lipase &gt;3x UNR [upper normal range] or characteristic findings on CT [computer tomography]/MRI [magnetic resonance imaging]), must be withdrawn from the trial<br> 6. A subject should be referred to a Mental Health Professional (MHP) if he/she has:<br> • a PHQ‐9 [Patient Health Questionnaire] score ≥ 10, OR,<br> • any suicidal behaviour, OR,<br> • any suicidal ideation of type 4 (active suicidal ideation with some intent to act, without specific plan) or type 5 (active suicidal ideation with specific plan and intent) on any C‐SSRS assessment ‐ A referral to a Mental Health Professional (MHP) should also be made if in the opinion of the Investigator it is necessary for the safety of the subject. If a subject's psychiatric disorder can be adequately treated with psycho‐ and/or pharmacotherapy, then the subject, at the discretion of the Investigator (in agreement with the MHP), may be continued in the trial on randomised therapy, otherwise, the subject must be withdrawn. In case of withdrawal, the End of Trial form must be filled in and in the IV/WRS the Withdrawal session must be completed. If possible, the subject should be called in for a final visit. Procedures according to Visit 17 should be performed for all subjects who discontinue the trial prematurely." </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Randomization was performed with the use of a telephone or Web‐based system provided by the sponsor." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Randomization was performed with the use of a telephone or Web‐based system provided by the sponsor." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> all‐cause/cardiovascular mortality </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Treatment allocation for subjects with pre‐diabetes will be double‐blind for the first year (Novo Nordisk, Investigator and subject are blinded), and single blind for the remaining 2 years (i.e. Novo Nordisk is unblinded, whereas investigator and subjects remain blinded)." </p> <p><b>Comment</b>: adjudicated outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> health‐related quality of life </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Treatment allocation for subjects with pre‐diabetes will be double‐blind for the first year (Novo Nordisk, Investigator and subject are blinded), and single blind for the remaining 2 years (i.e. Novo Nordisk is unblinded, whereas investigator and subjects remain blinded)." </p> <p><b>Comment</b>: self‐reported outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Treatment allocation for subjects with pre‐diabetes will be double‐blind for the first year (Novo Nordisk, Investigator and subject are blinded), and single blind for the remaining 2 years (i.e. Novo Nordisk is unblinded, whereas investigator and subjects remain blinded)." </p> <p><b>Comment</b>: self‐reported and investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> incidence of T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Treatment allocation for subjects with pre‐diabetes will be double‐blind for the first year (Novo Nordisk, Investigator and subject are blinded), and single blind for the remaining 2 years (i.e. Novo Nordisk is unblinded, whereas investigator and subjects remain blinded)." </p> <p><b>Comment</b>: investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Treatment allocation for subjects with pre‐diabetes will be double‐blind for the first year (Novo Nordisk, Investigator and subject are blinded), and single blind for the remaining 2 years (i.e. Novo Nordisk is unblinded, whereas investigator and subjects remain blinded)." </p> <p><b>Comment</b>: investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> non‐fatal myocardial infarction/stroke, congestive heart failure </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Treatment allocation for subjects with pre‐diabetes will be double‐blind for the first year (Novo Nordisk, Investigator and subject are blinded), and single blind for the remaining 2 years (i.e. Novo Nordisk is unblinded, whereas investigator and subjects remain blinded)." </p> <p><b>Comment</b>: investigator‐assessed outcome measurement/adjudicated outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> non‐serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Treatment allocation for subjects with pre‐diabetes will be double‐blind for the first year (Novo Nordisk, Investigator and subject are blinded), and single blind for the remaining 2 years (i.e. Novo Nordisk is unblinded, whereas investigator and subjects remain blinded)." </p> <p><b>Comment</b>: self‐reported and investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Treatment allocation for subjects with pre‐diabetes will be double‐blind for the first year (Novo Nordisk, Investigator and subject are blinded), and single blind for the remaining 2 years (i.e. Novo Nordisk is unblinded, whereas investigator and subjects remain blinded)." </p> <p><b>Comment</b>: investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> time to progression to T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Treatment allocation for subjects with pre‐diabetes will be double‐blind for the first year (Novo Nordisk, Investigator and subject are blinded), and single blind for the remaining 2 years (i.e. Novo Nordisk is unblinded, whereas investigator and subjects remain blinded)." </p> <p><b>Comment</b>: investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> all‐cause/cardiovascular mortality </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Treatment allocation for subjects with pre‐diabetes will be double‐blind for the first year (Novo Nordisk, Investigator and subject are blinded), and single blind for the remaining 2 years (i.e. Novo Nordisk is unblinded, whereas investigator and subjects remain blinded)." </p> <p><b>Comment</b>: adjudicated outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> health‐related quality of life </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Treatment allocation for subjects with pre‐diabetes will be double‐blind for the first year (Novo Nordisk, Investigator and subject are blinded), and single blind for the remaining 2 years (i.e. Novo Nordisk is unblinded, whereas investigator and subjects remain blinded)." </p> <p><b>Comment</b>: self‐reported outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Treatment allocation for subjects with pre‐diabetes will be double‐blind for the first year (Novo Nordisk, Investigator and subject are blinded), and single blind for the remaining 2 years (i.e. Novo Nordisk is unblinded, whereas investigator and subjects remain blinded)." </p> <p><b>Comment</b>: self‐reported and investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> incidence of T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Treatment allocation for subjects with pre‐diabetes will be double‐blind for the first year (Novo Nordisk, Investigator and subject are blinded), and single blind for the remaining 2 years (i.e. Novo Nordisk is unblinded, whereas investigator and subjects remain blinded)." </p> <p><b>Comment</b>: investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Treatment allocation for subjects with pre‐diabetes will be double‐blind for the first year (Novo Nordisk, Investigator and subject are blinded), and single blind for the remaining 2 years (i.e. Novo Nordisk is unblinded, whereas investigator and subjects remain blinded)." </p> <p><b>Comment</b>: investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> non‐fatal myocardial infarction/stroke, congestive heart failure </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Treatment allocation for subjects with pre‐diabetes will be double‐blind for the first year (Novo Nordisk, Investigator and subject are blinded), and single blind for the remaining 2 years (i.e. Novo Nordisk is unblinded, whereas investigator and subjects remain blinded)." </p> <p><b>Comment</b>: investigator‐assessed outcome measurement/adjudicated outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> non‐serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Treatment allocation for subjects with pre‐diabetes will be double‐blind for the first year (Novo Nordisk, Investigator and subject are blinded), and single blind for the remaining 2 years (i.e. Novo Nordisk is unblinded, whereas investigator and subjects remain blinded)." </p> <p><b>Comment</b>: self‐reported and investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Some types of AEs [adverse events] were also evaluated via a blinded adjudication process by an independent, external adjudication committee of medical experts (those marked 'Adjudicated' below). Based on predefined diagnostic criteria, the adjudication committee could either confirm or not confirm the AE classification/diagnosis." </p> <p><b>Comment</b>: deaths, cardiovascular events, pancreatitis/suspicion of pancreatitis and neoplasms were evaluated by an independent adjudication committee </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> time to progression to T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Treatment allocation for subjects with pre‐diabetes will be double‐blind for the first year (Novo Nordisk, Investigator and subject are blinded), and single blind for the remaining 2 years (i.e. Novo Nordisk is unblinded, whereas investigator and subjects remain blinded)." </p> <p><b>Comment</b>: investigator‐assessed outcome measurement </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> all‐cause/cardiovascular mortality </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: not described how missing data were handled </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> health‐related quality of life </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: only about half of participants completed assessment of health‐related quality of life, this proportion of missingness is high enough to indicate relevant bias. Missing data were imputed with last observation carried forward method </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> hypoglycaemia </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Missing values were imputed with the use of the last observation carried forward method for measurements made after baseline." </p> <p><b>Comment</b>: only about half of participants completed the trial, this proportion of missingness was high enough to indicate relevant bias </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> incidence of T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Missing values were imputed with the use of the last observation carried forward method for measurements made after baseline" and "Data from all pre‐diabetic subjects in the FAS will be analysed using a Weibull model. Pre‐diabetic subjects who incorrectly entered the re‐randomised treatment period will be censored at the date corresponding to visit 17 unless they had onset of type 2 diabetes prior to this date. The model will include treatment, gender and BMI stratification factor as fixed factors and baseline FPG will be included as a covariate." </p> <p><b>Comment</b>: only about half of participants completed the trial, this proportion of missingness was high enough to indicate relevant bias </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> measures of blood glucose control </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Missing values were imputed with the use of the last observation carried forward method for measurements made after baseline." </p> <p><b>Comment</b>: only about half of the participants completed the trial, this proportion of missingness was high enough to indicate relevant bias </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> non‐fatal myocardial infarction/stroke, congestive heart failure </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: not described how missing data were handled </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> non‐serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Missing values were imputed with the use of the last observation carried forward method for measurements made after baseline." </p> <p><b>Comment</b>: only about half of participants completed the trial, this proportion of missingness was high enough to indicate relevant bias. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> serious adverse events </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: not described how missing data were handled. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> time to progression to T2DM </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: 1128 completed 160 weeks (52.6% on liraglutide, 45% on placebo). Proportion of missingness was high enough to indicate clinical relevant bias. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: trial protocol was available and all the trial's prespecified (primary and secondary) outcomes that are of interest of the review were reported in the prespecified way. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other bias</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Comment</b>: trial conducted by Novo Nordisk. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Note: where the judgement was 'unclear' with a blank 'Support for judgement', the trial did not report that particular outcome. </p> <p>ACS: acute coronary syndrome; ADA: American Diabetes Association; AV: atrioventricular; BEGAMI: beta‐cell function in glucose abnormalities and acute myocardial Infarction; BMI: body mass index; FPG: fasting plasma glucose; GAD: glutamic acid decarboxylase; GITS: glipizide gastrointestinal therapeutic system; GV: glycaemic variability; h: hour; HbA1c: glycosylated haemoglobin A1c; HDL: high‐density lipoprotein; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; LDL: low‐density lipoprotein; n: number of participants; NR: not reported; NYHA: New York Heart Association; OGTT: oral glucose tolerance test; RCT: randomised controlled trial; SCALE: Satiety and Clinical Adiposity ‐ Liraglutide Evidence in Nondiabetic and Diabetic Individuals; T1DM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus; WHO: World Health Organization. </p> </div> </div> </p> </section> <section class="characteristicsOfExcludedStudies" lang=""> <div class="section-header" id="CD012204-sec2-0037"> <h3 class="title">Characteristics of excluded studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD012204-sec2-0036" class="jump-to">included studies</a></li> <li><a href="#CD012204-sec2-0038" class="jump-to">awaiting classification</a></li> <li><a href="#CD012204-sec2-0039" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reason for exclusion</p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0008">Acosta 2015</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Included obese participants, but did not state intermediate hyperglycaemia as an inclusion criterion. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0009">ACTRN12615001029583</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for a randomised trial including participants with cystic fibrosis‐related diabetes or IGT. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0010">Almeda‐Valdes 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Duration of intervention &lt; 12 weeks.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0011">Aoki 2014</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol of trial described it as a non‐randomised trial, but both full‐text articles stated that participants were randomised. Authors did not respond to this question. Not possible to obtain separate data for the participants with IGT. Single administration of interventions applied, and duration &lt; 12 weeks. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0012">Armato 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not a randomised clinical trial.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0013">BEGAMI 2013</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Included participants with intermediate hyperglycaemia and acute coronary syndrome.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0014">Best 2015</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants were HIV positive.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0015">Bock 2010</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Duration of intervention &lt; 12 weeks.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0016">Cui 2016</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants had hepatic steatosis.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0017">Daniele 2015</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Duration of intervention 26 days according to publication, stated as 12 weeks on ClinicalTrials.gov. Trial included both participants with IGT and T2DM. Authors did not provide separate data. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0018">Dushay 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not possible to obtain separate data on the participants with prediabetes. Authors contacted. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0019">EudraCT 2011‐005980‐26</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for a trial including participants with intermediate hyperglycaemia and stroke.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0020">EudraCT 2013‐001240‐64</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for a trial where exenatide was administered intravenously.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0021">Gonzalez‐Ortiz 2015</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial compared 2 different types of GLP‐1 analogues with each other.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0022">Gudipaty 2014</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>All participants had a history of T2DM.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0023">Ishikawa 2014</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not possible to obtain separate data on the participants with IGT. Authors contacted twice, but no replies. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0024">Kaku 2015</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Duration of intervention &lt; 12 weeks.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0025">Koska 2015</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Exenatide administered intravenously, duration of intervention &lt; 12 weeks.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0026">Larsen 2014</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for a randomised clinical trial including participants on antipsychotic medicine and intermediate hyperglycaemia. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0027">NCT00101712</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for a randomised clinical trial including participants with T2DM.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0028">NCT00198146</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for a trial including participants with T2DM.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0029">NCT00721552</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for trial including glucocorticoid‐induced impairment of glucose metabolism.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0030">NCT00845182</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Authors did not reply to our request for separate data on the participants with IGT.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0031">NCT00845559</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for a trial fulfilling the inclusion criteria, but stopped prior to enrolment.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0032">NCT00886626</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for a randomised clinical trial including obese children.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0033">NCT00961363</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for a trial fulfilling the inclusion criteria. However, the trial was terminated early due to difficulties in recruiting participants. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0034">NCT01006018</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for a trial that according to the primary investigator never was initiated. According to ClinicalTrials.gov: "Unanticipated delays due to sterilization/stabilization testing of GLP‐1." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0035">NCT01018602</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not possible to obtain separate data on the people with intermediate hyperglycaemia.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0036">NCT01038648</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for a trial that was never initiated.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0037">NCT01054118</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Included participants with T2DM. Cross‐over trial with a duration of intervention of 28 days for each intervention period. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0038">NCT01122641</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial protocol for a completed trial including obese participants with high FinRisk score. Principal investigator approached twice to request clarification if there are separate data on people with IFG, IGT or intermediate elevated HbA1c but without any reply. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0039">NCT01346254</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Included participants with prediabetes after kidney transplantation.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0040">NCT01472640</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not possible to obtain separate data on the participants with IGT.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0041">NCT01845259</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for a randomised clinical trial including participants on antipsychotic medicine and intermediate hyperglycaemia. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0042">NCT01970462</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for a trial including participants with stress hyperglycaemia or mild diabetes following cardiac surgery. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0043">NCT02016846</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for trial including glucocorticoid‐induced impairment of glucose metabolism.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0044">NCT02022007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for trial including participants with polycystic ovary syndrome and IFG, IGT, or both. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0045">NCT02284230</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Included participants with IGT or IFG (or both) and kidney failure. Not completed due to inability to recruit participants. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0046">NCT02446834</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for trial including participants with polycystic ovary syndrome and IGT.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0047">Schwartz 2010</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Duration &lt; 12 weeks. Included participants with T2DM and IGT.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0048">Tsuchiya 2011</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not possible to obtain separate data for participants with intermediate hyperglycaemia. Authors approached twice through email, but no reply. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0049">UMIN000006197</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for a non‐randomised clinical trial.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0050">UMIN000014249</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Protocol for non‐randomised clinical study including participants with IGT or diabetes due to partial pancreatectomy. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0051">Utzschneider 2008</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not a randomised clinical trial.</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD012204-bbs2-0052">Werzowa 2013</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Included participants with IGT after renal transplantation.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>GLP‐1: glucagon‐like peptide‐1; HbA1c: glycosylated haemoglobin A1c; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; T2DM: type 2 diabetes mellitus. </p> </div> </div> </p> </section> <section class="characteristicsOfAwaitingStudies" lang=""> <div class="section-header" id="CD012204-sec2-0038"> <h3 class="title">Characteristics of studies awaiting assessment [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD012204-sec2-0036" class="jump-to">included studies</a></li> <li><a href="#CD012204-sec2-0037" class="jump-to">excluded studies</a></li> <li><a href="#CD012204-sec2-0039" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Astrup 2009 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Allocation</b>: randomised clinical trial </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: double blind for liraglutide and placebo (participants and investigators), open label for orlistat </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: normoglycaemia and intermediate hyperglycaemia </p> <p><b>Enrolment</b>: total number of participants 564. From baseline table, it is stated that about one‐third had intermediate hyperglycaemia </p> <p><b>Inclusion criteria</b>: men and women aged 18‐65 years, body mass index 30‐40 kg/m², stable body weight (&lt; 5% reported change during the previous 3 months) and fasting plasma glucose &lt; 7 mmol/L </p> <p><b>Exclusion criteria</b>: key criteria included known T1DM or T2DM, obesity induced by drug treatment, use of approved weight‐lowering pharmacotherapy or participation in a clinical weight control study within the previous 3 months, previous surgical obesity treatment and major medical conditions </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention (1)</b>: liraglutide 1.2 mg, subcutaneous </p> <p><b>Intervention (2)</b>: liraglutide 1.8 mg, subcutaneous </p> <p><b>Intervention (3)</b>: liraglutide 2.4 mg, subcutaneous </p> <p><b>Intervention (4)</b>: liraglutide 3.0 mg, subcutaneous </p> <p><b>Comparator (1)</b>: orlistat, PO </p> <p><b>Comparator (2)</b>: placebo, subcutaneous </p> <p><b>Duration of intervention</b>: 20 weeks of intervention followed by an 84‐week open‐label extension period </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcomes</b>: intervention period: mean change from baseline in body weight at week 20. Interim analysis (weeks 21‐52): efficacy of liraglutide to induce weight loss. Extension period (weeks 21‐104): long‐term safety and tolerability of liraglutide </p> <p><b>Secondary outcomes</b>: intervention period: secondary efficacy endpoints included change in waist circumference, systolic and diastolic blood pressure, prevalence of metabolic syndrome, prediabetes status, fasting lipids (total cholesterol, LDL cholesterol, HDL cholesterol, very‐low‐density lipoprotein cholesterol and triglycerides), cardiovascular biomarkers (highly sensitive C‐reactive protein, plasminogen activator inhibitor‐1, fibrinogen and adiponectin), glucose metabolism parameters (fasting plasma glucose, fasting insulin and HbA1c) and homoeostasis model assessment of β‐cell function and insulin resistance; 2‐h glucose, insulin and C‐peptide concentrations during OGTT; patient‐reported outcome scores with Impact of Weight on Quality of Life ‐ Lite </p> <p>Interim analysis (weeks 21‐52): to compare weight‐lowering effect of liraglutide to orlistat; to investigate long‐term efficacy of liraglutide to induce and maintain weight loss; to investigate effects induced by liraglutide on: body composition as assessed by waist circumference; cardiovascular risk factors as assessed by systolic and diastolic blood pressures and fasting lipid profile; glucose metabolism, including β‐cell function, as assessed by prediabetes status; presence of the metabolic syndrome as assessed using criteria introduced by the Adult Treatment Panel III under the National Cholesterol Education Program. Extension period (weeks 21‐104): to summarise long‐term efficacy of liraglutide to induce and maintain weight loss; to summarise effects induced by liraglutide on: waist circumference; cardiovascular risk markers as assessed by blood pressure, lipids, cardiovascular biomarkers, metabolic syndrome status and glucose metabolism; patient‐reported quality of life; prediabetes status </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: English </p> <p><b>Funding</b>: commercial funding </p> <p><b>Publication status</b>: peer‐reviewed journal/full article for complete study population </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "The purpose of the 20‐week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long term safety and tolerability of liraglutide." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Application sent to Novo Nordisk to request separate data on participants with intermediate hyperglycaemia. Novo Nordisk has approved access to raw trial data, but data are not yet available </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT01521312 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: double blind (participants and investigators) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: impaired glucose tolerance </p> <p><b>Enrolment</b>: 24 </p> <p><b>Inclusion criteria</b>: social security affiliation; people without tutorship that can freely agree to participate to study; aged 18‐70 years; impaired glucose tolerance diagnosed during the previous month </p> <p><b>Exclusion criteria</b>: pregnancy; breastfeeding; diabetes; no contraception; BMI &gt; 45 kg/m²; arterial blood pressure &gt; 160/110 mmHg; creatinine clearance &lt; 60 mL/minute; severe hepatocellular insufficiency; chronic respiratory disease; anaemia (haemoglobin &lt; 10 g/dL); peripheral arterial occlusive disease; heart failure; cardiac arrhythmia </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: sitagliptin 5 mg, PO </p> <p><b>Comparator</b>: placebo pill, PO </p> <p><b>Duration of intervention</b>: 11‐14 weeks </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcomes</b>: vago‐sympathetic activity; arterial stiffness; endothelial function; OGTT </p> <p><b>Secondary outcomes</b>: NR </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early</b>: NR </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: not published </p> <p><b>Funding</b>: NR </p> <p><b>Publication status</b>: not published </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Glucose ACCES study will explore the acute and long term (12‐week treatment) effects of saxagliptin in patients with impaired glucose tolerance during fasting and after a standardised breakfast. The investigations will be performed on: </p> <p> <ul id="CD012204-lst1-0030"> <li> <p>glycemic parameters</p> </li> <li> <p>on cardiovascular parameters."</p> </li> </ul> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial registered in ClinicalTrials.gov as completed in September 2014. However, it is not published. Authors asked for publication status and data, but no reply provided. As it can take time to obtain data published, the trial is characterised as awaiting classification </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT01960205 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: open label </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: obese with glucose intolerance. </p> <p><b>Enrolment</b>: 80 </p> <p><b>Inclusion criteria</b>: newly diagnosed insulin resistance or glucose intolerance; age 20‐70 years; BMI ≥ 28 kg/m² or &gt; 25 kg/m² beside waist line ≥ 80 cm (women); ≥ 90 cm (men) </p> <p><b>Exclusion criteria</b>: under diabetes mellitus treatment; allergy to DPP‐4 inhibitors; active heart failure; unwilling or unable to sign inform consents </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention (1)</b>: saxagliptin 5 mg PO, once daily + lifestyle intervention </p> <p><b>Intervention (2)</b>: saxagliptin 2.5 mg PO, once daily + lifestyle intervention </p> <p><b>Comparator (1)</b>: lifestyle intervention </p> <p><b>Comparator (2)</b>: metformin 500 mg PO, 3 times daily + lifestyle intervention </p> <p><b>Duration of intervention</b>: 6 months </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome</b>: OGTT (change of blood sugar from baseline at 6 months) </p> <p><b>Secondary outcomes</b>: NR </p> <p><b>Other outcomes</b>: NR </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early</b>: unknown </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: not published </p> <p><b>Funding</b>: NR </p> <p><b>Publication status</b>: not published </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "The purpose of the study is to examine the effect of saxagliptin in the newly diagnosed people with pre‐diabetes and obesity besides lifestyle intervention, there to evaluate DPP 4 inhibitors of reversing pre‐diabetes curative effect to normal blood sugar, and observe its influences on the targets of obesity related metabolic abnormalities, to explore new ways for intervention on populations with pre‐diabetes and obesity." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial registered as completed in December 2014, investigators were contacted and no data available yet </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT02294084 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: double blind (participants, investigator) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: impaired glucose tolerance </p> <p><b>Enrolment</b>: 30 </p> <p><b>Inclusion criteria</b>: men, white, born in the Netherlands, age 35‐50 years, BMI &gt; 25 and &lt; 30 kg/m², plasma glucose levels 2 h after OGTT between 7.8 and 11 mM (e.g. impaired glucose tolerance) </p> <p><b>Exclusion criteria</b>: T2DM (determined on basis of OGTT) defined by American Diabetes Association criteria; BMI &gt; 30 kg/m² or &lt; 25 kg/m²; plasma glucose levels 2 h after OGTT &lt; 7.8 or &gt; 11.1 mM; use of medication known to influence glucose or lipid metabolism (or both) or BAT activity (e.g. beta‐blockers); any significant chronic disease renal, hepatic or endocrine disease; smoking; participation in an intensive weight‐loss programme or vigorous exercise programme during last year before start of the study; difficulties to insert an intravenous catheter; recent participation in other research projects (within the last 3 months) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: sitagliptin 100 mg/day, PO </p> <p><b>Comparator</b>: placebo, PO </p> <p><b>Duration of intervention</b>: 12 weeks </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcomes</b>: effect of sitagliptin treatment on BAT activity in overweight, prediabetic people, BAT volume and activity measured by cold‐induced 18F‐FDG PET‐CT scans (after 12 weeks of treatment); BAT volume and activity measured by cold‐induced 18F‐FDG PET‐CT scans </p> <p><b>Secondary outcomes</b>: energy expenditure (indirect calorimetrie) (after 12 weeks of treatment), muscle glucose metabolism, expression or activation (or both) of biomarkers for insulin signalling and glucose and lipid metabolism in skeletal muscle biopsies (after 12 weeks of treatment), fat mass (measured via DEXA scan) (after 12 weeks of treatment); glucose metabolism (serum glucose, insulin and HbA1c); Insulin secretion (determined by OGTT and C‐peptine, glucose and insulin area under the curve) (after 12 weeks of treatment); plasma lipid levels (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides and free fatty acids in plasma) (after 12 weeks of treatment) </p> <p><b>Other outcomes</b>: none </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early</b>: unknown </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: not published </p> <p><b>Funding</b>: NR </p> <p><b>Publication status</b>: not published </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "The investigators hypothesize that STG [sitagliptin] enhances BAT activation, thereby increasing energy expenditure and combustion of TG‐derived fatty acids, resulting in lowering of plasma TG levels and body weight." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>According to ClinicalTrials.gov, the trial should be completed in May 2016. However, no data available yet </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Santilli 2015 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: open label </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: impaired glucose tolerance, impaired fasting glucose or newly diagnosed T2DM </p> <p><b>Enrolment</b>: 29 </p> <p><b>Inclusion criteria</b>: metformin‐treated obese participants with impaired glucose tolerance, impaired fasting glucose or newly diagnosed T2DM </p> <p><b>Exclusion criteria</b>: NR </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention(s)</b>: liraglutide, subcutaneous </p> <p><b>Comparator (s)</b>: placebo </p> <p><b>Duration of intervention</b>: 4 months </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcomes</b>: not specified, assume: change in subcutaneous fat and visceral adipose tissue </p> <p><b>Secondary outcomes</b>: not specified, assume: degree of non‐alcoholic fatty liver disease, weight loss, insulin sensitivity, β‐cell performance, C‐reactive protein, leptin, glycaemic measures </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: English </p> <p><b>Funding</b>: NR </p> <p><b>Publication status</b>: abstract </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "... we hypothesized that this class of drugs may exert additional cardiometabolic actions on top of those anticipated for lifestyle intervention‐mediated weight loss." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Separate data for participants with intermediate hyperglycaemia are not yet available, but will be provided from the authors when the full article is published </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">SCALE 2013 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel </p> <p><b>Masking</b>: double blind (participants and investigators) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: normoglycaemia and intermediate hyperglycaemia </p> <p><b>Enrolment</b>: in total 422 participants; abstract stated that 224 participants had impaired fasting glucose at baseline<br> <b>Inclusion criteria</b>: men and women age ≥ 18 years, with stable body weight and BMI ≥ 30 kg/m² or ≥ 27 kg/m² with comorbidities of treated or untreated dyslipidaemia or treated or untreated hypertension (or both) </p> <p><b>Exclusion criteria</b>: main criteria: diagnosis of T1DM or T2DM; fasting plasma glucose ≥ 7 mmol/L at run‐in (week 12); treatment with glucagon‐like peptide‐1 receptor agonists or medications causing significant weight gain/loss; bariatric surgery; history of idiopathic acute or chronic pancreatitis; history of major depressive disorder or other severe psychiatric disorders; or clinically significant active cardiovascular disease </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: liraglutide 3.0 mg, subcutaneous </p> <p><b>Comparator</b>: placebo, subcutaneous </p> <p><b>Duration of intervention</b>: 12‐week run‐in period followed by a 56‐week main trial period and a 12‐week follow‐up period </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcomes</b>: change in body weight; percentage of maintained run‐in fasting weight loss; percentage of who lost ≥ 5% of fasting body weight </p> <p><b>Secondary outcomes</b>: percentage who lost &gt; 10% of fasting body weight; percentage with weight regain ≥ 5%; percentage with weight regain ≥ 10%; percentage with weight regain &gt; 50% of fasting run‐in weight loss maintained; percentage with weight regain &gt; 75% of fasting run‐in weight loss maintained; change from baseline in fasting weight; change from baseline in fasting weight for participants completing the main trial period and entering the follow‐up period; change from baseline in blood pressure; change from baseline in pulse; change from baseline in fasting lipid profile and cardiovascular biomarkers; metabolic syndrome status; waist circumference; BMI; glycaemic parameters; β‐cell function; insulin resistance; insulin; concomitant medication; Binge Eating Scale </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: English </p> <p><b>Funding</b>: commercial funding </p> <p><b>Publication status</b>: peer‐reviewed journal/full article </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "The present trial provides the first evaluation of liraglutide for maintenance of prior weight loss achieved by treatment with a LCD in obese/overweight individuals without T2D [type 2 diabetes]." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>To qualify for randomisation, participants had to lose ≥ 5% of initial body weight during a variable‐length (4‐12 weeks) low calorie diet run‐in period. </p> <p>Application sent to Novo Nordisk to request separate data on the participants with intermediate hyperglycaemia. Novo Nordisk has approved access to raw trial data, but data are not yet available </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">SCALE‐SLEEP </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel </p> <p><b>Masking</b>: double blind (participants and investigators) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: normoglycaemia and intermediate hyperglycaemia </p> <p><b>Enrolment</b>: in total 359 participants; the abstract stated that 63.2% of participants had intermediate hyperglycaemia at baseline </p> <p><b>Inclusion criteria</b>: informed consent; BMI ≥ 30 kg/m²; stable body weight (&lt; 5% self‐reported change during the previous 3 months); diagnosis of moderate or severe obstructive sleep apnoea; unwilling or unable to use continuous positive airway pressure (or other positive airway pressure) treatment. No continuous positive airway pressure (or other positive airway pressure) treatment for at least 4 weeks prior to screening; ability and willingness to comply with all protocol procedures, e.g. correct handling of trial product, compliance to visit schedule and dietary advice and complete trial related questionnaires </p> <p><b>Exclusion criteria</b>: treatment with glucagon‐like peptide‐1 receptor agonists, DPP‐4 inhibitors or insulin within the last 3 months prior to screening; diagnosis of T1DM or T2DM per judgement of investigator; HbA1c ≥ 6.5%; significant craniofacial abnormalities that may cause obstructive sleep apnoea; respiratory and neuromuscular diseases that could interfere with the results of the trial in the opinion of investigator; use of central stimulants, hypnotics, mirtazapine, opioids or trazodone within the previous 3 months prior to screening; obesity induced by drug treatment; treatment with pramlintide, sibutramine, orlistat, zonisamide, topiramate or phentermine within the last 3 month prior to screening; previous surgical treatment for obesity; screening calcitonin ≥ 50 ng/L; familial or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma; personal history of non‐familial medullary thyroid carcinoma; history of chronic pancreatitis or idiopathic acute pancreatitis; history of major depressive disorder or suicide attempts; systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg (or both) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: liraglutide 3.0 mg, subcutaneous </p> <p><b>Comparator</b>: placebo, subcutaneous </p> <p><b>Duration of intervention</b>: 32 weeks </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome</b>: change from baseline in apnoea‐hypopnoea index </p> <p><b>Secondary outcomes</b>: change from baseline in body weight; glycaemic measures </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study details</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial terminated early</b>: no </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Publication details</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Language of publication</b>: English </p> <p><b>Funding</b>: commercial funding </p> <p><b>Publication status</b>: peer‐reviewed journal/full article </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated aim of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "The aim of the trial is to investigate the effect of liraglutide in obese subjects with sleep apnoea." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Application sent to Novo Nordisk to request separate data on the participants with intermediate hyperglycaemia. Novo Nordisk has approved access to raw trial data, but data are not yet available </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>18F‐FDG PET‐CT: 18‐fluorodeoxyglucose positron emission tomography computed tomography; BAT: brown adipose tissue; BMI: body mass index; DEXA: dual‐energy x‐ray absorptiometry; DPP‐4: dipeptidyl‐peptidase‐4; h: hour; HbA1c: glycosylated haemoglobin A1c; HDL: high‐density lipoprotein; LDL: low‐density lipoprotein; OGTT: oral glucose tolerance test; PO: per os (orally); NR: not reported; T1DM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus. </p> </div> </div> </p> </section> <section class="characteristicsOfOngoingStudies" lang=""> <div class="section-header" id="CD012204-sec2-0039"> <h3 class="title">Characteristics of ongoing studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD012204-sec2-0036" class="jump-to">included studies</a></li> <li><a href="#CD012204-sec2-0037" class="jump-to">excluded studies</a></li> <li><a href="#CD012204-sec2-0038" class="jump-to">awaiting classification</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">EudraCT 2013‐000418‐39 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Acronym</b>: ePREDICE </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type of trial</b>: efficacy trial </p> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: double blind </p> <p><b>Primary purpose</b>: not specified in protocol </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: IGT or IFG, or both </p> <p><b>Enrolment</b>: 3000 </p> <p><b>Inclusion criteria</b>: age 45‐74 years; IFG (FPG 6.1‐6.9 mmol/L and 2‐h PG &lt; 7.8 mmol/L) or IGT (FPG &lt; 7.0 mmol/L and 2‐h PG ≥ 7.8 to &lt; 11.1 mmol/L) or both conditions; informed consent given </p> <p><b>Exclusion criteria</b>: T1DM; known or unknown T2DM (including screen‐detected T2DM) with or without pharmacological treatment; use of a GLP‐1 receptor agonist (exenatide or other) or pramlintide or any DPP‐4 inhibitor or metformin within the 3 months prior to enrolment; use of insulin or long‐acting insulin analogue within 3 months prior to enrolment; any previous cardiovascular or cerebrovascular clinically documented event or revascularisation procedure; clinical evidence of macrovascular complications (overt clinical cardiovascular disease) at enrolment, including angina (stable or unstable) and evidence of previous myocardial infarction in baseline electrocardiogram; current renal replacement therapy; previous diagnosis of liver cirrhosis or chronic hepatitis, or an elevation of liver enzymes (aspartate aminotransferase and or alanine aminotransferase) &gt; 3 times normal ranges; previous diagnosis of chronic heart failure (NYHA class III or higher); prior solid organ transplant or awaiting solid organ transplant; malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy in the previous 5 years. Participants with intraepithelial squamous cell carcinoma of the skin (Bowen's disease) treated with topical 5‐fluorouracil and people with basal cell skin cancer allowed to enter trial; any acute condition or exacerbation of chronic condition that would, in investigator's opinion, interfere with the initial trial visit schedule and procedures; known or suspected hypersensitivity to trial products or related products; known use of non‐prescribed narcotics or illicit drugs; simultaneous participation in any other clinical trial of an investigational agent; women of childbearing potential who are pregnant (all fertile women will be tested for before randomisation), breastfeeding or intend to become pregnant; presence of cataract that impedes the retinal evaluation of both eyes; other previously diagnosed retinal diseases; any diseases that would prevent the measurement of primary endpoints; dementia, mental disorder or evident cognitive impairment unable to give informed consent; end‐stage or metastatic cancer; institutionalisation; renal function impairment: GFR &lt; 60 mL/minute/1.73 m².; contraindication to any of the study drugs (metformin or linagliptin). This includes: alanine aminotransferase &gt; 3 times the upper limit of normal, history of cirrhosis or hepatitis, suspected renal artery stenosis, recent gastrointestinal bleeding (within last year), pregnant, breastfeeding or a female of childbearing potential not on reliable contraception and also any circumstance where ongoing medication might lead to potential adverse drug interaction with components of the trial medications; any other reason, medical condition, ongoing medication or significant disability that would prevent the participant complying with trial consent, treatment and follow‐up procedures or potentially jeopardise her/his medical care </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: 2 tablets of linagliptin 5 mg + diet and physical activity </p> <p><b>Comparator (1)</b>: 2 tablets of metformin 850 mg/day + diet and physical activity </p> <p><b>Comparator (2)</b>: 2 tablets of linagliptin 2.5 mg + metformin 850 mg plus diet and physical activity </p> <p><b>Comparator (3)</b>: 2 tablets of placebo + diet and physical activity </p> <p><b>Duration of intervention</b>: at least 3 years, and additional follow‐up to 5 years </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome</b>: a combined continuous variable, "the microvascular complication índex" (MCI), composed of linear combination of ETDRS score, the level of urinary albumin to creatinine ratio, and sudomotor test (SUDOSCAN) score, measured during the 36th and 60th month visits. </p> <p>From email correspondence: primary purpose: prevention of complications of hyperglycaemia/ prevention of progression to diabetes </p> <p><b>Secondary outcomes</b>: retinopathy score at last visit defined as 2 steps' progression on ETDRS scale between baseline and visits at months 36 and 60; 1 SD increase in level of urinary albumin to creatinine ratio between baseline and visits at months 36 and 60; 1 SD decrease change in level of hands and feet conductance in SUDOSCAN between baseline and visits at months 36 and 60; change in microvascular endothelial function measured by EndoPAT method (in a subset); change in the Non‐Alcoholic Fatty Liver Index (in a subset); change in biomarkers of microvascular damage, endothelial function, per‐oxidation, inflammation and metabolomics (in a subset); change in the insulin secretion and β‐cell function; change in self‐perceived quality of life; change in symptoms of peripheral neuropathy; change in neuropsychological parameters: cognitive function, anxiety and depressive symptoms and indices; changes in obstructive sleep apnoea indices as measured by Somnomedics (in a subset); changes in ambulatory blood pressure monitoring (in a subset); change in the mean common carotid intimae‐media thickness (in a subset); incidence of major cardiovascular events, defined as an expanded composite of total coronary events, total stroke events, revascularisation procedures (coronary artery bypass graft, percutaneous coronary angioplasty and peripheral revascularisation), hospitalisation for heart failure, TIA and cardiovascular or cerebrovascular death. Secondary outcomes will be evaluated at 36 and 60 months </p> <p><b>Other outcome</b>: none </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial start date</b>: 2015 </p> <p><b>Trial completion date</b>: 2018 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Responsible party/principal investigator</b>: Prof Jaakko Tuomilehto; Prof Rafael Gabriel (co‐principal investigators) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study identifier</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>EudraCT‐number</b>: 2013‐000418‐39 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Official title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Early Prevention of Diabetes Complications in People with Hyperglycaemia in Europe</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated purpose of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "To assess the effect of treatment with linagliptin, metformin or the combination of linagliptin with metformin, plus lifestyle intervention (diet and physical activity), compared to lifestyle intervention alone, for at least 3 years, and up to 5 years, on different microvascular parameters (retinal, renal and neurological), as defined by the primary and secondary endpoints, in adults with non diabetic hyperglycaemia (IGT, IFG or IFG plus IGT)." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Multinational trial with 15 clinical centres from 12 countries: Australia, Austria, Bulgaria, Germany, Greece, Italy, Lithuania, Poland, Serbia, Spain, Switzerland and Turkey. </p> <p>Clarified though e‐mail correspondence that the trial is double‐blind, trial start date and trial completion date </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Naidoo 2016 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Acronym</b>: SiMePreD </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type of trial</b>: efficacy trial </p> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: double blind </p> <p><b>Primary purpose</b>: efficacy </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: IGT, IFG, or both </p> <p><b>Enrolment</b>: 820 </p> <p><b>Inclusion criteria</b>: informed consent; IGT (2‐h postprandial glucose 7.8‐11.0 mmol/L); IFG glucose (fasting glucose 5.6‐6.9 mmol/L); age 18‐65 years; no history of liver disease; negative pregnancy test. </p> <p><b>Exclusion criteria</b>: impaired liver function tests; cardiac failure or history of congestive heart failure in the close family; medication that may affect insulin resistance (e.g. oral hypoglycaemic agents, thiazide diuretics); contraindications to exercise; pregnancy; planning to move residence within the next 5‐10 years; history of hypersensitivity reaction to sitagliptin, such as anaphylaxis or angio‐oedema </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: sitagliptin 25 mg/day + metformin extended release 500 mg/day </p> <p><b>Comparator</b>: placebo + metformin extended release 500 mg/day </p> <p><b>Duration of intervention</b>: 5 years </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcomes</b>: number of participants progressing from prediabetes to T2DM, number of cardiovascular events and number of deaths </p> <p><b>Secondary outcomes</b>: lipo grams, urea and electrolytes, liver function tests, full blood count, fasting blood glucose, fasting blood insulin, weight, blood pressure. Other anthropometric parameters </p> <p><b>Other outcomes</b>: adverse effects </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial start date</b>: not stated </p> <p><b>Trial completion date</b>: not stated </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Responsible party/principal investigator</b>: not defined, presumably the corresponding author of the article: N Poobalan, Johannesburg, South Africa </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study identifier</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study has not started</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Official title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Sitagliptin and Metformin in PreDiabetes (SiMePreD) Study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated purpose of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "The aim of this study is to determine the effect of sitagliptin and metformin on progression from prediabetes to type 2 DM." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study currently searching for funding. Study has not started</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT01234649 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effects of Intervention with the Glucagon‐like Peptide 1 (GLP‐1) Analog Liraglutide Plus Metformin Versus Metformin Monotherapy in Overweight/Obese Women with Metabolic Defects and Recent History of Gestational Diabetes Mellitus (GDM) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type of trial</b>: efficacy trial </p> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: double blind (participant, carer, investigator) </p> <p><b>Primary purpose</b>: prevention </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: obese with previous GDM and IFG, IGT, or both with or without β‐cell dysfunction postpartum requiring pharmacological intervention </p> <p><b>Enrolment</b>: 150 </p> <p><b>Inclusion criteria</b>: women age 18‐45 years who experienced GDM within 52 weeks of index pregnancy; actual BMI &gt; 25 kg/ m²; written consent for participation in the trial; women completed lactation; dysglycaemia (IFG, IGT, or both) or β‐cell dysfunction postpartum requiring pharmacological intervention (except T1DM or T2DM), or both </p> <p><b>Exclusion criteria</b>: personal or family history of medullary thyroid carcinoma or in people with multiple endocrine neoplasia syndrome type 2; history of pancreatitis; significant cardiovascular, cerebrovascular, renal or hepatobiliary diseases (viral hepatitis, toxic hepatic damage, jaundice of unknown aetiology); serum liver enzymes (aspartate aminotransferase or alanine aminotransferase (or both) levels) exceeding more than twice normal laboratory values; uncontrolled hypertension (systolic blood pressure &gt; 150 mmHg or diastolic blood pressure &gt; 90 mmHg, or both); fasting serum triglycerides ≥ 800 mg/dL at screening. Lipid‐lowering medications must have been maintained at the same dose for 3 months prior to enrolment; haematological profiles considered to be clinically significant; cholestasis during past pregnancy; presence of contradictions for GLP‐1 receptor agonist or metformin administration such as allergy or hypersensitivity; current use of metformin, thiazolidinediones, DPP‐4 inhibitors or GLP‐1 receptor agonist medications; use of drugs known to exacerbate glucose tolerance; use of prescription or non‐prescription weight‐loss drugs; diabetes postpartum or history of diabetes or prior use of medications to treat diabetes other than GDM; creatinine clearance &lt; 60 mL/minute; history or currently undergoing chemotherapy or radiotherapy for cancer; pregnancy planned during the coming 2 years; currently breastfeeding; any condition that, in the opinion of investigator, would place the woman at increased risk or otherwise make the women unsuitable for participation in trial </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: liraglutide, subcutaneous (titrated up to 1.8 mg) + metformin, PO (titrated up to 1000 mg twice daily) </p> <p><b>Comparator</b>: placebo, subcutaneous plus metformin, PO (titrated up to 1000 mg twice daily) </p> <p><b>Duration of intervention</b>: 84 weeks at full dose (8‐12 weeks for up titrate to full dose) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcomes</b>: index of insulin secretion in relation to insulin resistance will be calculated (change in index from baseline at 32‐36 weeks, 56 ‐60 weeks and study end (80‐84 weeks)). β‐cell compensatory capacity will be evaluated by insulin sensitivity‐secretion index defined as the product of composite insulin sensitivity index and first‐phase insulin release index (insulinogenic index) </p> <p><b>Secondary outcomes</b>: insulin resistance ‐ baseline (HOMA‐IR) and composite insulin sensitivity index), and pancreatic β‐cell function (corrected insulin response (CIRglupeak) and insulinogenic index/HOMA‐IR (change in indexes from baseline at 32‐36 weeks, 56‐60 weeks, and trial end (80‐84 weeks)). Indexes of insulin sensitivity and secretion using the serum glucose and insulin concentrations obtained in the fasting state and during the 2‐h glucose tolerance test with insulin levels will be computed by several measures previously validated in women. </p> <p>Cardiometabolic risk measures (change in measures (lipids, liver enzymes, blood pressure) from baseline at 32‐36 weeks, 56‐60 weeks and study end (80‐84 weeks). Lipids, liver enzymes, blood pressure. </p> <p>Anthropometric measurements (change in measures of total and central adiposity from baseline at 32‐36 weeks, 56‐60 weeks, and study end (80‐84 weeks)). BMI, absolute body weight, waist circumference, waist:hip ratio. </p> <p>Development of dysglycaemia (changes in glucose tolerance will be evaluated at baseline, 32‐36 weeks, 56‐60 weeks and study end (80‐84 weeks)). Change in glycaemic status from baseline (at 32‐36 weeks, 56‐60 weeks and study end (80‐84 weeks). Dysglycaemia will be defined as IFG, IGT, combined IFG/IGT and diabetic according to the American Diabetes Association. Women diagnosed with diabetes will be withdrawn and referred to a specialised physician </p> <p><b>Other outcomes</b>: none specified </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial start date</b>: January 2011 </p> <p><b>Trial completion date</b>: October 2017 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Responsible party/principal investigator</b>: Karen E Elkind‐Hirsch, PhD and Martha Paterson, MD, Woman's Hospital, Louisiana </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study identifier</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>NCT number</b>: NCT01234649 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Official title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effects of Intervention with the Glucagon‐like Peptide 1 (GLP‐1) Analog Liraglutide Plus Metformin Versus Metformin Monotherapy in Overweight/Obese Women with Metabolic Defects and Recent History of Gestational Diabetes Mellitus (GDM) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated purpose of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "This study will examine if the addition of liraglutide to metformin therapy is more effective than metformin alone in improving insulin sensitivity and normalizing insulin secretion in at‐risk overweight/obese women with prior GDM." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Investigator clarified the intervention period through email correspondence</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT01336322 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Acronym</b>: SITA‐previousGDM </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type of trial</b>: efficacy trial </p> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: double blind (participants, investigator) </p> <p><b>Primary purpose</b>: treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: IFG or IGT in women with previous GDM </p> <p><b>Enrolment</b>: 45 </p> <p><b>Inclusion criteria</b>: women age 18‐45 years; Caucasian race; history of GDM (in screening) during pregnancy, defined according to Carpenter and Coustan criteria; women of childbearing potential must use effective contraceptive measures for at last 1 month prior to entry into study and should continue to use some contraceptive method during overall trial period; written informed consent obtained. IFG and IGT not listed in inclusion criteria, but in the text it is stated: "Women with IFG or IGT will be recruited and undergo to a hyperglycaemic clamp with arginin bolus at the end of the test." </p> <p><b>Exclusion criteria</b>: diagnosed with type 1 insulin‐dependent diabetes; diagnosis of diabetes in OGTT 75‐g glucose performed at entry; BMI ≤ 18 or ≥ 50 kg/m²; chronic impaired renal function; impaired liver function as shown by transaminase levels ≥ twice above upper normal range; history of hypersensitivity to metformin; pregnant or breastfeeding women, or women planning to become pregnant during trial; failure to use adequate contraception (women of current reproductive only); mental condition rending the person unable to understand the nature, scope and possible consequences of trial; any clinically significant major organ system disease; underlying concomitant illness requiring a long‐term use of drugs potentially acting on glucose metabolism (e.g. corticosteroids, diuretics, beta‐adrenergic drugs or others); treatment or likelihood of requiring treatment during the study period with drugs not permitted by the clinical trial protocol; history of drug or alcohol abuse within the last 2 years or current addiction to substances of abuse; any disease or condition that, in the opinion of investigator, may interfere with the completion of the trial; unlikely to comply with protocol </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention (1)</b>: sitagliptin 100 mg, PO, once daily </p> <p><b>Intervention (2)</b>: sitagliptin 100 mg, PO, once daily + metformin 850 mg, PO, twice daily </p> <p><b>Comparator</b>: metformin 850 mg, PO, twice daily </p> <p><b>Duration of intervention</b>: 4 months </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome</b>: β‐cell function (at 4 months) </p> <p><b>Secondary outcomes</b>: insulin resistance (at 4 months); glucose control (at 4 months) </p> <p><b>Other outcomes</b>: none </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial start date</b>: May 2011 </p> <p><b>Trial completion date</b>: according to ClinicalTrials.gov December 2012, but principal investigator informed us through email that trial is still ongoing </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Responsible party/principal investigator</b>: Stefano Del Prato, MD, University of Pisa </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study identifier</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>NCT number</b>: NCT01336322 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Official title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effects of Treatment with Metformin and/or Sitagliptin on Beta‐cell Function and Insulin Resistance in Women with Previous Gestational Diabetes </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated purpose of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "The goal of the present research is to compare the effects of treatment with metformin and sitagliptin, alone or in association, in women with previous gestational diabetes to evaluate the impact of the two drugs on beta‐cell function." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Through correspondence it was clarified that the trial was extended due to delay in study drug supply </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT01548651 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect of Saxagliptin Treatment on Myocardial Fat Content, Left Ventricular Function, and Monocyte Inflammation in Patients with Impaired Glucose Tolerance </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type of trial</b>: not reported in available protocol, but assume efficacy </p> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: double blind (participant, carer, investigator, outcomes assessor) </p> <p><b>Primary purpose</b>: treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: IGT </p> <p><b>Enrolment</b>: estimated 40 </p> <p><b>Inclusion criteria</b>: men and women with IGT (i.e. FPG ≤ 125 mg/dL, 2‐h post OGTT 75‐g glucose 140‐199 mg/dL, HbA1c &lt; 6.5% as per American Diabetes Association criteria; age 30‐70 years; using an acceptable method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimised; BMI 30‐35 kg/m² and stable body weight </p> <p><b>Exclusion criteria</b>: must not be on anti‐diabetes therapy for treatment of IGT and must have a FPG concentration ≤ 125 mg/dL; T1DM or T2DM (FPG &gt; 125 mg/dL); must not be on or have received metformin, thiazolidinediones, sulphonylureas, DPP‐4 inhibitor or exenatide/liraglutide treatment for IGT at any time; must not be receiving any of the following: thiazide or furosemide diuretics, beta‐blockers or other chronic medications such as hormone replacement therapy with known adverse effects on glucose tolerance levels; people taking systemic glucocorticoids excluded; history of clinically significant heart disease, peripheral vascular disease or pulmonary disease; must not have clinically significant liver disease (aspartate aminotransferase &lt; 2.5 times upper limit of normal, alanine transaminase &lt; 2.5 times upper limit of normal, alkaline phosphatase &lt; 2.5 times upper limit of normal), kidney disease (serum creatinine &lt; 1.5 mg/dL in men and 1.4 mg/dL in women) or significant anaemia (hematocrit &lt; 34 vol%); history of any serious hypersensitivity reaction to saxagliptin or a DPP‐4 inhibitor; concomitant treatment with systemic cytochrome P450 3A4 inducers; pregnant or breastfeeding </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: saxagliptin 5 mg/day, PO </p> <p><b>Comparator</b>: placebo daily </p> <p><b>Duration of intervention</b>: 6 months </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcomes</b>: myocardial and hepatic fat content (%) (at 6 months); % change in hepatic fat and myocardial fat from baseline as measured by magnetic resonance imaging and spectroscopy </p> <p><b>Secondary outcomes</b>: left ventricular ejection fraction (%) (at 6 months); % change in left ventricular ejection fraction from baseline as measured by magnetic resonance imaging; monocyte inflammatory protein NFkappaB (%) (at 6 months); % change in monocyte inflammatory proteins NFkappaB from baseline </p> <p><b>Other outcomes</b>: none </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial start date</b>: February 2012 </p> <p><b>Trial completion date</b>: December 2016 (final data collection date for primary outcome measure) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Responsible party/principal investigator</b>: Mandeep Bajaj, MD, Baylor College of Medicine </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study identifier</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>NCT number</b>: NCT01548651 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Official title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect of Saxagliptin Treatment on Myocardial Fat Content, Left Ventricular Function, and Monocyte Inflammation in Patients with Impaired Glucose Tolerance </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated purpose of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "The purpose of the study is to examine the effect of saxagliptin, an anti‐diabetes medication, on hepatic and myocardial fat content and monocyte inflammation in patients with Impaired Glucose Tolerance (IGT)." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT01779362 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Acronym</b>: RISE Adult </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type of trial</b>: efficacy trial </p> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: double blind (participants, carer, investigator, outcomes assessor) </p> <p><b>Primary purpose</b>: treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: prediabetes and early T2DM </p> <p><b>Enrolment</b>: 255 </p> <p><b>Inclusion criteria</b>: FPG 95‐125 mg/dL + 2‐h glucose ≥ 140 mg/dL on OGTT 75‐g glucose + HbA1c ≤ 7.0%. No upper limit for the 2‐h glucose on OGTT; age 20‐65 years; BMI ≥ 25 kg/m² but ≤ 50 kg/m²; self‐reported diabetes &lt; 1 year in duration; drug naive (no prior to oral glucose lowering agent(s), insulin or other injectable glucose lowering agents) </p> <p><b>Exclusion criteria</b>: underlying disease likely to limit life span or increase risk of intervention (or both) or an underlying condition that is likely to limit ability to participate in outcomes assessment; underlying disease that affects glucose metabolism other than T2DM; taking medications that affect glucose metabolism, or has an underlying condition that is likely to require such medications; active infections; renal disease (serum creatinine &gt; 1.4 mg/dL for men; &gt; 1.3 mg/dL for women) or serum potassium abnormality (&lt; 3.4 mmol/L or &gt; 5.5 mmol/L); anaemia (haemoglobin &lt;11 g/dL for women, &lt; 12 g/dL for men) or known coagulopathy; cardiovascular disease, including uncontrolled hypertension; intolerant to administration of intravenous fluids required during clamp studies; history of conditions that may be precipitated or exacerbated by a study drug (pancreatitis, serum alanine transaminase more than 3 times the upper limit of normal, excessive alcohol intake, suboptimally treated thyroid disease, medullary carcinoma of the thyroid or multiple endocrine neoplasia‐2 (in participant or a family history), hypertriglyceridaemia (&gt; 400 mg/dL despite treatment); conditions or behaviours likely to affect the conduct of the RISE Study; unable or unwilling to give informed consent; unable to adequately communicate with clinic staff; another household member is a participant or staff member in RISE; current, recent or anticipated participation in another intervention research project that would interfere with any of the interventions/outcomes in RISE; weight loss &gt; 5% in past 3 months for any reason other than postpartum weight loss; taking weight loss drugs or using preparations taken for intended weight loss; likely to move away from participating clinics in next 2 years; women of childbearing potential unwilling to use adequate contraception; current (or anticipated) pregnancy and lactation; major psychiatric disorder that, in the opinion of clinic staff, would impede the conduct of RISE; additional conditions may serve as criteria for exclusion at the discretion of the local site </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: liraglutide + open‐label metformin. Liraglutide titrated to maximum dose tolerated (up to 1.8 mg/day) after which metformin titrated to maximum dose tolerated (up to 2000 mg/day) </p> <p><b>Comparator</b>: metformin alone. Metformin titrated to maximum dose tolerated (up to 2000 mg/day). Participants randomised to metformin‐alone arm will be blinded to intervention </p> <p><b>Duration of intervention</b>: participants will have 12‐months of active therapy and 3‐months of washout </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome</b>: β‐cell function measured by hyperglycaemic clamp techniques (at 3‐months after a medication washout). Participants will have 12‐months of active therapy and 3 months of washout after which the primary outcome will be assessed </p> <p><b>Secondary outcome</b>: hyperglycaemic clamp and OGTT measures of β‐cell function and glucose tolerance (at 3‐months after a medication washout). Measures derived from the hyperglycaemic clamp that are not specified as primary outcomes and measures derived from the OGTT </p> <p><b>Other outcomes</b>: hyperglycaemic clamp and OGTT measures of β‐cell function and glucose tolerance (at after 12 months of active treatment); measures derived from the hyperglycaemic clamp and the OGTT related to treatment effect at end of 12‐month active intervention period compared to pretreatment baseline </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial start date</b>: April 2013 </p> <p><b>Trial completion date</b>: March 2019 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Responsible party/principal investigator(s)</b>: David Ehrmann, MD, Kieren Mather, MD, Steven Kahn, MB, ChB </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study identifier</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>NCT number</b>: NCT01779362 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Official title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Restoring Insulin Secretion Adult Medication Study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated purpose of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "The primary clinical question RISE will address is: Are improvements in β‐cell function following 12 months of active treatment maintained for 3 months following the withdrawal of therapy? Secondary outcomes will assess durability of glucose tolerance following withdrawal of therapy, and whether biomarkers obtained in the fasting state predict parameters of β‐cell function, insulin sensitivity and glucose tolerance and the response to an intervention." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Other treatment arms in the trial are: insulin glargine followed by metformin; placebo</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT01795248 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Acronym</b>: GDM‐TREAT </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type of trial</b>: efficacy trial </p> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: double blind (participants, carer, investigator) in 1 year, thereafter open‐label </p> <p><b>Primary purpose</b>: prevention </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: NGT, IFG, IGT or a combination </p> <p><b>Enrolment</b>: 100 </p> <p><b>Inclusion criteria</b>: informed oral and written consent; previous diagnosis of GDM according to current Danish guidelines (mainly PG concentration at 120 minutes after OGTT 75‐g glucose ≥ 9.0 mM) during pregnancy within last 5 years; age &gt; 18 years; BMI 25‐45 kg/m²; NGT, IFG, IGT or a combination, safe contraception and negative pregnancy test </p> <p><b>Exclusion criteria</b>: diabetes, HbA1c ≥ 6.5%, previous pancreatitis or previous neoplasia, pregnant or breastfeeding, anaemia (haemoglobin &lt; 7 mM), women planning to become pregnant within the next 5 years, women using other contraception than IUD or oral contraceptives (women who do not use safe contraception will be offered an IUD), women treated with statins, corticosteroids or other hormone therapy (except oestrogens and gestagens); ongoing abuse of alcohol or narcotics; impaired hepatic function (liver transaminases &gt; 3 times upper normal limit); impaired renal function (serum creatinine &gt; 120 μM or albuminuria (or both)), uncontrolled hypertension (systolic blood pressure &gt; 180 mmHg, diastolic blood pressure &gt; 100 mmHg); any condition that investigator feels would interfere with trial participation, receiving any investigational drug within the last 3 months </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: liraglutide 1.8 mg, subcutaneous, once daily </p> <p><b>Comparator</b>: placebo, subcutaneous, once daily. Placebo only given in first year, thereafter no intervention </p> <p><b>Duration of intervention</b>: 5 years </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcomes</b>: change in glucose tolerance (from baseline to 52, 53, 260 and 261 weeks), changes in glucose measured by area under the curve for the PG excursion following 4‐h OGTT 75‐g glucose. </p> <p><b>Secondary outcomes</b>: deterioration in glycaemic status (from baseline to 52, 53, 260 and 261 weeks), % in each treatment arm with NGT at inclusion who develop IFG or IGT (or both) or T2DM; or with IFG or IGT who develop combined IFG/IGT; or with combined IFG/IGT who develop T2DM </p> <p><b>Other outcomes</b>: changes in HbA1c (from baseline to 52 and 260 weeks), from normoglycaemic to prediabetic or T2DM and from prediabetic to T2DM, changes in anthropometric measurements (from baseline to 52 and 260 weeks), changes in BMI, absolute body weight, and waist:hip ratio, changes in β‐cell secretory responses (from baseline to 52, 53, 260 and 261 weeks), changes in area under the curve during OGTT and isoglycaemic intravenous glucose infusion, homeostatic model assessment and proinsulin ratio, changes in insulin sensitivity assessed by homeostatic model assessment and proinsulin ratio and Matsuda insulin sensitivity index (from baseline to 52, 53, 260 and 261 weeks), changes in incretin hormone secretion (baseline to 52, 53, 260 and 261 weeks), measured as fasting plasma concentrations and plasma responses of GLP‐1, GLP2, and glucose‐dependent insulinotropic polypeptide and plasma glucagon during OGTT, changes in incretin effect (from baseline to 52, 53, 260 and 261 weeks), insulin and C‐peptide responses after OGTT vs isoglycaemic intravenous glucose infusion, changes in cardiometabolic risk measures (from baseline to 52 and 260 weeks), changes in subjective appetite (from baseline to 52, 53, 260 and 261 weeks), quality of life (from baseline to 52 and 260 weeks) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial start date</b>: July 2012 </p> <p><b>Trial completion date</b>: August 2019 (final data collection date for primary outcome measure) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Responsible party/principal investigator</b>: Tina Vilsbøll, MD, DMSc, University Hospital Gentofte, Denmark </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study identifier</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>NCT number</b>: NCT01795248 </p> <p><b>EudraCT number</b>: 2012‐001371‐37 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Official title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women with Previous Gestational Diabetes Mellitus </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated purpose of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "It is well‐known that women with previous gestational diabetes mellitus are in risk of developing type 2 diabetes later in life; approximately half of the women develop overt type 2 diabetes within the first 10 years after pregnancy. Knowing this, we want to examine the effect of the type 2 diabetes medicine, liraglutide (Victoza), in women with previous gestational diabetes with the aim of reducing the risk of developing type 2 diabetes." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>15 healthy women without previous GDM will make up a baseline control group.</p> <p>There has been correspondence with the principal investigator, Tina Vilsbøll. So far 2 out 3 of the included participants have IFT or IGT (or both). The first year, the trial is double blind </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT01856907 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A Randomized Pilot Study Evaluating Combination Dipeptidyl Peptidase‐4 Inhibitor Sitagliptin Plus Metformin Compared to Metformin Monotherapy and Placebo on Metabolic Abnormalities in Women with a Recent History of GDM </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type of trial</b>: efficacy trial </p> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: single blind (investigator) </p> <p><b>Primary purpose</b>: treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: IFG, IGT, or both postpartum </p> <p><b>Enrolment</b>: 36 </p> <p><b>Inclusion criteria</b>: women age 18‐42 years who experienced GDM during recent (within 12 months) pregnancy with prediabetic hyperglycaemia determined by an OGTT 75‐g glucose postpartum; IFG, IGT, or both postpartum; written consent for participation in trial </p> <p><b>Exclusion criteria</b>: cholestasis during the past pregnancy; any hepatic diseases in the past (viral hepatitis, toxic hepatic damage, jaundice of unknown aetiology); serum aspartate transaminase or alanine aminotransferase level exceeding more than twice normal laboratory values; presence of hypersensitivity to sitagliptin or other DPP‐4 inhibitor; current use of metformin, thiazolidinediones, GLP‐1 receptor agonists, DPP‐4 inhibitors or weight loss medications (prescription or non‐prescription); prior use of medication to treat diabetes except GDM; use of drugs known to exacerbate glucose tolerance; history of diabetes or prior use of medications to treat diabetes except GDM; creatinine clearance &lt; 60 mL/minute; pregnancy planned during the coming 2 years; currently lactating; not willing to use adequate contraception during trial period (unless sterilised) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: sitagliptin 5 mg + metformin 1000 mg, PO, twice daily </p> <p><b>Comparator (1)</b>: placebo tablet, PO, twice daily </p> <p><b>Comparator (2)</b>: metformin, PO, twice daily </p> <p><b>Duration of intervention</b>: 16 weeks (inclusive up titration period) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcomes</b>: β‐cell compensatory function (change from baseline to 16 weeks); surrogate measures of insulin sensitivity and secretion (change from baseline to 16 weeks); fasting and 2‐h glucose levels after glucose load (change from baseline to 16 weeks) </p> <p><b>Secondary outcome</b>: cardiometabolic risk factors (change from baseline to 16 weeks) </p> <p><b>Other outcome</b>: liver enzymes (change from baseline to 16 weeks) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial start date</b>: September 2013 </p> <p><b>Trial completion date</b>: February 2017 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Responsible party/principal investigator</b>: Karen Elkind‐Hirsch, PhD, and Martha Paterson, MD, Woman's Hospital, Louisiana </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study identifier</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>NCT number</b>: NCT01856907 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Official title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>A Randomized Pilot Study Evaluating Combination Dipeptidyl Peptidase‐4 Inhibitor Sitagliptin Plus Metformin Compared to Metformin Monotherapy and Placebo on Metabolic Abnormalities in Women With a Recent History of GDM </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated purpose of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "This study will examine if combination sitagliptin (a DPP‐4 inhibitor)‐plus metformin is more effective than metformin alone or placebo in improving metabolic parameters, specifically the impact on β‐cell function, in prior GDM women with glucose abnormalities." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT02104739 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comparative Effects of Antidiabetic Medications on Postprandial Hyperlipidemia, Free Fatty Acid Signaling, and Endothelial Dysfunction in Individuals with Prediabetes </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type of trial</b>: efficacy trial </p> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: cross‐over assignment </p> <p><b>Masking</b>: double blind (participant, carer, investigator, outcomes assessor) </p> <p><b>Primary purpose</b>: treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: obese with intermediate hyperglycaemia </p> <p><b>Enrolment</b>: 40 </p> <p><b>Inclusion criteria</b>: men and women; age 30‐70 years of age inclusive; diagnosis of prediabetes defined as either IFG (fasting glucose 100‐125 mg/dL), IGT (2‐h postprandial blood glucose of 140‐199 mg/dL after 75‐g oral glucose challenge), HbA1c 5.7‐6.4%, or a combination of these; participants are allowed, but not required, to be on statins, ACE‐inhibitors, beta‐blockers, angiotensin‐receptor blockers, thiazide diuretics, loop diuretics, or a combination of these, at doses stable ≥ 3 months; BMI 30‐35 kg/m² (± 1 kg/m²); body weight stable (± 4‐5 pounds) over the prior 3 months; women of childbearing age using acceptable contraception (barrier methods, abstinence or surgical sterilisation) for duration of trial; must have: hematocrit ≥ 34 vol%, serum creatinine &lt; 1.5 mg/dL in men and 1.4 mg/dL in women, aspartate aminotransferase &lt; 2.5 times upper limit of normal, alanine aminotransferase &lt; 2.5 times upper limit of normal, alkaline phosphatase &lt; 2.5 times upper limit of normal </p> <p><b>Exclusion criteria</b>: history of T1DM or T2DM; history of diabetic ketoacidosis or hyperosmolar non‐ketotic coma; pregnant or breastfeeding; receiving lipid‐lowering medications other than statins within the last 3 months; receiving metformin, DPP‐IV inhibitors, GLP‐1 agonists, thiazolidinediones, insulin, sulphonylureas, acarbose, sodium‐glucose co‐transporter‐2 inhibitors, corticosteroids or immunosuppressive therapy within the last 3 months and cannot take them for duration of study; receiving non‐steroidal anti‐inflammatory drugs or antioxidant vitamins within the last 1 week, and cannot take them for duration of study; receiving hormone replacement therapy; diabetic gastroparesis; current tobacco use; active malignancy; history of urinary bladder cancer; dietary restrictions precluding a high‐fat meal; history of clinically significant heart disease (NYHA III or IV; more than non‐specific ST‐T wave changes on the electrocardiogram), peripheral vascular disease (history of claudication) or pulmonary disease (dyspnoea on exertion of 1 flight of stairs or less; abnormal breath sounds on auscultation); history of any serious hypersensitivity reaction to study medications; prisoners or people who are involuntarily incarcerated; people who are compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness; known allergic reactions to study medications or test meal; unwilling or unable to provide informed consent; people determined by investigator(s) to not be appropriate candidates for the trial </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention (1)</b>: saxagliptin 5 mg PO, once daily </p> <p><b>Intervention (2)</b>: exenatide 10 μg subcutaneous, once daily </p> <p><b>Comparator (1)</b>: pioglitazone 45 mg PO, once daily </p> <p><b>Comparator (2)</b>: placebo tablets and placebo (normal saline) injections </p> <p>All drugs taken immediately before a high‐fat meal</p> <p><b>Duration of intervention</b>: participants receive 1 dose (1 day for each intervention). Minimum 10‐day washout between interventions </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome</b>: free fatty acids (6 h after ingestion of meal) </p> <p><b>Secondary outcome</b>: triglycerides (6 h after ingestion of meal) </p> <p><b>Other outcome</b>: forearm blood flow (6 h after meal) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial start date</b>: March 2014 </p> <p><b>Trial completion date</b>: March 2018 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Responsible party/principal investigator</b>: Absalaon D Gutierrez, MD, University of Texas Health Science Center at Houston, Dept of Medicine </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study identifier</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>NCT number</b>: NCT02104739 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Official title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comparative Effects of Antidiabetic Medications on Postprandial Hyperlipidemia, Free Fatty Acid Signaling, and Endothelial Dysfunction in Individuals with Prediabetes </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated purpose of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "This project addresses cardiovascular disease risk in patients with prediabetes." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Duration of intervention is less than required for inclusion in this review, but the trial will be listed in 'Supplementary table' when completed. Investigators planning an extension period </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT02140983 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Acronym</b>: LGT </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type of trial</b>: efficacy trial </p> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: double blind (participants, carer, outcome assessors) </p> <p><b>Primary purpose</b>: not specified </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: IFG 100‐125 mg/dL or impaired 2‐h glucose concentration 140‐199 mg/dL and &lt; 200 mg/dL on OGTT 75‐g glucose, or both </p> <p><b>Enrolment</b>: 80 </p> <p><b>Inclusion criteria</b>: men and women age 50‐70 years, BMI 27‐37 kg/m² and ≥ 12 years of education; medically stable (i.e. no uncontrolled or poorly controlled medical illnesses); cognitively intact as defined by MMSE score &gt; 27 and will have adequate visual and auditory acuity to allow for cognitive testing; metabolic function determined as IFG 100‐125 mg/dL or impaired 2‐h glucose concentration 140‐199 mg/dL and &lt; 200 mg/dL (or both) on 75‐g oral glucose challenge; half of participants will have a family history of dementia </p> <p><b>Exclusion criteria</b>: diagnosis of possible or probable Alzheimer's dementia, mild cognitive impairment or any other dementia; evidence of cognitive decline by MMSE score &lt; 27 or self‐reported significant decline in memory within the past year (per the Memory Function Questionnaire); history of T1DM or T2DM, or FPG &gt; 126 mg/dL; history of significant cardiovascular disease or myocardial infarction; unstable cerebrovascular or pulmonary disease, gallstones, pancreatitis or cancer, multiple endocrine neoplasia untreated hypothyroidism, unstable or untreated hypertension, anaemia as determined by hematocrit &lt; 30%; abnormal renal clearance as determined by serum creatinine 1.5 mg/dL, hepatic dysfunction as determined by alanine aminotransferase &gt; 2 times the upper limit of normal; presence of medications known to affect insulin action or insulin secretion; premature birth (which may affect magnetic resonance imaging findings), history of neurological disorder (ischaemic attacks, carotid bruits or lacunes upon magnetic resonance imaging scan), or evidence of neurological or other physical illness that could produce cognitive deterioration; use of any drug that may significantly affect the OGTT results or cognitive testing results; drug or alcohol abuse or dependence within the past 6 months; positive urine toxicology screen for illicit substances at eligibility screening; history of mental illness, with the exception of past mood disorder, or evidence of acute depression as determined by a 17‐item Hamilton Depression Rating Scale score ≥ 8; participants with history of mood disorder must be in remission for at least 6 months prior to study entry </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: liraglutide up to 1.8 mg/day, subcutaneous </p> <p><b>Comparator</b>: placebo, subcutaneous </p> <p><b>Duration of intervention</b>: 90 days </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcomes</b>: cognitive outcomes (change from baseline to 3 months); the following battery of tests will take approximately 90 minutes (at both baseline and 12‐week follow‐up) to complete and will be administered during the afternoon to avoid diurnal effects: Auditory Consonant Trigrams; Benton Visual Retention Test 5th Edition, Boston Naming Test, Buschke‐Fuld Selective Reminding Test, DKEFS, Color‐Word subtest, DKEFS Tower Test, DKEFS Trail Making Test, DKEFS Verbal Fluency subtest, Purdue Pegboard, Rey‐Osterrieth Complex Figure Test, Taylor Complex Figure Task, Wechsler Abbreviated Scale of Intelligence, and the Wechsler Adult Intelligence Scale‐3rd Edition; OGTT (change from baseline to 3 months) </p> <p><b>Secondary outcomes</b>: none reported </p> <p><b>Other outcomes</b>: none reported </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial start date</b>: August 2013 </p> <p><b>Trial completion date</b>: according to ClinicalTrials.gov in February 2016; however, investigator has replied that trial will be completed at end of 2016 as they had to wait for drug supply (internal communication) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Responsible party/principal investigator</b>: Natalie Rasgon, Professor, Stanford University </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study identifier</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>NCT number</b>: NCT02140983 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Official title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults with Prediabetes </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated purpose of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "The purpose of this study is to evaluate the effects of liraglutide on the memory and attention of people with insulin resistance." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>It was clarified through correspondence that the trial is still ongoing</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT02488057 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Improving Beta Cell Function in Mexican American Women with Prediabetes</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type of trial</b>: efficacy trial </p> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: open label </p> <p><b>Primary purpose</b>: prevention </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: IGT </p> <p><b>Enrolment</b>: 450<br> <b>Inclusion criteria</b>: Mexican‐American women aged 18‐40 years, BMI 31‐42 kg/m², willingness to complete protocol </p> <p><b>Exclusion criteria</b>: pregnant, ≥ 30 minutes of moderate‐to‐vigorous activity &gt; 3 times per week, cardiovascular disease, physical limitations that might be aggravated by moderate physical activity, planning to move in next 12‐24 months, diabetic </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: weight loss + liraglutide 0.6 mg injection daily for 1 week, increased to 1.2 mg for 1 week and then 3.0 mg for the next 10 weeks </p> <p><b>Comparator</b>: diet‐induced weight loss </p> <p><b>Duration of intervention</b>: 12 weeks </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcomes</b> : </p> <p><b>Secondary outcomes</b>: waist circumference; fasting glucose; triglycerides; high‐density lipoprotein cholesterol; blood pressure; highly sensitive C‐reactive protein; presence of genetic polymorphisms </p> <p><b>Other outcomes</b>: none </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial start date</b>: July 2015 </p> <p><b>Trial completion date</b>: September 2020 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Responsible party/principal investigator</b>: Willa A Hsueh, MD, Ohio State University </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study identifier</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>NCT number</b>: NCT02488057 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Official title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Improving Beta Cell Function in Mexican American Women with Prediabetes</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated purpose of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "This study will examine the benefits of weight loss alone or in combination with a GLP1 receptor agonist, liraglutide, on beta cell function in young adult Mexican American (MA) women with prediabetes." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Through correspondence we were informed that the diagnostic criterion for prediabetes was IGT defined by the American Diabetes Association </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT02576288 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Acronym</b>: SAVORO </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type of trial</b>: safety/efficacy trial </p> <p><b>Allocation</b>: randomised (3:1) </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: double blind (participants, carer, investigator, outcomes assessor) </p> <p><b>Primary purpose</b>: treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: FPG 100‐125 mg/dL, HbA1c 5.7‐6.4% or HOMA‐IR ≥ 3.0 and abdominal obesity </p> <p><b>Enrolment</b>: 40 </p> <p><b>Inclusion criteria</b>: age 18‐40 years; stable weight (no change &gt; 3% in prior 6 months); waist circumference ≥ 102 cm for men, ≥ 88 cm for women; FPG 100‐125 mg/dL, HbA1c 5.7‐6.4% or HOMA‐IR* ≥ 3.0. </p> <p><b>Exclusion criteria</b>: regular use of non‐steroidal anti‐inflammatory drug; unwilling to stop non‐steroidal anti‐inflammatory drug; receiving statin or other prescription anti‐inflammatory drugs; diabetes or clinically evident cardiovascular disease; smoking daily or consuming &gt; 200 g alcohol/day </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: sitagliptin 100 mg, PO, once daily </p> <p><b>Comparator</b>: placebo, PO, once daily </p> <p><b>Duration of intervention</b>: 28 days </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome</b>: ultrasound quantification of change in brachial artery flow‐mediated dilation and carotid stiffness (elasticity and dispensability) (immediately before and after 28 days of study therapy) </p> <p><b>Secondary outcome</b>: deep subcutaneous adipose tissue inflammation (immediately before and after 28 days of study therapy) </p> <p><b>Other outcomes</b>: systemic markers of inflammation/atherogenic mediators and insulin resistance (immediately before and after 28 days of study therapy) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial start date</b>: January 2016 </p> <p><b>Trial completion date</b>: July 2017 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Responsible party/principal investigator</b>: Fred Sattler, MD, University of Southern California </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study identifier</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>NCT number</b>: NCT02576288 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Official title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effects of Sitagliptin on Arterial Vasoreactivity and Proatherogenic Mediators in Obesity </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated purpose of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "The investigators will evaluate a novel approach using a dipeptidyl peptidase 4 inhibitor (DPP4i) sitagliptin, which blocks signal transduction for monocyte/macrophage activation." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Duration of intervention is less than required for inclusion in this review, but the trial will be listed in 'Supplementary table' when completed </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT02847403 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Acronym</b>: DRINN </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type of trial</b>: efficacy trial </p> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: open label </p> <p><b>Primary purpose</b>: treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: dysglycaemia/prediabetes defined as FPG 100‐125 mg/dL or 2‐h PG 140‐199 mg/dL after a OGTT 75‐g glucose or HbA1c 5.7‐6.4% or a combination of these </p> <p><b>Enrolment</b>: 40 </p> <p><b>Inclusion criteria</b>: dysglycaemia/prediabetes defined as FPG 100‐125 mg/dL or 2‐h PG 140‐199 mg/dL after a OGTT 75‐g glucose or HbA1c 5.7‐6.4%, or a combination of these; mild cognitive impairment; age 50‐80 years; stable medication for past 3 months; white </p> <p><b>Exclusion criteria</b>: age &lt; 50 or &gt; 80 years; incapability to give informed consent; T2DM; clinically significant liver or kidney dysfunction; endocrinological diseases other than well‐controlled hypothyroidism, personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome, severe gastrointestinal diseases (i.e. gastroparesis, dumping syndromes), current or history of chronic or acute pancreatitis; any contraindication to use of exenatide as per the 'Summary of product characteristics'; known abuse of alcohol or drugs; ferromagnetic prosthesis, pacemaker or other metals incorporated in the body; significant neurological disease other than mild cognitive impairment (i.e. Parkinson's disease, multiple system atrophy, normal pressure hydrocephalus, progressive supranuclear palsy, subarachnoid haemorrhage, brain neoplasms, Huntington's disease, epilepsy or head trauma); BMI ≤ 22 kg/m² in people age ≥ 70 years; magnetic resonance imaging/computer tomography showing unambiguous aetiological evidence of cerebrovascular disease with regard to mild cognitive impairment; severe sensory defects; current presence of clinically significant psychiatric disorder; warfarin treatment, clinically significant systemic condition; history of cancer within the last 5 years; known allergy to exenatide or any of other components </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: long‐acting exenatide 2 mg, subcutaneously once‐weekly </p> <p><b>Comparator</b>: not clear whether placebo is provided or no intervention </p> <p><b>Duration of intervention</b>: 32 weeks </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome</b>: improvement of Alzheimer's Disease Assessment Scale ‐ cognitive at 16 and 32 weeks compared to baseline </p> <p><b>Secondary outcomes</b>: at 16 and 32 weeks compared to baseline: improvement of MMSE test, MMSE quality test, Phonemic verbal fluency test, Semantic verbal fluency test, Geriatric Depression Scale test, Clinical Dementia Rating Scale test, Activities of Daily Living test, Neuropsychiatric Inventory test and Instrumental Activities of Daily Living; changes in structural and functional connectivity of neural networks as assessed by functional magnetic resonance imaging </p> <p><b>Other outcomes</b>: not stated </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial start date</b>: February 2016 </p> <p><b>Trial completion date</b>: July 2018 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Responsible party/principal investigator</b>: Alessandra Dei Cas, MD, Azienda Ospedaliero‐Universitaria di Parma, Italy </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study identifier</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>NCT number</b>: NCT02847403 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Official title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Long‐acting Exenatide and Cognitive Decline in Dysglycemic Patients (DRINN)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated purpose of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "The overall objective of the study is to assess the potential effects of the long‐acting GLP‐1 analogue exenatide in preventing/slowing the progression of cognitive dysfunction and related biomarkers in dysglycaemic/prediabetic patients with mild cognitive impairment (MCI)." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT02969798 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Pre‐diabetes in Subject with Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type of trial</b>: efficacy trial </p> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: crossover assignment </p> <p><b>Masking</b>: open label </p> <p><b>Primary purpose</b>: treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: IGT and IFG </p> <p>NGT participants will serve as controls and will be matched in age, gender, ethnicity and BMI to IGT and IFG participants </p> <p><b>Enrolment</b>: 700 </p> <p><b>Inclusion criteria</b>: age 18‐65 years; FPG &lt; 100 mg/dL and 2‐h PG &lt; 140 mg/dL; BMI 24‐40 kg/m²; stable body weight (± 4 pounds) over the preceding 3 months; no evidence of major organ system disease as determined by physical examination, history and screening laboratory data; women of childbearing potential with a negative pregnancy test at screening and treatment visits, using contraception for the duration of participation in the study (i.e. until follow‐up 7‐14 days after last dose) (oral contraceptive, injectable progesterone, subdermal implant, spermicidal foam/gel/film/cream/suppository, diaphragm with spermicide, copper or hormonal‐containing IUD, vasectomised male partner &gt; 6 month predosing); signed and dated informed consent document indicating that participant has been informed of all pertinent aspects of study; willing and able to comply with scheduled visits, treatment, laboratory tests and study procedures </p> <p><b>Exclusion criteria</b>: recent (i.e. within 3 months prior to screening) evidence or medical history of unstable concurrent disease such as: documented evidence or history of clinically significant haematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, immunological or clinically significant neurological disease; family history of diabetes in a first‐degree relative; BMI &lt; 24 or &gt; 40 kg/m²; unstable body weight (change ± 4 pounds over the preceding 3 months); participating in an excessively heavy exercise programme; feeding/sleeping schedule different from a daytime feeding/night‐time sleeping schedule; receiving medications known to alter glucose metabolism (with the exception of metformin or pioglitazone, or both) or which effect brain neurosynaptic function; evidence of major organ system disease as determined by physical examination, history and screening laboratory data; pregnant or unwilling to use contraception during study; blood donation of approximately 1 pint (500 mL) within 8 weeks prior to screening; other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in judgement of investigator, would make participant inappropriate for entry into study; people haematuria; evidence or prior history of heart failure; family history of pancreatic, bladder and breast cancer; history of pancreatitis; estimated GFR &lt; 60 ± 5 mL/minute/1.73 m²; elevated serum creatinine (&gt; 1.5 mg/dL for men/1.4 mg/dL for women); history of orthostatic hypotension (&gt; 15/10 mmHg); liver enzymes &gt; 3‐fold above upper normal limit; history of hypersensitivity to pioglitazone, dapagliflozin or saxagliptin. </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: saxagliptin 5 mg/day </p> <p><b>Comparator (1)</b>: dapagliflozin 100 mg/day </p> <p><b>Comparator (2)</b>: pioglitazone 30 mg/day </p> <p><b>Comparator (3)</b>: metformin 200 mg/day </p> <p>The trial will randomise participants exclusively with IGT to 1 treatment group; participants exclusively with IFG to 1 treatment group and participants with IGT plus IFG to 1 treatment group </p> <p><b>Duration of intervention</b>: 24 months </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcomes</b>: β‐cell function, insulin sensitivity and glucose tolerance status in people with isolated IGT; β‐cell function, insulin sensitivity and glucose tolerance status in people with isolated IFG; β‐cell function, insulin sensitivity and glucose tolerance status in people with IGT plus IFG </p> <p><b>Secondary outcomes</b>: not stated </p> <p><b>Other outcomes</b>: not stated </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial start date</b>: January 2014 </p> <p><b>Trial completion date</b>: January 2017 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Responsible party/principal investigator</b>: Ralph A DeFronzo, The University of Texas Health Science Center at San Antonio </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study identifier</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>NCT number</b>: NCT02969798 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Official title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Preservation of Beta Cell Function in Pre‐diabetes in Subject with Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT). </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated purpose of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>There is a control arm with participants with NGT ‐ these will not be included in updates of our review </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT03004612 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Acronym</b>: PRELLIM </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type of trial</b>: efficacy trial </p> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: double blind </p> <p><b>Primary purpose</b>: prevention </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: IGT and IFG </p> <p><b>Enrolment</b>: 75 </p> <p><b>Inclusion criteria</b>: coexistence of IFG (fasting glucose 100‐125 mg/dL) and IGT (glucose 140‐199 mg/dL at 2‐h OGTT </p> <p><b>Exclusion criteria</b>: T2DM; actual treatment or during the last 3 months with metformin, pioglitazone or another antidiabetic drug, including insulin; serum creatinine &gt; 1.6 mg/dL; hypertriglyceridaemia very high (&gt; 500 mg/dL); pregnant women; altered arterial hypertension (systolic &gt; 180 mmHg or diastolic &gt; 105 mmHg); excessive alcohol intake; medications or medical conditions that affect glucose homeostasis </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: linagliptin 2.5 mg/day + metformin 850 mg/day every 12 h </p> <p><b>Comparator</b>: metformin 850 mg every 12 h </p> <p><b>Duration of intervention</b>: 12 months </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcome</b>: change from basal fasting and post 2‐h OGTT glucose levels at 6 and 12 months </p> <p><b>Secondary outcomes</b>: change from basal pancreatic β‐cell function at 12 months; change from basal insulin sensitivity at 6 and 12 months; change from basal weight at 6 and 12 months; change from basal lipid profile at 6 and 12 months </p> <p><b>Other outcomes</b>: not stated </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial start date</b>: December 2015 </p> <p><b>Trial completion date</b>: August 2018 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Responsible party/principal investigator</b>: Rodolfo Guardado‐Mendoza, Universidad de Guanajuato, Mexico </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study identifier</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>NCT number</b>: NCT03004612 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Official title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect of Linagliptin + Metformin vs Metformin Alone in Patients with Prediabetes (PRELLIM) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated purpose of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "The goal of this clinical trial is to evaluate the effect of linagliptin + metformin vs metformin alone on physiopathological parameters, such as glucose metabolism, insulin resistance, insulin secretion and pancreatic beta cell function in patients with impaired fasting glucose plus impaired glucose tolerance, during 12 months." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The study is currently recruiting participants</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">UMIN000008620 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Acronym</b>: VOGUE‐KOBE </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Type of trial</b>: efficacy trial </p> <p><b>Allocation</b>: randomised </p> <p><b>Intervention model</b>: parallel assignment </p> <p><b>Masking</b>: open label </p> <p><b>Primary purpose</b>: efficacy </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Condition</b>: people with coronary artery disease and IGT </p> <p><b>Enrolment</b>: 50 </p> <p><b>Inclusion criteria</b>: undergoing percutaneous coronary intervention, untreated IGT and 2‐h plasma/serum glucose level: 140‐199 mg/dL in 75‐g OGTT, LDL cholesterol &lt; 100 mg/dL in people not taking statins; LDL‐cholesterol &lt; 120 mg/dL in people taking statins; age 20‐80 years; written consent for participation in study </p> <p><b>Exclusion criteria</b>: severe T1DM or T2DM liver dysfunction; severe renal dysfunction; severe heart failure (NYHA Stage III or more severe); malignancies or other diseases with poor prognosis; pregnant, lactating and possibly pregnant women and women planning to become pregnant; history of hypersensitivity to investigational drugs; judged as ineligible by clinical investigators </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention</b>: vildagliptin 50 mg/day </p> <p><b>Comparator</b>: diet + exercise </p> <p><b>Duration of intervention</b>: 6 months </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Primary outcomes</b>: change in coronary plaque character analysed by coronary angiography, intravascular ultrasound and optical coherence tomography; daily glucose profile analysed by 24‐h continuous glucose monitoring system before and after 6 months </p> <p><b>Secondary outcomes</b>: changes in the intima media thickness value measured by carotid arterial echography; changes in HbA1c and OGTT 75‐g glucose (glucose and insulin levels after glucose load) </p> <p><b>Other outcomes</b>: not stated </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial start date</b>: July 2012 </p> <p><b>Trial completion date</b>: not stated </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Responsible party/principal investigator</b>: Toshiro Shinke, Kobe University Graduate School of Medicine, Japan </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study identifier</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>UMIN number</b>: 000008620 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Official title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The Impact of Vildagliptin on Daily Glucose Profile and Coronary PlaqUE Character in Impaired Glucose Tolerance Patients with Coronary Artery Disease: VOGUE‐KOBE </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Stated purpose of study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quote</b>: "Comparison of vildagliptin versus conventional treatment without DDP‐4 inhibitor on daily glucose profile analyzed by 24‐hour continuous glucose monitoring system and coronary plaque character using coronary imaging devices in IGT patients with coronary artery disease." </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Investigators asked for completion date</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACE: angiotensin‐converting enzyme; BMI: body mass index; DPP‐4: dipeptidyl‐peptidase‐4; DKEFS: Delis Kaplan Executive Function System; ETDRS: Early Treatment Diabetic Retinopathy Study Scale; FPG: fasting plasma glucose; GDM: gestational diabetes mellitus; GFR: glomerular filtration rate; GLP‐1; glucagon‐like peptide‐1; h: hour; HbA1c: glycosylated haemoglobin A1c; HOMA‐IR: homeostatic model assessment insulin resistance; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; IUD: intrauterine device; LDL: low‐density lipoprotein; MMSE: Mini Mental State Examination; NGT: normal glucose tolerance; NYHA: New York Heart Association; OGTT: oral glucose tolerance test; PG: plasma glucose; PO: per os (orally); SD: standard deviation; T1DM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus; TIA: transient ischaemic attack. </p> </div> </div> </p> </section> </section> <section class="dataAndAnalyses" id="dataAndAnalyses"> <section class="dataAndAnalyses" lang="en"> <div class="section-header section-collapse-header" id="CD012204-sec1-0011"> <h2 class="title section-collapse-title">Data and analyses<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <div class="table" id="CD012204-tbl-0003"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00101"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-001-01.png?filename=nCD012204-CMP-001-01.ppt&amp;title=1.1&amp;caption=Comparison%201%20Dipeptidyl%E2%80%90peptidase%20%28DPP%29%E2%80%904%20inhibitors%20versus%20metformin%2C%20Outcome%201%20Non%E2%80%90serious%20adverse%20events.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.1</div> </div> <hr class="top"><img data-id="CD012204-fig-00101" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-01.png" alt="Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 1 Non‐serious adverse events."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 1 Non‐serious adverse events. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00102"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-001-02.png?filename=nCD012204-CMP-001-02.ppt&amp;title=1.2&amp;caption=Comparison%201%20Dipeptidyl%E2%80%90peptidase%20%28DPP%29%E2%80%904%20inhibitors%20versus%20metformin%2C%20Outcome%202%20Fasting%20blood%20glucose.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.2</div> </div> <hr class="top"><img data-id="CD012204-fig-00102" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-02.png" alt="Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 2 Fasting blood glucose."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 2 Fasting blood glucose. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 2‐hour glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00103"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-001-03.png?filename=nCD012204-CMP-001-03.ppt&amp;title=1.3&amp;caption=Comparison%201%20Dipeptidyl%E2%80%90peptidase%20%28DPP%29%E2%80%904%20inhibitors%20versus%20metformin%2C%20Outcome%203%202%E2%80%90hour%20glucose.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.3</div> </div> <hr class="top"><img data-id="CD012204-fig-00103" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-03.png" alt="Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 3 2‐hour glucose."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 3 2‐hour glucose. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Haemoglobin A1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00104"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-001-04.png?filename=nCD012204-CMP-001-04.ppt&amp;title=1.4&amp;caption=Comparison%201%20Dipeptidyl%E2%80%90peptidase%20%28DPP%29%E2%80%904%20inhibitors%20versus%20metformin%2C%20Outcome%204%20Haemoglobin%20A1c.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.4</div> </div> <hr class="top"><img data-id="CD012204-fig-00104" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-04.png" alt="Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 4 Haemoglobin A1c."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 4 Haemoglobin A1c. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD012204-tbl-0004"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">DDP‐4 inhibitors versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Incidence of type 2 diabetes mellitus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00201"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-002-01.png?filename=nCD012204-CMP-002-01.ppt&amp;title=2.1&amp;caption=Comparison%202%20DDP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%201%20Incidence%20of%20type%202%20diabetes%20mellitus.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.1</div> </div> <hr class="top"><img data-id="CD012204-fig-00201" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-01.png" alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 1 Incidence of type 2 diabetes mellitus."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 1 Incidence of type 2 diabetes mellitus. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00202"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-002-02.png?filename=nCD012204-CMP-002-02.ppt&amp;title=2.2&amp;caption=Comparison%202%20DDP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%202%20Serious%20adverse%20events.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.2</div> </div> <hr class="top"><img data-id="CD012204-fig-00202" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-02.png" alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 2 Serious adverse events."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 2 Serious adverse events.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Congestive heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00203"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-002-03.png?filename=nCD012204-CMP-002-03.ppt&amp;title=2.3&amp;caption=Comparison%202%20DDP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%203%20Congestive%20heart%20failure.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.3</div> </div> <hr class="top"><img data-id="CD012204-fig-00203" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-03.png" alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 3 Congestive heart failure."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 3 Congestive heart failure.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00204"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-002-04.png?filename=nCD012204-CMP-002-04.ppt&amp;title=2.4&amp;caption=Comparison%202%20DDP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%204%20Non%E2%80%90serious%20adverse%20events.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.4</div> </div> <hr class="top"><img data-id="CD012204-fig-00204" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-04.png" alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 4 Non‐serious adverse events."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 4 Non‐serious adverse events.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Fasting glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00205"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-002-05.png?filename=nCD012204-CMP-002-05.ppt&amp;title=2.5&amp;caption=Comparison%202%20DDP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%205%20Fasting%20glucose.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.5</div> </div> <hr class="top"><img data-id="CD012204-fig-00205" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-05.png" alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 5 Fasting glucose."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 5 Fasting glucose.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 2‐hour glucose values <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00206"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-002-06.png?filename=nCD012204-CMP-002-06.ppt&amp;title=2.6&amp;caption=Comparison%202%20DDP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%206%202%E2%80%90hour%20glucose%20values.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.6</div> </div> <hr class="top"><img data-id="CD012204-fig-00206" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-06.png" alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 6 2‐hour glucose values."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 6 2‐hour glucose values.</p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Haemoglobin A1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00207"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-002-07.png?filename=nCD012204-CMP-002-07.ppt&amp;title=2.7&amp;caption=Comparison%202%20DDP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%207%20Haemoglobin%20A1c.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.7</div> </div> <hr class="top"><img data-id="CD012204-fig-00207" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-07.png" alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 7 Haemoglobin A1c."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 7 Haemoglobin A1c.</p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD012204-tbl-0005"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 3.</span>&nbsp;<span class="table-title">Glucagon‐like peptide (GLP)‐1 analogues versus metformin</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00301"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-003-01.png?filename=nCD012204-CMP-003-01.ppt&amp;title=3.1&amp;caption=Comparison%203%20Glucagon%E2%80%90like%20peptide%20%28GLP%29%E2%80%901%20analogues%20versus%20metformin%2C%20Outcome%201%20Fasting%20blood%20glucose.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 3.1</div> </div> <hr class="top"><img data-id="CD012204-fig-00301" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-003-01.png" alt="Comparison 3 Glucagon‐like peptide (GLP)‐1 analogues versus metformin, Outcome 1 Fasting blood glucose."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 3 Glucagon‐like peptide (GLP)‐1 analogues versus metformin, Outcome 1 Fasting blood glucose. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> <div class="table" id="CD012204-tbl-0006"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 4.</span>&nbsp;<span class="table-title">Glucagon‐like peptide (GLP)‐1 analogues versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Incidence of type 2 diabetes mellitus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00401"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-004-01.png?filename=nCD012204-CMP-004-01.ppt&amp;title=4.1&amp;caption=Comparison%204%20Glucagon%E2%80%90like%20peptide%20%28GLP%29%E2%80%901%20analogues%20versus%20placebo%2C%20Outcome%201%20Incidence%20of%20type%202%20diabetes%20mellitus.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.1</div> </div> <hr class="top"><img data-id="CD012204-fig-00401" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-01.png" alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 1 Incidence of type 2 diabetes mellitus."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 1 Incidence of type 2 diabetes mellitus. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00402"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-004-02.png?filename=nCD012204-CMP-004-02.ppt&amp;title=4.2&amp;caption=Comparison%204%20Glucagon%E2%80%90like%20peptide%20%28GLP%29%E2%80%901%20analogues%20versus%20placebo%2C%20Outcome%202%20Serious%20adverse%20events.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.2</div> </div> <hr class="top"><img data-id="CD012204-fig-00402" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-02.png" alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 2 Serious adverse events."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 2 Serious adverse events. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00403"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-004-03.png?filename=nCD012204-CMP-004-03.ppt&amp;title=4.3&amp;caption=Comparison%204%20Glucagon%E2%80%90like%20peptide%20%28GLP%29%E2%80%901%20analogues%20versus%20placebo%2C%20Outcome%203%20Non%E2%80%90serious%20adverse%20events.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.3</div> </div> <hr class="top"><img data-id="CD012204-fig-00403" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-03.png" alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 3 Non‐serious adverse events."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 3 Non‐serious adverse events. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Mild hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00404"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-004-04.png?filename=nCD012204-CMP-004-04.ppt&amp;title=4.4&amp;caption=Comparison%204%20Glucagon%E2%80%90like%20peptide%20%28GLP%29%E2%80%901%20analogues%20versus%20placebo%2C%20Outcome%204%20Mild%20hypoglycaemia.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.4</div> </div> <hr class="top"><img data-id="CD012204-fig-00404" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-04.png" alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 4 Mild hypoglycaemia."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 4 Mild hypoglycaemia. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00405"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-004-05.png?filename=nCD012204-CMP-004-05.ppt&amp;title=4.5&amp;caption=Comparison%204%20Glucagon%E2%80%90like%20peptide%20%28GLP%29%E2%80%901%20analogues%20versus%20placebo%2C%20Outcome%205%20Fasting%20blood%20glucose.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.5</div> </div> <hr class="top"><img data-id="CD012204-fig-00405" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-05.png" alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 5 Fasting blood glucose."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 5 Fasting blood glucose. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 2‐hour glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00406"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-004-06.png?filename=nCD012204-CMP-004-06.ppt&amp;title=4.6&amp;caption=Comparison%204%20Glucagon%E2%80%90like%20peptide%20%28GLP%29%E2%80%901%20analogues%20versus%20placebo%2C%20Outcome%206%202%E2%80%90hour%20glucose.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.6</div> </div> <hr class="top"><img data-id="CD012204-fig-00406" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-06.png" alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 6 2‐hour glucose."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 6 2‐hour glucose. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Haemoglobin A1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD012204-fig-00407"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-004-07.png?filename=nCD012204-CMP-004-07.ppt&amp;title=4.7&amp;caption=Comparison%204%20Glucagon%E2%80%90like%20peptide%20%28GLP%29%E2%80%901%20analogues%20versus%20placebo%2C%20Outcome%207%20Haemoglobin%20A1c.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 4.7</div> </div> <hr class="top"><img data-id="CD012204-fig-00407" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-07.png" alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 7 Haemoglobin A1c."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 7 Haemoglobin A1c. </p> </div> </div> </div> </td> </tr> </tbody> </table> </div> </section> </section> <div class="figures-list"> <div class="figure" id="CD012204-fig-0001"> <img data-id="CD012204-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-AFig-FIG01.png" alt="Study flow diagram."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-fig-0001" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-AFig-FIG01.png?filename=nCD012204-AFig-FIG01.ppt&amp;title=1&amp;caption=Study%20flow%20diagram.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-AFig-FIG01.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0002"><img data-id="CD012204-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-AFig-FIG02.png" alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-fig-0002" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-AFig-FIG02.png?filename=nCD012204-AFig-FIG02.ppt&amp;title=2&amp;caption=Risk%20of%20bias%20graph%3A%20review%20authors%27%20judgements%20about%20each%20risk%20of%20bias%20item%20presented%20as%20percentages%20across%20all%20included%20trials%20%28blank%20cells%20indicate%20that%20the%20particular%20outcome%20was%20not%20measured%20in%20some%20trials%29.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-AFig-FIG02.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-0003"><img data-id="CD012204-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-AFig-FIG03.png" alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial (blank cells indicate that the particular outcome was not measured in some trials)."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial (blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-fig-0003" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-AFig-FIG03.png?filename=nCD012204-AFig-FIG03.ppt&amp;title=3&amp;caption=Risk%20of%20bias%20summary%3A%20review%20authors%27%20judgements%20about%20each%20risk%20of%20bias%20item%20for%20each%20included%20trial%20%28blank%20cells%20indicate%20that%20the%20particular%20outcome%20was%20not%20measured%20in%20some%20trials%29.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-AFig-FIG03.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00101"><img data-id="CD012204-fig-00101" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-01.png" alt="Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 1 Non‐serious adverse events."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 1 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00101" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-001-01.png?filename=nCD012204-CMP-001-01.ppt&amp;title=1.1&amp;caption=Comparison%201%20Dipeptidyl%E2%80%90peptidase%20%28DPP%29%E2%80%904%20inhibitors%20versus%20metformin%2C%20Outcome%201%20Non%E2%80%90serious%20adverse%20events.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00102"><img data-id="CD012204-fig-00102" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-02.png" alt="Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 2 Fasting blood glucose."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 2 Fasting blood glucose. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00102" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-001-02.png?filename=nCD012204-CMP-001-02.ppt&amp;title=1.2&amp;caption=Comparison%201%20Dipeptidyl%E2%80%90peptidase%20%28DPP%29%E2%80%904%20inhibitors%20versus%20metformin%2C%20Outcome%202%20Fasting%20blood%20glucose.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00103"><img data-id="CD012204-fig-00103" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-03.png" alt="Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 3 2‐hour glucose."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 3 2‐hour glucose. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00103" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-001-03.png?filename=nCD012204-CMP-001-03.ppt&amp;title=1.3&amp;caption=Comparison%201%20Dipeptidyl%E2%80%90peptidase%20%28DPP%29%E2%80%904%20inhibitors%20versus%20metformin%2C%20Outcome%203%202%E2%80%90hour%20glucose.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00104"><img data-id="CD012204-fig-00104" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-04.png" alt="Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 4 Haemoglobin A1c."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin, Outcome 4 Haemoglobin A1c. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00104" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-001-04.png?filename=nCD012204-CMP-001-04.ppt&amp;title=1.4&amp;caption=Comparison%201%20Dipeptidyl%E2%80%90peptidase%20%28DPP%29%E2%80%904%20inhibitors%20versus%20metformin%2C%20Outcome%204%20Haemoglobin%20A1c.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-001-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00201"><img data-id="CD012204-fig-00201" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-01.png" alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 1 Incidence of type 2 diabetes mellitus."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 1 Incidence of type 2 diabetes mellitus. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00201" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-002-01.png?filename=nCD012204-CMP-002-01.ppt&amp;title=2.1&amp;caption=Comparison%202%20DDP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%201%20Incidence%20of%20type%202%20diabetes%20mellitus.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00202"><img data-id="CD012204-fig-00202" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-02.png" alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 2 Serious adverse events."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 2 Serious adverse events.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00202" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-002-02.png?filename=nCD012204-CMP-002-02.ppt&amp;title=2.2&amp;caption=Comparison%202%20DDP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%202%20Serious%20adverse%20events.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00203"><img data-id="CD012204-fig-00203" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-03.png" alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 3 Congestive heart failure."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 3 Congestive heart failure.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00203" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-002-03.png?filename=nCD012204-CMP-002-03.ppt&amp;title=2.3&amp;caption=Comparison%202%20DDP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%203%20Congestive%20heart%20failure.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00204"><img data-id="CD012204-fig-00204" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-04.png" alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 4 Non‐serious adverse events."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 4 Non‐serious adverse events.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00204" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-002-04.png?filename=nCD012204-CMP-002-04.ppt&amp;title=2.4&amp;caption=Comparison%202%20DDP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%204%20Non%E2%80%90serious%20adverse%20events.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00205"><img data-id="CD012204-fig-00205" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-05.png" alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 5 Fasting glucose."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 5 Fasting glucose.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00205" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-002-05.png?filename=nCD012204-CMP-002-05.ppt&amp;title=2.5&amp;caption=Comparison%202%20DDP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%205%20Fasting%20glucose.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00206"><img data-id="CD012204-fig-00206" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-06.png" alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 6 2‐hour glucose values."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 6 2‐hour glucose values.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00206" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-002-06.png?filename=nCD012204-CMP-002-06.ppt&amp;title=2.6&amp;caption=Comparison%202%20DDP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%206%202%E2%80%90hour%20glucose%20values.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00207"><img data-id="CD012204-fig-00207" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-07.png" alt="Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 7 Haemoglobin A1c."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 DDP‐4 inhibitors versus placebo, Outcome 7 Haemoglobin A1c.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00207" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-002-07.png?filename=nCD012204-CMP-002-07.ppt&amp;title=2.7&amp;caption=Comparison%202%20DDP%E2%80%904%20inhibitors%20versus%20placebo%2C%20Outcome%207%20Haemoglobin%20A1c.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-002-07.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00301"><img data-id="CD012204-fig-00301" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-003-01.png" alt="Comparison 3 Glucagon‐like peptide (GLP)‐1 analogues versus metformin, Outcome 1 Fasting blood glucose."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Glucagon‐like peptide (GLP)‐1 analogues versus metformin, Outcome 1 Fasting blood glucose. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00301" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-003-01.png?filename=nCD012204-CMP-003-01.ppt&amp;title=3.1&amp;caption=Comparison%203%20Glucagon%E2%80%90like%20peptide%20%28GLP%29%E2%80%901%20analogues%20versus%20metformin%2C%20Outcome%201%20Fasting%20blood%20glucose.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-003-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00401"><img data-id="CD012204-fig-00401" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-01.png" alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 1 Incidence of type 2 diabetes mellitus."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 1 Incidence of type 2 diabetes mellitus. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00401" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-004-01.png?filename=nCD012204-CMP-004-01.ppt&amp;title=4.1&amp;caption=Comparison%204%20Glucagon%E2%80%90like%20peptide%20%28GLP%29%E2%80%901%20analogues%20versus%20placebo%2C%20Outcome%201%20Incidence%20of%20type%202%20diabetes%20mellitus.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00402"><img data-id="CD012204-fig-00402" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-02.png" alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 2 Serious adverse events."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 2 Serious adverse events. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00402" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-004-02.png?filename=nCD012204-CMP-004-02.ppt&amp;title=4.2&amp;caption=Comparison%204%20Glucagon%E2%80%90like%20peptide%20%28GLP%29%E2%80%901%20analogues%20versus%20placebo%2C%20Outcome%202%20Serious%20adverse%20events.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00403"><img data-id="CD012204-fig-00403" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-03.png" alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 3 Non‐serious adverse events."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 3 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00403" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-004-03.png?filename=nCD012204-CMP-004-03.ppt&amp;title=4.3&amp;caption=Comparison%204%20Glucagon%E2%80%90like%20peptide%20%28GLP%29%E2%80%901%20analogues%20versus%20placebo%2C%20Outcome%203%20Non%E2%80%90serious%20adverse%20events.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00404"><img data-id="CD012204-fig-00404" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-04.png" alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 4 Mild hypoglycaemia."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 4 Mild hypoglycaemia. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00404" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-004-04.png?filename=nCD012204-CMP-004-04.ppt&amp;title=4.4&amp;caption=Comparison%204%20Glucagon%E2%80%90like%20peptide%20%28GLP%29%E2%80%901%20analogues%20versus%20placebo%2C%20Outcome%204%20Mild%20hypoglycaemia.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00405"><img data-id="CD012204-fig-00405" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-05.png" alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 5 Fasting blood glucose."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 5 Fasting blood glucose. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00405" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-004-05.png?filename=nCD012204-CMP-004-05.ppt&amp;title=4.5&amp;caption=Comparison%204%20Glucagon%E2%80%90like%20peptide%20%28GLP%29%E2%80%901%20analogues%20versus%20placebo%2C%20Outcome%205%20Fasting%20blood%20glucose.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-05.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00406"><img data-id="CD012204-fig-00406" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-06.png" alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 6 2‐hour glucose."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 6 2‐hour glucose. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00406" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-004-06.png?filename=nCD012204-CMP-004-06.ppt&amp;title=4.6&amp;caption=Comparison%204%20Glucagon%E2%80%90like%20peptide%20%28GLP%29%E2%80%901%20analogues%20versus%20placebo%2C%20Outcome%206%202%E2%80%90hour%20glucose.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-06.png">Open in new tab</a></div> </div> <div class="figure" id="CD012204-fig-00407"><img data-id="CD012204-fig-00407" src="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-07.png" alt="Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 7 Haemoglobin A1c."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Glucagon‐like peptide (GLP)‐1 analogues versus placebo, Outcome 7 Haemoglobin A1c. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-fig-00407" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/ppt/CDSR/CD012204/image_n/nCD012204-CMP-004-07.png?filename=nCD012204-CMP-004-07.ppt&amp;title=4.7&amp;caption=Comparison%204%20Glucagon%E2%80%90like%20peptide%20%28GLP%29%E2%80%901%20analogues%20versus%20placebo%2C%20Outcome%207%20Haemoglobin%20A1c.&amp;citation=Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl%E2%80%90peptidase (DPP)%E2%80%904 inhibitors and glucagon%E2%80%90like peptide (GLP)%E2%80%901 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2017, 5. Art. No.: CD012204. DOI: http://dx.doi.org/10.1002/14651858.CD012204.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD012204.pub2/media/CDSR/CD012204/image_n/nCD012204-CMP-004-07.png">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD012204-tbl-0001" class="summary-of-findings framed"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span>&nbsp;<span class="table-title">DPP‐4 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</span></div> <tbody> <tr class="separated"> <td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>DPP‐4 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population</b>: people at risk for development of T2DM </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: DPP‐4 inhibitors </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>No of participants<br> (trial(s))</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Placebo</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>DPP‐4 inhibitors</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>179 (1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 trial on vildagliptin reported that none of the participants died (<a href="./references#CD012204-bbs2-0005">Rosenstock 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Incidence of T2DM</b> </p> <p>Definition: WHO criteria</p> <p>Follow‐up: 12 weeks</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>179 (1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 trial reported that 3/90 in the vildagliptin group vs 1/89 in the placebo group developed T2DM (<a href="./references#CD012204-bbs2-0005">Rosenstock 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>179 (1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 trial reported that 1/90 in the vildagliptin group vs 2/89 in the placebo group experienced a serious adverse event (<a href="./references#CD012204-bbs2-0005">Rosenstock 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Cardiovascular mortality</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>179 (1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 trial reported that none of the participants died (<a href="./references#CD012204-bbs2-0005">Rosenstock 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>(1) Non‐fatal myocardial infarction</b> </p> <p><b>(2) Non‐fatal stroke</b> </p> <p><b>(3) Congestive heart failure</b> </p> <p>Follow‐up: 12 weeks</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>(1) ‐</p> <p>(2) ‐</p> <p>(3) 179 (1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>(1) + (2): not reported</p> <p>(3): 1 trial on vildagliptin reported 1/90 in the vildagliptin group vs 0/89 in the placebo group experienced heart failure (<a href="./references#CD012204-bbs2-0005">Rosenstock 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br> <b>CI:</b> confidence interval; <b>DPP‐4:</b> dipeptidyl‐peptidase‐4; <b>RR:</b> risk ratio; <b>T2DM:</b> type 2 diabetes mellitus; <b>WHO:</b> World Health Organization. </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Assumed risk was derived from the event rates in the comparator groups.</p> <p><sup>a</sup>Downgraded by three levels because of indirectness, imprecision (very sparse data) and risk of publication bias (see <a href="./appendices#CD012204-sec2-0030">Appendix 15</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span>&nbsp;<span class="table-title">DPP‐4 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-tbl-0001" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD012204-tbl-0002" class="summary-of-findings framed"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>&nbsp;<span class="table-title">GLP‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</span></div> <tbody> <tr class="separated"> <td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GLP‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Population</b>: people at risk for development of T2DM </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: GLP‐1 analogues </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Placebo</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>GLP‐1 analogues</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>No of participants<br> (trial(s))</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-header"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: up to 172 weeks</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2281 (2)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 trial reported that 2/1501 in the liraglutide group vs 2/747 in the placebo group died after 160 weeks of intervention. </p> <p>Liraglutide used in doses approved for weight‐reducing purposes (3.0 mg) (<a href="./references#CD012204-bbs2-0007">SCALE</a>). </p> <p>1 trial using exenatide reported that none of the participants died (<a href="./references#CD012204-bbs2-0006">Rosenstock 2010</a>) </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Incidence of T2DM</b> </p> <p>Definition/description: 1 trial established the diagnosis of T2DM defined as HbA1c ≥ 6.5%, or fasting plasma glucose ≥ 7.0 mmol/L, or 2‐hour plasma glucose post‐challenge (oral glucose tolerance test) ≥ 11.1 mmol/L (<a href="./references#CD012204-bbs2-0007">SCALE</a>). Other trial did not report how the diagnosis of T2DM was established. </p> <p>Follow‐up: up to 172 weeks</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2243 (2)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>At 160 weeks, 26/1472 (1.8%) participants in the liraglutide group vs 46/738 (6.2%) participants in the placebo group developed T2DM (<a href="./references#CD012204-bbs2-0007">SCALE</a>). The incidence of T2DM after the 12‐week off‐treatment extension period (i.e. after 172 weeks) showed that 5 additional participants were diagnosed with T2DM in the liraglutide group, compared with 1 participant in the placebo group. </p> <p>Liraglutide used in doses approved for weight‐reducing purposes (3.0 mg).</p> <p>1 trial reported that 2/17 in the exenatide group vs1/16 in the placebo group developed T2DM (<a href="./references#CD012204-bbs2-0006">Rosenstock 2010</a>) </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: up to 172 weeks</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2312 (2)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> <b>Low<sup>b</sup> </b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 trial on liraglutide reported that 227/1501 (15.1%) participants in the liraglutide 3.0 mg group vs 96/747 (12.7%) participants in the placebo group experienced a serious adverse event after 160 weeks (<a href="./references#CD012204-bbs2-0007">SCALE</a>). </p> <p>1 trial on exenatide reported that none of the participants experienced a serious adverse event (<a href="./references#CD012204-bbs2-0006">Rosenstock 2010</a>) </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Cardiovascular mortality</b> </p> <p>Follow‐up: up to 172 weeks</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2281 (2)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1 trial reported that none of the participants died (<a href="./references#CD012204-bbs2-0006">Rosenstock 2010</a>). 1 trial reported that 1/1501 participants in the liraglutide group died from cardiac arrest; no participant in the placebo group died of cardiovascular reasons (<a href="./references#CD012204-bbs2-0007">SCALE</a>). </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>(1) Non‐fatal myocardial infarction</b> </p> <p><b>(2) Non‐fatal stroke</b> </p> <p><b>(3) Congestive heart failure</b> </p> <p>Follow‐up: up to 172 weeks</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>(1) 2279 (1)</p> <p>(2) See comments</p> <p>(3) 2279 (1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>(1) 1 trial reported 1/1524 participants in the liraglutide 3.0 mg group vs 0/755 participants in the placebo group (<a href="./references#CD012204-bbs2-0007">SCALE</a>) </p> <p>(2) Not reported</p> <p>(3) 1 trial reported 1/1524 in the liraglutide 3.0 mg group vs 1/755 participants in the placebo group (<a href="./references#CD012204-bbs2-0007">SCALE</a>) </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Health‐related quality of life</b> </p> <p>SF‐36 scale: total score 0‐100, 8 subscales. Higher values mean better health‐related quality of life. </p> <p>Follow‐up: 160 weeks</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1791 (1)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> <b>Very low<sup>a</sup> </b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Physical functioning component score had mean difference of 0.87 in favour of liraglutide (<a href="./references#CD012204-bbs2-0007">SCALE</a>) </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>See comment</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br> <b>CI:</b> confidence interval; <b>GLP‐1</b>: glucagon‐like peptide‐1; <b>HbA1c:</b> glycosylated haemoglobin A1c; <b>RR:</b> risk ratio; <b>SF‐36:</b> 36‐item Short Form health survey; <b>T2DM:</b> type 2 diabetes mellitus. </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by three levels because of indirectness, imprecision (sparse data) and risk of attrition and publication bias (see <a href="./appendices#CD012204-sec2-0031">Appendix 16</a>).<br> <sup>b</sup>Downgraded by two levels because of imprecision (sparse data) and risk of attrition and publication bias (see <a href="./appendices#CD012204-sec2-0031">Appendix 16</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>&nbsp;<span class="table-title">GLP‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-tbl-0002" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD012204-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span>&nbsp;<span class="table-title">Overview of trial populations</span></div> <tbody> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Trial (design)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Intervention and comparator</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Description of power and sample size calculation and handling of missing data</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Screened/eligible<br> (n)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Randomised<br> (n)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>ITT<br> (n)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Analysed<br> (n)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Finishing trial<br> (n)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Randomised finishing trial<br> (%)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Follow‐up<br> (extended follow‐up)<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b>Ariel 2014</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I: liraglutide 1.8 mg, once daily</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>"Targeted sample size of 30 subjects in each group provided 90% power to detect a 20% difference (2.2 mmol/L) in SSPG concentration. With 24 subjects per group, there was 82% power to detect a 20% difference. A difference of 20% was chosen because this is the degree of difference in SSPG concentration seen with modest weight loss of 7%." </p> <p>"Only subjects who had end‐of‐study testing were included in the analyses."</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>161</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>35</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>24</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>24</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>24</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>68.6</p> </td> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>14 weeks</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>C: placebo, once daily</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>33</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>27</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>27</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>27</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>81.8</p> </td> </tr> <tr> <td align="right" valign="top" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b>total:</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>68</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>51</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>51</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>51</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>75</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b>Kelly 2012</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I: exenatide 10 μg twice daily</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>25</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>25</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>25</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>25</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100</p> </td> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>3 months</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>C: metformin 1000 mg twice daily</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>25</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>25</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>25</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>25</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100</p> </td> </tr> <tr> <td align="right" valign="top" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b>total:</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>50</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>50</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>50</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>50</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b>Martinez‐Abundis 2015</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I: linagliptin 5 mg + placebo in the evening</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100</p> </td> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>90 days</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>C: metformin 500 mg twice daily</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100</p> </td> </tr> <tr> <td align="right" valign="top" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b>total:</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>100</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b>McLaughlin 2011</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I: exenatide 10 μg twice daily</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>32</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>32</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>32</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>30 weeks (1 year)</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>C: placebo</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>34</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>34</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>34</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="right" valign="top" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b>total:</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>66<sup>e</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>66</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>66</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b>Rosenstock 2008</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I: vildagliptin 50 mg once daily</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>ITT</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>956</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>90</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>89</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>89</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>84</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>93.3</p> </td> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>12 weeks</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>C: placebo</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>89</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>89</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>89</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>84</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>94.4</p> </td> </tr> <tr> <td align="right" valign="top" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b>total:</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>179</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>178</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>178</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>168</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>93.9</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b>Rosenstock 2010</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>I: exenatide 10 μg twice daily</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>Includes participants that received at least 1 dose of study drug</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>322<sup>b</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>17<sup>d</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>17<sup>d</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>17<sup>d</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>24 weeks</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>C: placebo</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16<sup>d</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16<sup>d</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16<sup>d</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="right" valign="top" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b>total:</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>38<sup>c</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>33<sup>d</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>33<sup>d</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>33<sup>d</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>86.8</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="4" bgcolor="#ffffff"> <p><b>SCALE</b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>I: liraglutide 3.0 mg, once daily</p> </td> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>"The power for the primary endpoint weight change is calculated based on a two sided t‐test with a significance level of 5%. The power with regard to the co‐primary dichotomous endpoints proportion of subjects with a weight loss of at least 5% or more than 10%, respectively, is calculated based on a two‐sided chi‐square test." </p> <p>"The large number of randomised subjects also provides sufficient power for the fourth primary endpoint new onset of diabetes among subjects with pre‐diabetes. The endpoint new onset of diabetes will be analysed using methods for analysis of interval censored failure time data. A conservative estimate of the power may be calculated as if the endpoint diabetes yes/no among completers during the 160 weeks is analysed by use of a two‐sided Chisquare test with a significance level of 5%. </p> <p>It is assumed that the annual conversion rate of subjects with pre‐diabetes to diabetes equals 7% among placebo treated subjects, whereas it is 60% lower, 2.1%, among liraglutide treated subjects. After 160 weeks of treatment with liraglutide/placebo, the percentage of subjects with diabetes is therefore equal to 1‐(1‐0.07)3 = 20% among liraglutide placebo treated subjects and 1‐(1‐0.021)<sup>3</sup> = 6% among liraglutide treated subjects. It is assumed that the drop‐out during the 160 weeks may be as large as 65% in both groups. The power for conversion rates for placebo of 5, 7 and 9% and conversion rates 60 and 70% lower in the liraglutide group may be seen in Table 18‐1." </p> <p>From the numbers in Table 18‐1 following numbers are specified:</p> <p>"Based on these figures it is apparent that a sample size of 2400 liraglutide treated subjects and 1200 liraglutide placebo treated subjects will provide sufficient power also for the fourth primary endpoint onset of diabetes" </p> <p>"Missing values were imputed with the use of the last‐observation‐carried‐forward method for measurements made after baseline." </p> </td> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p>4992<sup>b</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Period week 0‐56: 1528</p> <p>Period week 0‐172: 1505</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1472<sup>f</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1472<sup>f</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Period week 0‐56: 1110</p> <p>Period week 0‐172: 783<sup>g</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Period week 0‐56: 72.6</p> <p>Period week 0‐172: 52.0</p> </td> <td align="" valign="top" colspan="1" rowspan="4" bgcolor="#ffffff"> <p>160 weeks (172 weeks)</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>Period week 0‐56: 757</p> <p>Period week 0‐172: 749</p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>738<sup>f</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>738<sup>f</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>Period week 0‐56: 505</p> <p>Period week 0‐172: 327<sup>g</sup> </p> </td> <td align="" valign="top" colspan="1" rowspan="2" bgcolor="#ffffff"> <p>Period week 0‐56: 66.7</p> <p>Period week 0‐172: 43.7</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>C: placebo</p> </td> </tr> <tr> <td align="right" valign="top" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b>total:</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2285</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2210</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2210</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1110</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>48.6</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="3" bgcolor="#ffffff"> <p><b><i>Grand total</i> </b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>All interventions<sup>h</sup> </i> </b> </p> </td> <td align="" valign="top" colspan="2" rowspan="3" bgcolor="#ffffff"> <p>‐</p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>1718</i> </b> </p> </td> <td align="" valign="top" colspan="2" rowspan="3" bgcolor="#ffffff"></td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>924</i> </b> </p> </td> <td align="" valign="top" colspan="2" rowspan="3" bgcolor="#ffffff"> <p>‐</p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>All c</i><i>omparators<sup>h</sup> </i> </b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>946</i> </b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>471</i> </b> </p> </td> </tr> <tr> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>All interventions and c</i><i>omparators<sup>i</sup> </i> </b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>2702</i> </b> </p> </td> <td align="center" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b><i>1428<sup>j</sup> </i> </b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>‐ denotes not reported.</p> <p><sup>a</sup>Follow‐up under randomised conditions until end of trial or if not available, duration of intervention; extended follow‐up refers to follow‐up of participants once the original study was terminated as specified in the power calculation.<br> <sup>b</sup>Total number of screened.<br> <sup>c</sup>Article stated that 38 participants out of the total randomised population had impaired fasting glucose or impaired glucose tolerance, or both.<br> <sup>d</sup>Number retrieved from abstract.<br> <sup>e</sup>One of the abstracts reports that 68 participants were randomised and another abstract reports 66 participants.<br> <sup>f</sup>The SCALE had different number of participants included in the analyses depending on outcome. A full analyses set is reported in the table and was defined as: "All randomised subjects exposed to at least one dose of the trial product and with at least one post baseline assessment of any efficacy endpoint will be included. Subjects in the FAS will be analysed according to randomised treatment." Beside safety analysis set was defined as: "All randomised subjects who have been exposed to at least one dose of trial product. Subjects in the safety analysis set will be analysed "as treated" ". The number of participants started in the trial according to clinicaltrial.gov varied from the period of week 0 to week 56 and from week 0 to 172 due to misclassification of screened participants.<br> <sup>g</sup>In the publication reporting long‐term data, it was stated that 791 (53%) participants in the liraglutide group and 337 (15%) participants in the placebo group completed the trial (<a href="./references#CD012204-bbs2-0131">Le Roux 2017</a>).<br> <sup>h</sup>Not all trials described the number of participants randomised to each intervention/comparator group.<br> <sup>i</sup>One trial did not report the number of randomised participants per intervention group. Therefore, numbers do not add up accurately.<br> <sup>j</sup>Not all trials reported the number of participants finishing the trial. </p> <p>C: comparator; I: intervention; ITT: intention to treat; n: number of participants; N/A: not applicable; RCT: randomised controlled trial; SCALE: Satiety and Clinical Adiposity ‐ Liraglutide Evidence in Nondiabetic and Diabetic Individuals; SSPG: steady‐state plasma glucose. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span>&nbsp;<span class="table-title">Overview of trial populations</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/full#CD012204-tbl-0007" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD012204-tbl-0003" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 2‐hour glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Haemoglobin A1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Dipeptidyl‐peptidase (DPP)‐4 inhibitors versus metformin</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-tbl-0003" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD012204-tbl-0004" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">DDP‐4 inhibitors versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Incidence of type 2 diabetes mellitus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Congestive heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Fasting glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 2‐hour glucose values <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Haemoglobin A1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">DDP‐4 inhibitors versus placebo</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-tbl-0004" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD012204-tbl-0005" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 3.</span>&nbsp;<span class="table-title">Glucagon‐like peptide (GLP)‐1 analogues versus metformin</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span>&nbsp;<span class="table-title">Glucagon‐like peptide (GLP)‐1 analogues versus metformin</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-tbl-0005" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD012204-tbl-0006" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 4.</span>&nbsp;<span class="table-title">Glucagon‐like peptide (GLP)‐1 analogues versus placebo</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Incidence of type 2 diabetes mellitus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Mild hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Fasting blood glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">6 2‐hour glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">7 Haemoglobin A1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span>&nbsp;<span class="table-title">Glucagon‐like peptide (GLP)‐1 analogues versus placebo</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD012204.pub2/references#CD012204-tbl-0006" class="tableList">Navigate to table in Review</a></div> </div> </div> <section class="translation-notes-modal" style="display: none" data-modal-title="Translation notes" data-modal-class="translation-notes" data-ok-btn-selector=".ok-btn"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012204-note-1206">Español</a> </li> <li class="section-language"> <a class="" href="ms#CD012204-note-1204">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh#CD012204-note-1205">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" id="citeProcText" data-load-error="Unable to load citation data"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a href="#" class="addthis_button_citeulike at300b btn btn-link">CiteULike</a></li> <li><a href="#" class="addthis_button_mendeley at300b btn btn-link">Mendeley</a></li> <li><a href="#" class="citation-btn-refworks at300b btn btn-link" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <h4>Copy or download citation</h4> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button type="button" class="btn btn-link">Plain text</button></li> <li class="citation-option" data-option="endnote"><button type="button" class="btn btn-link">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button type="button" class="btn btn-link">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button type="button" class="btn btn-link">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button type="button" class="btn btn-link">BibteX</button></li> </nav> <div class="citation-content"> <pre id="citationContent" tabindex="0" data-load-error="Unable to load citation data"></pre> </div> <div class="clearfix"> <form class="download-citation-form" method="GET" target="citation-download-iframe" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=citation-citeproc&p_p_cacheability=cacheLevelPage&p_p_col_id=column-1&p_p_col_count=1"> <input type="hidden" id="siteId" name="siteId" value="" /> <input type="hidden" id="downloadType" name="downloadType" value="" /> <input type="hidden" id="style" name="style" value="" /> <input type="hidden" id="articleId" name="articleId" value="" /> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay" /><input name="p_p_lifecycle" type="hidden" value="2" /><input name="p_p_state" type="hidden" value="normal" /><input name="p_p_mode" type="hidden" value="view" /><input name="p_p_resource_id" type="hidden" value="citation-download" /><input name="p_p_cacheability" type="hidden" value="cacheLevelPage" /><input name="p_p_col_id" type="hidden" value="column-1" /><input name="p_p_col_count" type="hidden" value="1" /> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withAbstract"> <input class="checkbox" type="checkbox" name="withAbstract" /> <span class="checkbox-label">Include abstract</span> </label> </div> </form> <iframe title="Citation download frame" name="citation-download-iframe" src="" style="display: none; visibility: hidden" aria-hidden="true"></iframe> </div> </div> </div> </div> <div class="print-modal" style="display: none;" data-modal-title="Print this review"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input title="Select/deselect all" type="checkbox" class="print-options-select-all" checked="checked" /> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i class="fa fa-print" aria-hidden="true"></i> Print</button> </div> </div> <div class="download-stats-data-modal" style="display: none;" data-modal-title="Download statistical data"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <p> Downloaded data can only be viewed using <a class="external" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/tools/review-production-tools/revman-5" target="_blank">Review Manager software.</a> </p> <p> Please note that: <ul> <li>data are only available for Cochrane Reviews that contain one or more forest plots; and</li> <li>data in the downloaded RevMan file are editable and therefore the review data can be amended without warning.</li> </ul> </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input type="hidden" name="content-disposition" value="attachment" /> <input type="hidden" name="mime-type" value="application/octet-stream" /> <p class="print-options-controls"> <input type="checkbox" class="download-stats-data-toc-check-box" aria-label="I agree to these terms and conditions" /> <span class="checkbox-label" aria-hidden="true">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i class="fa fa-download" aria-hidden="true"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" style="display:none;" data-modal-title="Share this review"> <div class="add-this"> <div class="addthis_toolbox addthis_default_style addthis_32x32_style"> <nav class="stacked-nav-list"> <li> <a href="#" class="addthis_button_twitter at300b" title="Tweet">Twitter</a> </li> <li> <a href="#" class="addthis_button_mendeley at300b" target="_blank" title="Mendeley">Mendeley</a> </li> <li> <a href="#" class="addthis_button_facebook at300b" title="Facebook">Facebook</a> </li> <li> <a href="#" class="addthis_button_linkedin at300b" target="_blank" title="LinkedIn">LinkedIn</a> </li> <li> <a href="#" class="addthis_button_email at300b" target="_blank" title="Email">Email</a> </li> <li> <a href="#" class="addthis_button_whatsapp at300b" target="_blank" title="WhatsApp">WhatsApp</a> </li> <li class="clearfix"> <a href="#" class="addthis_button_more btn primary pull-right" target="_blank" title="View more"> <i class="fa fa-plus" aria-hidden="true"></i> View more</a> </li> </ul> </div> </div> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button type="button" class="btn btn-link" id="figureOptionBtn">Figures</button></li> <li class="table-options-btn-container"><button type="button" class="btn btn-link" id="tableOptionBtn">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div id="figureThumbnails" class="figure-thumbnails is-visible"></div> <div id="tableThumbnails" class="table-thumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a href="#" class="figure-viewer-menu-toggle"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-table-show-text="Show table list" data-table-hide-text="Hide table list" data-figure-show-text="Show thumbnails" data-figure-hide-text="Hide thumbnails">Hide thumbnails</span> </a> <a href="#" class="figure-viewer-zoomin"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a href="#" class="figure-viewer-zoomout"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a href="#" class="figure-viewer-nav previous"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a href="#" class="figure-viewer-nav next"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_  portlet-static portlet-static-end kaleo-designer-portlet " id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a title="Cochrane logo" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/">
<img class="footer-logo logo-part-1" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-1.png" alt="Cochrane logo" /> <img class="footer-logo logo-part-2" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-2.png" alt="" /> </a> </div> <nav class="footer-links"> <ul class="root"> <li class="footer-item"> <a class="footer-item-link" href="/about-cochrane1">About Cochrane</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/evidence" target="_blank">Cochrane.org</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank">Who we are</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NJYXT5SPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Get involved</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX665WNWTYE63PMNYXG4DTMFYGKLUQPJUB/" target="_blank">Consumer Network</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-funders-and-partners" target="_blank">Partners</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYXZ5DQPF4XT7LNF3SX8Z5IPJRX63JPN73GH/" target="_blank">Colloquium</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news" target="_blank">In the news</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/publications">Publications</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="/library">Cochrane Library</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/" target="_blank">Library Homepage</a> </li> <li class="footer-item"> <a class="footer-item-link" href="cdsr/about-cdsr" target="_blank">Cochrane Reviews (CDSR)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/central" target="_blank">Trials (CENTRAL)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cca/about" target="_blank">Cochrane Clinical Answers</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/cochrane-library-app" target="_blank">Cochrane Library App</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cdsr/journal-club" target="_blank">Journal Club</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/podcasts" target="_blank">Podcasts</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/community">Community</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Community</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MF3GG4DJMVYGG55DNB3GC5UFF3YYE3D/" target="_blank">Archie log-in</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/PS3GC4LPNFYGPLUDN7SXR6UBN3TT655TMH/" target="_blank">Training and support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/NWTYI4DQMS3T6Z5QMNVHEZLPMVYG86UH/" target="_blank">Methods</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/help" target="_blank">Software</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news/jobs" target="_blank">Jobs and opportunities</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/contact-us">Contact Us</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/contact" target="_blank">General enquiries</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/help/contact-us" target="_blank">Cochrane Library support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/chief-executive-officers-office/team" target="_blank">Chief Executive Officer</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/editorial-methods/team" target="_blank">Editor in Chief</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-global-community" target="_blank">Cochrane groups</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/media" target="_blank">Media</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/accessibility" target="_blank">Accessibility</a> </li> </ul> </li> </ul> </nav> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/advertisers">Advertisers & Agents</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Help & Support</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/terms-and-conditions">Terms & Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright &copy; 2000 - 2020 by <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUYNFXGK8JPMNYXN/" class="">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br /> Review our <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUYNFXGK8JPMNYXN/en-gb/privacy"><strong>Privacy Policy</strong></a> </p> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MW4T675JNSTYTLUDN7XB/"><img class="logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_wiley-footer-logo.png" alt="Wiley logo" /></a> </div> </div> <span class="wiley-semi-circle"></span> </div> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" style="display: none" data-modal-title="Feature in English only" data-modal-class="english-only-modal"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1581422282000" type="text/javascript"></script> <!--<![endif]--> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/theme.js?t=1581422282000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/checkout.js"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MN3G865UNWRYE43NMNTG6LUDPJYYG65TMWUC655TMH/widget/v2.0/widget.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MRZXE8DIHB4XC63SNWYHPN3PMNXG87LEM33G85UVF3YGK7A/assets/embed.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718249000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718249000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012204\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012204\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012204\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012204\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012204\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581422282000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a href="#" class="rh-nav-close-btn"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a href="#" class="rh-nav-open-btn"> <span>Review tools & navigation</span> </a> </div> <iframe title="Print frame" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" aria-hidden="true"></iframe> <div class="mobile-navigation"> <div class="close-container"> <a href="#" class="main-nav-back-btn" aria-label="Navigate back"><i class="fa fa-chevron-left"></i></a> <a href="#" class="main-nav-close-btn" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="ymag__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=EfT7x5RD&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
 <div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012204.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012204.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<a href="/en/browse-by-topic" class="btn secondary">Browse </a>
<a href="/en/advanced-search" class="btn secondary advanced-search-button">Advanced search</a>
</div>
<div class="menu-items parent">
<ul>
<li class="nav-root-item parent">
<a href="#" title="Select language" class="language-selection-title-link">
<span class="mobile-nav-language-title">Select your preferred language</span><span class="icon fa fa-caret-down"></span>
<ul class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="fdkn__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div id="active-content-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div id="active-portal-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="/en/cdsr/doi/10.1002/14651858.CD012204.pub2/references/en" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD012204.pub2/references/es" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</ul>
</a>
</li>
<li class="parent">
<a class="mobile-link signin" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012204.pub2%2Freferences" data-redirect="false" rel="nofollow">
Sign In
</a>
</li>
</ul>
<div class="menu-items-footer">
<div class="utility-links">
<a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/" class="cochrane-link" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
<div class="basic-login-form-content" style="display: none;" data-modal-title="Sign in">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="dbam__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1583243361395" /> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x2f;references" /> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value="" /> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true" /> <input checked class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onClick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true" /> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user-registration" target="_blank" class="btn secondary">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" style="display: none;" data-modal-title="Institutional login">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="obft__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text">
</div>
<button class="btn primary" type="submit" name="button">Go</button>
</div>
<div id="institutionLookupErrorDiv" class="message error" style="display:none">
'<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
</div>
</div>
<input type="hidden" id="entityId" name="entityId" value="">
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="joiu__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1583243361399" /> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD012204&#x2e;pub2&#x2f;references" /> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value="" /> </div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true" /> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" style="display: none;" data-modal-title="Unlock the potential of Cochrane evidence">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="wpdq__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text"> </div> <button class="btn primary" type="submit" name="button">Go</button> </div> <div id="institutionLookupErrorDiv" class="message error" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input type="hidden" id="entityId" name="entityId" value=""> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'> <input type="hidden" name="openlabel" id="openlabel" value='Open access'> </div> </section> </div> </div>  <script>window.urlTitle="/cdsr/doi/10.1002/14651858.CD012204.pub2";addthis_config={pubid:"ra-593597d01cdf9a55",ui_508_compliant:true};addthis_share={url:window.location.href,title:document.title};</script> <script src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-593597d01cdf9a55"></script> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> </body> </html> 